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Abstract
Tools for Large-scale Genomic Analysis and Gene Expression Outlier Modeling for
Precision Therapeutics
by
John Vivian
In terms of data acquisition, storage, and distribution, genomics data will soon become the
largest big data domain in science and, as such, needs appropriate tools to process the ever-
increasing amount of genomic data so researchers can leverage the power afforded by such
enormous datasets. I present my work on Toil: a portable, open-source workflow software that
supports contemporary workflow definition languages and can securely and reproducibly run
scientific workflows efficiently at large-scale. Yet efficient computation is only one component
of enabling scientific research, as data is not always accessible to researchers who can use it.
Data barriers hinder scientific progress and stymie research collaboration by denying access
to large amounts of biomedical information, due to the need for patient privacy and potential
liability on behalf of data stewards. As such, research institutions and consortiums should prior-
itize making large datasets open-access to enable research teams to develop novel therapeutics
and garner valuable insight into a wide variety of diseases. One such research group who ben-
efits from both large open-access datasets is Treehouse, a pediatric cancer research group that
investigates the role of RNA-seq in therapeutics. However, Treehouse also needs methods to
extract rare pediatric cancer data from information silos. Treehouse uses RNA-seq to iden-
tify target drug candidates by comparing gene expression for individual patients to their own
xix
public compendium, which combines multiple open-access datasets with thousands of pediatric
samples. I discuss a solution for extracting data from information silos by using portable and
reproducible software that produces anonymized secondary output that can be sent back to the
researcher for analysis. This computation-to-data method also addresses the logistical difficulty
of securely sharing and storing large amounts of primary sequence data. Finally, I propose a
robust Bayesian statistical framework for detecting gene expression outliers in single samples
that leverages all available data to produce a consensus background distribution for each gene
of interest without requiring the researcher to manually select a comparison set and provides
posterior predictive p-values to quantify over- or under-expression.
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“For me, it is far better to grasp the Universe as it really is than to persist in delusion, however
satisfying and reassuring.”
Carl Sagan
“Take the risk of thinking for yourself — much more happiness, truth, beauty, and wisdom will
come to you that way.”
Christopher Hitchens
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1Introduction
“Hofstadter’s Law: It always takes longer than you expect, even when you
take into account Hofstadter’s Law”
– Douglas Hofstadter
1.1 Introduction
The discovery of DNA as the genetic code of life and the subsequent sequencing of
the human genome in the last century stand alongside other monumental accomplishments of
science such as general and special relativity, the discovery of the Higgs boson, evidence of dark
matter, and the detection of gravitational waves. Just as physicists search for the ever-elusive
fundamental unit of matter, DNA is the underlying code from which the vast spectrum of life
arises, which is why genetics aptly takes its name from the Greek word γενετικoα, or origin.
Understanding this code is imperative to furthering our comprehension of life, death, disease,
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and aging, and provides the framework by which we may someday eradicate illness entirely.
If that goal is ever reached, it will be accomplished due to successful collaborations like The
Human Genome Project and The Cancer Genome Atlas (TCGA) [4, 1].
Transforming genetic code into useful information is not without its obstacles – ge-
netic sequencing is one of the largest sources of scientific data and strategies to effectively store,
manage, process, and analyze the data while keeping up with its ever-increasing rate of gener-
ation are necessary to continue scientific advancement [5]. Apart from requisite innovations
in algorithms, data storage, and computing, the ability to quickly share and access genetic data
comes with its own difficulties. Despite efforts from leaders in the genomics community, a large
amount of sequencing data necessary for critical research is locked behind information silos [6].
These information silos impede the work of research groups that leverage the power afforded
by large-scale datasets to make advances in our understanding of disease. Such hurdles to data
processing and sharing require innovation in how the genomics community builds tools so that
they are both scalable and portable.
1.1.1 Big Data in Genomics
After humanity entered the digital age at the dawn of the 21st century, digital stor-
age paved the way for an explosion in information storage as the total global capacity to store
information grew from 54 exabytes (1018 bytes) in the year 2000 to 295 exabytes by the year
2007 [7]. By 2011, a report from the International Data Corporation estimated the total created
and copied data volume in the world was 1.8 zetabytes (1021 bytes) [8]. The ability to store,
analyze, and make useful interpretation of these enormous datasets has driven interdisciplinary
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innovation and allowed for fields such as genomics to exist and modern astrophysics to flourish.
Just this year, the monumental achievement of imaging the first black hole stored data on half
a ton of hard drives and the final image was extracted from over 5 petabytes of data [9]. Un-
like astronomy data, which is acquired from a small number of centralized facilities, genomics
data acquisition is highly distributed and encompasses many heterogeneous formats, the vast
majority of which is sequence data [10, 11].
The explosion of data in genomics due to the plummeting cost of genome sequenc-
ing which dropped from $100,000,000 per genome in 2001 to ∼$1,000 per genome in 2018
dovetailed with large-scale collaborative projects like The 1000 Genomes Project, The Can-
cer Genome Atlas (TCGA) and the Exome Aggregation Consortium, doubled the rate of data
growth in genomics every seven months between 2005 and 2015 (Figure 1.1) [12, 1, 10, 13, 14].
Converting this massive amount of data into useful information often requires a series of pro-
cessing steps that must be easily reproducible by other research groups. This need led to one of
the cornerstones of bioinformatics – the creation of genomic workflows that distill sequencing
data into information related to alignment, mutation calls, gene expression, fusion detection,
alternative splicing, and much more.
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Figure 1.1: Cost per genome over the last two decades. 2008 marks the time when sanger-based
sequencing was replaced with second generation or next-generation sequencing which highly
parallelized the sequencing process. For detailed information see section A.1. Figure taken
from DNA Sequencing Costs: Data by Kris A. Wettterstrand. Updated June 7th, 2019 (https:
//www.genome.gov/about-genomics/fact-sheets/DNA-Sequencing-Costs-Data).
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1.2 Genomic workflows
A workflow comprises a set of tasks, or jobs, that are orchestrated by specification
of a set of dependencies that map the inputs and outputs between jobs. This definition allows
workflows to be visualized as graphs, where the nodes represent jobs and the directed lines
represent dependencies. There are many workflow engines that allow a user to describe their
graph of jobs and dependencies and handle efficiently parallelizing and executing jobs in the
graph [15, 16, 17, 18, 19]. These workflow engines differ in what language the workflows
are described in, how failures are handled, management and storage of intermediate output,
and the ability to run on distributed cloud computing environments. In an effort to make these
workflows more reproducible and consistent, many workflows now isolate genomic tools within
a virtual environment and the workflow simply manages the inputs, outputs, and execution of
these isolated environments.
Docker is a virtualization software that allows any software, e.g. genomic tools, to be
encapsulated within an immutable environment such that it will deterministically provide the
same output given the same input disregarding stochastic elements within the software itself
[20]. Additionally, Docker images are easy to distribute and hashes of those images can be used
to ensure reproducibility [21, 22]. This gives researchers confidence that results do not contain
computational batch effects that result from differences in software versioning, dependencies,
and environment [23]. Deterministic output is a critical achievement for scientific computing
and collaboration as researchers have traditionally used data produced from workflows that are
prone to computational batch effects. For example, TCGA initially processed its RNA-seq data
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by distributing instructions to multiple institutions that included a list of tools, versions of those
tools to use and versions of some of those tools dependencies, commands for each tool, and what
order to run them in. This approach invites the introduction of batch effects through multiple
avenues: user error in installing the proper tool version, version differences in dependencies that
werent listed, typos or errors in the tool commands, and underlying differences in the software
on the base operating system.
1.3 Data barriers in genomics
Given the increasing production of genomic data, keeping pace with storage and data
processing might appear to be the primary difficulty [10]. Unfortunately, the other impedi-
ment to using this data in research is data sharing between data stewards and those who want
access[24]. Even at genomics scale, the rise of cloud computing has provided the infrastructure
to support efficient data sharing. The problem stems from institutions that hoard data in the
name of patient privacy and make efforts to minimize risks associated with violating HIPAA
that can have severe consequences – unfortunately it’s the patients who lose out in these cir-
cumstances [25, 24]. In response to genomics data silos, several international efforts have been
started, such as the Global Alliance for Genomics and Health (GA4GH), the FAIR Data Prin-
ciples project, and the Bermuda Principles project [26, 27, 28, 29, 30]. GA4GH’s mission is
to accelerate progress in human health by helping to establish a common Framework of har-
monized approaches to enable effective and responsible sharing of genomic and clinical data
and to catalyze data sharing projects that drive and demonstrate the value of data sharing, fol-
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lowed by specific mention of rights for data producers to be credited for their contribution
to research efforts [26]. Other solutions for sharing genomic data revolve around cloud in-
frastructure and centralized government-funded hosting platforms such as the National Cancer
Institute’s Genomic Data Commons, which contains genomic data as well as clinical metadata
data from NCI-funded projects such as TCGA and the Therapeutically Applicable Research
to Generate Effective Treatments (TARGET) program, The National Center for Biotechnology
Information’s database of Genotypes and Phenotypes (dbGaP), which is a public repository for
individual-level phenotype, exposure, genotype and sequence data and the associations between
them, and Sequence Read Archive (SRA), which preserves experimental sequence data for re-
producibility [31, 32, 33]. Even private sector groups are making efforts to share genomic data,
such as the St. Jude Cloud which promises access to over 5,000 whole-genomes from pediatric
cancer patients [34]. Sharing of pediatric cancer data is particularly necessary as many pediatric
cancers are rare and there are often not enough comparable samples for sufficiently confident
statistical claims to be made [35]. For example, Treehouse, a pediatric cancer group that uses
RNA-seq data to aid in therapeutic assessment of patients, currently only has access to a couple
thousand pediatric samples spanning a wide breadth of disease subtypes, despite the existence
of many pediatric hospitals, due to the difficulties of genomic data sharing [36].
1.4 RNA sequencing
Almost all known life forms comprise cells whose functions are governed by infor-
mation located in DNA, which most commonly resides in the cells nucleus. Sections of DNA,
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Figure 1.2: standard Illumina RNA-seq library preparation. The sample is enriched for mRNA
via poly-A selection. The remaining RNA is converted into cDNA by fragmentation then ad-
dition of reverse transcriptase and primers. The 5’ and 3’ ends of the strand are prepared
to ease ligation of special adapters which contain an embedded barcode and primer bind-
ing sites for downstream PCR amplification. Figure taken from A comprehensive review of
RNA-seq methodologies by David Corney and Georgeta Basturea. Updated May 22nd, 2019
(https://www.labome.com/method/RNA-seq.html).
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called genes, are first transcribed into RNA, an almost identical copy that is capable of leav-
ing the nucleus, which is then translated into what eventually become proteins. Proteins are
the workers of the cell responsible for structural, functional, and regulatory activity within
the cell. Sequencing allows the decoding of the information stored in DNA, made up of four
unique molecules called nucleotides. The human genome is about 3 billion nucleotides long
and retrieving this information accurately is exceptionally difficult.
DNA sequencing can be understood as a series of simple steps (for more detailed
information see section A.1). First, a biological sample is collected from a patient and the DNA
is isolated and broken up into segments called reads. After some processing, the DNA is fed into
a sequencing machine which outputs the sequence identity of the reads. The sequence identity
is typically stored as letters representing the four nucleotides in DNA: A, G, T, and C. Effective
techniques to isolate and sequence RNA have also been invented within the past decade. Since
RNA is almost an exact copy of DNA, it may not be obvious what additional information is
gained from sequencing RNA that isnt provided by DNA sequencing.
RNA sequencing (RNA-seq) reveals the presence and quantity of RNA in a biologi-
cal sample at a given moment [37]. The amount of DNA in a cell is typically static until cell
division, but RNA is in a constant state of flux as the needs of the cell change based on inter-
nal and external stimuli. Since messenger RNA (mRNA) is translated into protein, the relative
abundance of mRNA can be used to approximate the amount of each different protein created
by a cell, although the relationship between mRNA and expressed protein is not perfectly linear
[38]. This is valuable for studying how the cell environment is affected by drugs, environmental
conditions, and diseases such as cancer. Cancer causes massive disruptions in the cell environ-
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ment which lead to changes in gene expression. Understanding differences in gene expression
between normal cells and cancer cells directs the development of therapeutics and helps sci-
entists understand the mechanisms that allow cancerous cells to so effectively replicate, avoid
apoptosis signaling, and evade the immune system.
Before RNA-seq became the standard method of investigating gene expression, stud-
ies used microarrays, i.e. chips with a large number of fluorescently labelled DNA molecules
that hybridize to complementary DNA (cDNA) and provide relative abundance estimations of
the target [39]. Problems stemming from cross-hybridization, poor discrepancy between genes
with low and high expression, and needing to know the target sequence beforehand made the
transition to sequencing based methods preferential [40]. Conveniently, RNA-seq only requires
a different library preparation step before traditional DNA sequencers can be used (Figure 1.2).
First, RNA is isolated, purified, and quality controlled for degradation using standard gel elec-
trophoresis [41]. The RNA is then filtered using one of two primary methods, each with their
own advantages. Poly-A selection, using magnetic beads, only includes RNA with 3’ poly-A
tails and ensures capture of RNA that comes from coding sequences, but introduces 3’ bias, i.e.
an artifact introduced during the generation of cDNA [42]. 3’ bias is avoided in the other fil-
tering option, ribosomal depletion, but also includes mRNA, lncRNA, and other types of RNA
that may make up a large fraction of the reads after sequencing [43, 44]. The last step in library
preparation is the reverse transcription of isolated RNA to cDNA which allows for the use of
DNA sequencers.
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Figure 1.3: Depiction of checkpoint inhibitors. Some tumors will develop PD-L1 receptors on
their surface that they use to activate PD-1 on T-cells which deactivates the T-cell and allows
them to remain icognito from the immune system. If either PD-1 on the T-cell or PD-L1 on the
tumor is inhibited it prevents the tumor cell from binding to PD-1 and teh T-cell remains active
giving the immune system a better chance to identify and attack the tumor. Figure taken from
The new era of immune checkpoint inhibitors by Malini Guha, published November 18th 2014.
(https://tinyurl.com/y5gjfrcj)
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1.4.1 RNA Sequencing and Cancer Therapeutics
RNA-seq allows researchers to quantify gene and alternatively spliced transcript ex-
pression, identify gene fusions and post-transcriptional modifications, and even do variant call-
ing. Different forms of RNA can be collected with RNA-seq, such as miRNA, tRNA, and
lncRNA, by adjusting the library preparation method [45, 46, 47]. Recently, RNA-seq has
been employed by precision medicine researchers as a way to identify potential therapeutic
leads in cancer patients by identifying gene fusions and drug targets based on gene expression
[48, 49, 50, 51]. Some cancers, like leukemia, are particularly appropriate for RNA-seq analy-
sis as their high mutation rate makes them candidates for developing gene fusions which can be
excellent therapeutic targets as gene fusions typically have unique markers (epitopes) that are
absent from normal cells [52]. There are now several antineoplastics whose administration is de-
pendent upon overexpression of a particular gene or group of genes. Trastuzumab, also known
as Herceptin, is a monoclonal antibody drug for certain subtypes of breast cancer that exhibit
overexpression of a specific gene, HER2, which is amplified in up to 30% of breast cancers
[53, 54]. A class of drugs, many of which are now FDA-approved, called checkpoint inhibitors,
attempt to block the mechanism that cancer cells use to circumvent the immune system, and
improved clinical outcome for drugs that target PD-1 may be associated with overexpression of
PD-L1 [55]. Given the efficacy of these expression-based drugs, identifying overexpression in
individual patients is a simultaneously important as well as difficult task. Existing tools for de-
tecting differential expression are designed under optimal experimental conditions where both
groups consist of several technical or biological replicates, which are not typically available in
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a clinical setting where one group consists of only a single patient [56, 57, 58, 59, 60].
1.5 Additional work and contributions
During my time as a doctoral student, I was able to contribute to several projects and
manuscripts that are outside the primary scope of the thesis and will be briefly summarized
in this section. While preparing for the large-scale RNA-seq compute described in chapter 2, I
collaborated with Kate Rosenbloom of the UCSC Genome Browser to generate the browers first
gene expression track based on GTEx data [2, 61]. This GTEx track visualizes tissue-specific
gene expression data across 53 tissues from 570 donors with annotations from GENCODE and
displays a bar graph of expression for each gene, per-sample read density, and tissues colored
by GTEx project conventions [61]. After successful completion of the Toil compute project, I
collaborated with Jingchun Zhu, Mary Goldman, and Brian Craft of the UC Santa Cruz Xena
Platform to publicly host all of the gene expression data the Xena browser [62]. Xena both
publicly hosts the raw data and also provides a visualization platform to view the data which
combines the ability to view genomic data alongside clinical metadata that I curated for TCGA,
GTEx, and TARGET. This collaboration led to my appointment as a GTEx consortium author
as part of the Genome Browser Data Integration & Visualization group [63].
My interest in cancer research led me to start collaborating with the Treehouse pedi-
atric group who are interested in leveraging the Toil RNA-seq data for their research in iden-
tifying therapeutic leads for pediatric patients who fail to respond to standard-of-care therapy.
They achieve this by comparing gene expression data from the patient to the Treehouse gene
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expression compendium – the bulk of which comprises data I generated during the Toil compute
project (chapter 2) [?]. Treehouse uses the toil-rnaseq workflow I wrote to ensure all of their
RNA-seq data is uniformly processed [64]. Gene expression quantification data that I produced
formed the majority of data used in two of Treehouse’s abstract submissions to the American
Association for Cancer Research (AACR), which discuss gene expression comparisons for sin-
gle pediatric patients as well as a framework for integrating pan-cancer analysis into clinical
interpretation of pediatric cancer genomic data [65, 66].
I also assisted Treehouse in their processing of RNA-seq expression data by develop-
ing a tool for efficient pairing of FASTQ files. The toil-rnaseq workflow has strict QC criterion
that rejects improperly paired FASTQ files, as some downstream tools, like STAR, will silently
toss out thousands or even millions of reads during alignment as it searches for the mismatched
read pair. Treehouse informed me that ∼10-20% of their input data fails due to this reason
alone, and that existing FASTQ pairing algorithms were very slow or consumed a large amount
of memory and scaled poorly as the size of the sequence data increased. I collaborated with
my colleague, Joel Armstrong to evaluate existing FASTQ pairing algorithms [67, 3]. One of
these algorithms inefficiently reads and stores the entirety of one FASTQ into an in-memory
hash table and then iterates over the second file to find pairs and output them. The second
method iterates through both files simultaneously and only stores unpaired reads until its mate
pair is eventually encountered. We rewrote both of these algorithms in Rust, a modern low-level
language that is comparable to C in terms of achievable algorithm speed, and designed two ad-
ditional algorithms based on storing the byte position of the read for retrieval with seek [68].
The time and memory improvements of our Rust implementations were significant and can be
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Method Time (m) Max Memory (G)
EdwardsLab 9.9 16
Store 2.1 7.5
Seek 4.25 1.9
Iter 1.45 < 0.5
Table 1.1: Benchmarks of different FASTQ pairing implementations for a pair of 6GB FASTQ
files where one file had 10% of its reads shuffled. The Store method is the same algorithm
employed by EdwardsLab, but written in Rust. The Iter method is taken from the Bernatchez
lab, but their Python implementation was not functioning at the time of benchmarking for com-
parison [3]. The Seek method stores the byte position of every read in the first FASTQ file and
during iteration of the 2nd FASTQ file, seeks to the appropriate mate pair. We are currently
developing a Seek-Iter method, that aims to combine the benefits of iterating through both files
simultaneously with the efficiency of storing byte positions of the reads instead of the entire
read sequence and quality score.
seen in Table 1.1. I have made this software freely available for anyone to use or modify at
https://github.com/jvivian/fastq_pair.
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2Scalable workflow execution platform for
large-scale genomic analysis
“We scientists are clever – too clever – are you not satisfied? Is four square
miles in one bomb not enough? Men are still thinking. Just tell us how big you want
it!”
– Richard Feynmann, Genius: The Life and Science of Richard Feynman
In this chapter, I describe a computational tool that can be used to write genomic
workflows that are capable of efficiently scaling to thousands of samples using distributed cloud
computing without requiring any changes to the underlying source code. I demonstrate its
use by writing an RNA-seq quantification workflow and uniformly processing ∼20,000 patient
samples on a commercial cloud system in only a few days. This tool is well-suited for describing
and executing genomic workflows cheaply and efficiently due to design considerations that
allow users to take advantage of commercial cloud provision bidding and generate job graphs
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dynamically, which is not a feature found in most workflow languages. This work was originally
published in April 2017 in Nature Biotechnology under the title “Toil enables reproducible, open
source, big biomedical data analyses”.
2.1 Abstract
Toil is portable, open-source workflow software that supports contemporary workflow
definition languages and can be used to securely and reproducibly run scientific workflows
efficiently at large-scale. To demonstrate Toil, we processed over 20,000 RNA-seq samples
to create a consistent meta-analysis of five datasets free of computational batch effects that
we make freely available. Nearly all the samples were analysed in under four days using a
commercial cloud cluster of 32,000 preemptable cores
2.2 Introduction
Contemporary genomic data sets contain tens of thousands of samples and petabytes
of sequencing data [1, 69, 70]. Pipelines to process genomic data sets often comprise dozens
of individual steps, each with their own set of parameters [71, 72]. Processing data at this scale
and complexity is expensive, can take an unacceptably long time, and requires significant engi-
neering effort. Furthermore, biomedical data sets are often siloed, both for organizational and
security considerations and because they are physically difficult to transfer between systems,
owing to bandwidth limitations. The solution to better handling these big data problems is
twofold: first, we need robust software capable of running analyses quickly and efficiently, and
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second, we need the software and pipelines to be portable, so that they can be reproduced in any
suitable compute environment.
Here, we present Toil, a portable, open-source workflow software that can be used
to run scientific workflows on a large scale in cloud or high-performance computing (HPC)
environments. Toil was created to include a complete set of features necessary for rapid large-
scale analyses across multiple environments. While several other scientific workflow software
packages offer some subset of fault tolerance, cloud support and HPC support, none offers
these with the scale and efficiency to process petabyte and larger-scale data sets efficiently
[73, 18, 16]. This sets Toil apart in its capacity to produce results faster and for less cost
across diverse environments. We demonstrate Toil by processing > 20,000 RNA-seq samples
(Figure 2.1). The resulting meta-analysis of five data sets is available to readers [62]. The
large majority (99%) of these samples were analyzed in under 4 days using a commercial cloud
cluster of 32,000 preemptable cores.
To support the sharing of scientific workflows, we designed Toil to execute common
workflow language and provide draft support for workflow description language (WDL). Both
CWL and WDL are standards for scientific workflows [74, 75]. A workflow comprises a set
of tasks, or jobs, that are orchestrated by specification of a set of dependencies that map the
inputs and outputs between jobs. In addition to CWL and draft WDL support, Toil provides a
Python application program interface (API) that allows workflows to be declared statically, or
generated dynamically, so that jobs can define further jobs during execution and therefore as
needed (Toil architecture B.1). The jobs defined in either CWL or Python can consist of Docker
containers, which permit sharing of a program without requiring individual tool installation or
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Figure 2.1: RNA-seq pipeline and expression concordance. (left) A dependency graph of the
RNA-seq pipeline we developed. CutAdapt was used to remove extraneous adapters, STAR was
used for alignment and read coverage, and RSEM and Kallisto were used to produce quantifica-
tion data. (right) Scatter plot showing the Pearson correlation between the results of the TCGA
best-practices pipeline and the CGL pipeline. 10,000 randomly selected sample and/or gene
pairs were subset from the entire TCGA cohort and the normalized counts were plot against
each other; this process was repeated five times with no change in Pearson correlation. The unit
for counts is: log2(normalized counts + 1).
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configuration within a specific environment. Open-source workflows that use containers can
be run regardless of environment. We provide a repository of genomic workflows as examples
[76]. Toil supports services, such as databases or servers, that are defined and managed within a
workflow. Through this mechanism it integrates with Apache Spark, and can be used to rapidly
create containerized Spark clusters [77, 78].
Toil runs in multiple cloud environments including those of Amazon Web Services
(AWS), Microsoft Azure, Google Cloud, OpenStack, and in HPC environments running Gri-
dEngine or Slurm and distributed systems running Apache Mesos (Forest Hill, MD, USA)
[79, 80, 81]. Toil can run on a single machine, such as a laptop or workstation, to allow for
interactive development, and can be installed with a single command. This portability stems
from pluggable backend APIs for machine provisioning, job scheduling and file management
(Toil architecture B.1). Implementation of these APIs facilitates straightforward extension of
Toil to new compute environments. Toil manages intermediate files and checkpointing through
a job store, which can be an object store like AWSs S3 or a network file-system. The flexibility
of the backend APIs allow a single script to be run on any supported compute environment,
paired with any job store, without requiring any modifications to the source code.
Toil includes numerous performance optimizations to maximize time and cost effi-
ciencies. Toil implements a leader/worker pattern for job scheduling, in which the leader del-
egates jobs to workers. To reduce pressure on the leader, workers can decide whether they are
capable of running jobs immediately downstream to their assigned task (in terms of resource
requirements and workflow dependencies). Frequently, next-generation sequencing workflows
are I/O bound, owing to the large volume of data analyzed. To mitigate this, Toil uses file
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Figure 2.2: Costs and core usage. (left) Scaling tests were run to ascertain the price per sample
at varying cluster sizes for the different analysis methods. TCGA (red) shows the cost of running
the TCGA best- practices pipeline as re-implemented as a Toil workflow (for comparison).
CGL-One-Sample/Node (cyan) shows the cost of running the revised Toil pipeline, one sample
per node. CGL (blue) denotes the pipeline running samples across many nodes. CGL-Spot
(green) is the same as CGL, but denotes the pipeline run on the Amazon spot market. The
slight rise in cost per sample at 32,000 cores was due to a couple of factors: aggressive instance
provisioning directly affected the spot price (dotted line), and saving bam and bedGraph files
for each sample. (right) Tracking number of cores during the recompute. The two red circles
indicate where all worker nodes were terminated and subsequently restarted shortly thereafter.
21
caching and data streaming. Where possible, successive jobs that share files are scheduled on
a single node, and caching prevents the need for repeated transfers from the job store. Toil is
robust to job failure because workflows can be resumed after any combination of leader and
worker failures. This robustness enables workflows to use low-cost machines that can be ter-
minated by the provider at short notice and are currently available at a significant discount on
AWS and Google Cloud. We estimate the use of such preemptable machines on AWS lowered
the cost of our RNA-seq compute job 2.5-fold, despite encountering over 2,000 premature ter-
minations (Figure 2.2). Toil also supports fine-grained resource requirements, enabling each
job to specify its core, memory and local storage needs for scheduling efficiency.
Controlled-access data requires appropriate precautions to ensure data privacy and
protection. Cloud environments offer measures that ensure stringent standards for protected
data. Input files can be securely stored on object stores, using encryption, either transparently
or with customer managed keys. Compute nodes can be protected by SSH key pairs. When run-
ning Toil, all intermediate data transferred to and from the job store can be optionally encrypted
during network transmission and on the compute nodes drives using Toils cloud-based job store
encryption. These and other security measures help ensure protection of the input data, and
as part of a broader security plan, can be used to ensure compliance with strict data security
requirements.
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2.3 Results
To demonstrate Toil, we used a single script to compute gene- and isoform-level ex-
pression values for 19,952 samples from four studies: The Cancer Genome Atlas (TCGA),
Therapeutically Applicable Research To Generate Effective Treatments (TARGET), Pacific
Pediatric Neuro-Oncology Consortium (PNOC), and the Genotype Tissue Expression Project
(GTEx) [1, 2]. The data set comprised 108 terabytes. The Toil pipeline uses STAR to generate
alignments and read coverage graphs, and performs quantification using RSEM and Kallisto
[60, 57, 82] (Figure 2.1). Processing the samples in a single batch on ∼32,000 cores on AWS
took 90 h of wall time, 368,000 jobs and 1,325,936 core hours. The cost per sample was
$1.30, which is an estimated 30-fold reduction in cost, and a similar reduction in time, com-
pared with the TCGA best-practices workflow [72]. We achieved a 98% gene-level concordance
with the previous pipelines expression predictions (Figure 2.1). Notably, we estimate that the
pipeline, without STAR and RSEM, could be used to generate quantifications for $0.19/sam-
ple with Kallisto. To illustrate portability, the same pipeline was run on the I-SPY2 data set
(156 samples) using a private HPC cluster, achieving similar per sample performance [83].
Expression-level signal graphs (read coverage) of the GTEx data (7,304 samples from 53 tis-
sues, 570 donors) are available from a UCSC Genome Browser public track hub [84]. Gene and
isoform quantifications for this consistent, union data set are publicly hosted on UCSC Xena
and are available for direct access through a public AWS bucket [62].
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2.4 Discussion
Although there is an extensive history of open-source workflow-execution software,
the shift to cloud platforms and the advent of standard workflow languages is changing the
scale of analyses [73, 18, 16]. Toil is a portable workflow software that supports open com-
munity standards for workflow specification and enables researchers to move their computation
according to cost, time and data location. For example, in our analysis the sample data were
intentionally co-located in the same region as the compute servers in order to provide optimal
bandwidth when scaling to thousands of simultaneous jobs. This type of flexibility enables
larger, more comprehensive analyses. Further, it means that results can be reproduced using
the original computations set of tools and parameters. If we had run the original TCGA best-
practices RNA-seq pipeline with one sample per node, it would have cost ∼$800,000. Through
the use of efficient algorithms (namely STAR and Kallisto) and Toil, we were able to reduce
the final cost to $26,071. We have demonstrated the utility of Toil by creating one of the single
largest, consistently analyzed, public human RNA-seq expression repositories, which we have
made publicly available to the community.
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3Leveraging reproducible software to
circumvent data barriers
“All in all, you’re just another brick in the wall”
– Pink Floyd, The Wall
In this chapter, I describe how a properly designed reproducible and portable work-
flow is capable of running on thousands of samples in the cloud and be used as a tool to extract
critical research data from data silos like pediatric hospitals. We demonstrate this second point
by describing how Treehouse, a pediatric precision medicine group that leverages RNA-seq to
identify potential therapeutic leads for patients, used such a workflow to extract > 200 sam-
ples from four separate pediatric hospitals in both the United States as well as Canada, without
ever exposing the patient’s underlying sequence data to risk. In addition, this same workflow
is being used to process more than 900 samples in the St. Judes cloud repository. This work
is in the process of submission under the title “Leveraging reproducible software to circumvent
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data barriers: a case study for pediatric cancer research,” with the following co-authors: Holly
C. Beale, Rob Currie, Isabel Bjork, Katrina Learned, Lauren Sanders, Ellen Kephart, Olena
Morozova Vaske, and Benedict Paten.
3.1 Abstract
Data barriers hinder scientific progress and stymie research collaboration by denying
access to large amounts of biomedical information. Such barriers occur due to the twin needs
for patient privacy and protection against potential liability on behalf of data stewards. One
potentially effective solution to this problem relies on the design of reproducible software, ca-
pable of running on a third partys system that produces anonymized secondary output to be sent
back to the researcher for analysis. This computation-to-data method also addresses the logis-
tical difficulty of securely sharing and storing large amounts of primary sequence data. Here
we present a case study on how Treehouse, a pediatric cancer research group, leverages this
strategy to expand the amount of pediatric cancer samples in their compendium, which they use
for analysis and make freely available to researchers everywhere.
3.2 Introduction
In terms of data acquisition, storage, and distribution, researchers project genomics
data to become the largest big data domain in science [10]. Efforts like Trans-Omics for Preci-
sion Medicine, Centers for Common Disease Genomics, All-of-Us, Regeneron Genome Project,
and The 100,000 Genomes Project each produce massive amounts of researcher accessible data
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[85, 86, 87, 88, 89]. To ease and broaden access, initiatives like the Global Alliance for Ge-
nomics and Health (GA4GH) aim to establish protocols and standards for how to share ge-
nomics data [26]. Yet despite the genomics communitys long-standing practice of promoting
responsible data sharing, access to primary data often remains a challenge that prevents scien-
tists from comparing findings [90, 91, 24, 92]. While modern informed consent agreements
for adult studies tend to include a data sharing clause that the patient can opt out of, pediatric
consent forms tend to be more restrictive as the child cannot provide consent and therefore only
allow medical personnel directly involved in the study access to the patients DNA sequence [93].
Despite one studys finding that 74% of parents are willing to consent to broad public release of
genomic data, there are significant ethical dilemmas associated with a guardian agreeing to pub-
lically share genomics information of a minor [94]. Of particular concern is access to sequence
data, which is understandably restrictive given the possibility of patient re-identification. Even
when the sequence data is only exposed through a binary yes/no allele-presence query response,
such as a GA4GH Beacon, re-identification is possible through repeated queries, as the vast ma-
jority of functionally important variants are rare [95]. As a consequence, most sequencing data
intended for qualified researchers is subject to controlled access and often requires proposals
for data use that are complicated by internal review, legal review, and international law [36].
This is particularly bothersome given that the primary sequence data is not always directly
needed by analysts and researchers, but rather some secondary output like a gene-level variant
interpretation, or measure of RNA-seq expression. Another barrier to data access is practical-
ity: securely transferring and storing large amounts of sequence data is often a computational
bottleneck when collaborating across institutions and systems, and is oftentimes both logisti-
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cally difficult as well as prohibitively expensive. These trends have pushed institutions to host
genomics data in centralized or cloud-based repositories that ease access and, in some cases,
allow analysis to be done remotely by processing the data in situ [31, 34]. Despite the trend
toward more centralized cloud environments, however, the landscape of data silos remains large
and complex. Furthermore, due to regulatory and privacy concerns, this situation will likely be
slow to evolve. The Treehouse Childhood Cancer Initiative at UC Santa Cruz collects RNA-seq
expression data from patients and compares this to other pediatric and adult cancers to identify
situations where an adult drug may be applicable [36]. As Treehouses methodology compares
samples to similar patients, and many pediatric cancers are rare, greater access to pediatric data
strengthens the power of Treehouses analysis [35]. Treehouses compendia draw samples from
multiple sources, large contributions coming from The Cancer Genome Atlas, the Genotype
Tissue Expression Consortium, and the Therapeutically Applicable Research to Generate Ef-
fective Treatments [1, 63, 96]. Data collected from disparate sources often suffers from labora-
tory and computational batch effects the latter of which necessitates the need for reproducible
analysis workflows. Efforts like Dockstore, a repository for scientific workflows, emphasize
the communitys commitment to making it possible to readily reproduce analysis workflows
[97]. Dockstore requires that all hosted workflows use description languages adopted by the
GA4GH driver projects Common Workflow Language, Workflow Description Language, and
Nextflow [74, 75, 98]. As an example of the utility of this reproducible workflow approach,
a majority of Treehouses samples were computed in a large-scale project that used a scalable
and reproducible RNA-seq workflow to process around 20,000 samples in just a few days on
a commercial cloud system highlighting the value of moving genomics data to the cloud [19].
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This workflow uses Toil, a scalable and efficient cross-platform workflow management system,
which has allowed us to progressively update the dataset from the recompute over time and
keep it computationally consistent. For example, our group has since added gene expression
data for the entirety of the Cancer Cell Line Encyclopedia to this repository located on the pub-
licly accessible Xena Browser at https://bit.ly/2HR7wKN [99, 62]. Here we describe how,
after encountering barriers and delays while attempting to access primary sequence data from
several sources, Treehouse was able to ship the compute method to the data in order to build
larger compendia of pediatric data that they make publicly available.
3.3 Methods
Docker is a cross-platform compatible virtualization system that ensures research is
computationally reproducible, regardless of where the software is run or what environment and
hardware the institution may possess [100]. Additionally, Docker images are easily distributed
and image hashes can be used to validate that the proper image is always being used giving
researchers confidence the results do not contain computational batch effects that stem from
differences in software versioning, dependencies, and environment. The RNA-seq workflow
that Treehouse uses, toil-rnaseq, encapsulates individual tools within immutable Docker images
so that each tools unique set of dependencies are isolated and do not conflict with any other tool
or dependency (Figure B.3) [101]. Treehouse employs gene expression data obtained from
one path in the workflow: sequence data is aligned with STAR and then gene expression is
generated from RSEM [82, 57]. This data is then publicly hosted on the Xena Browser, a
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platform for analyzing and visualizing genomics data sets [62]. Using this distributable compute
system, Treehouse reached out to collaborators who possess controlled access data that they are
unable to share. For example, collaborators in Canada are unable to move pediatric sequencing
data out of the hospital due to Canadian law. An ambassador for Treehouse contacted several
pediatric hospitals and explained that they could contribute valuable information to pediatric
research without exposing the underlying sequence data, violating patient privacy concerns,
or exposing the data stewards to risk. Treehouse then worked with amenable hospitals to get
the software running on each hospitals own compute infrastructure, securing more than 100
additional pediatric samples with more than 150 additional samples on the way (Table 3.3).
Treehouse also has taken advantage of the St. Jude Cloud, which allows Dockerized analysis
software to run on hundreds of pediatric RNA-seq samples and illustrates the collaborative
opportunities that emerge when data is moved to cloud-based repositories [34].
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Institution # of Patient Samples Deposited in Compendium / Available
Canada’s Michael Smith
Genome Sciences Centre
39 Yes
The Hospital for
Sick Children
130 Awaiting data
Nationwide Childrens Hospital 65 Yes
Childrens Hospital
of Los Angeles
30 Awaiting data
St. Judes 905
106 in compendium and
796 out of 799 remaining
samples processed
Table 3.1: Number of patient samples obtained from different pediatric hospitals using the
methodology we describe of sending the compute directly to the data. This allowed expeditious
acquisition of pediatric samples that may have never been obtainable, or taken months to procure
due to the stringent data agreements required to transfer the patients sequence data. Underly-
ing sequence data for patients was never exposed to non-credentialed individuals and all gene
expression information was generated on-site by the hospital, patient labels were anonymized,
and then transferred to Treehouse.
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3.4 Discussion
The FAIR principles of scientific data management: Findable, Accessible, Interoper-
able, and Reproducible, are critical for scientific progress by easing the sharing of both data and
analytical tools [28]. By designing deterministic, portable, and cloud-compatible workflows,
we enable interoperability and reproducibility between large compendium datasets and small
silo datasets. This leaves a need for findable and accessible datasets ideally centralized in a
cloud environment with broad accessibility to research groups who can easily download the
data. For more controlled datasets, there needs to exist a standard system for sending analytical
tools that can run on the protected data in order to allow researchers to gather necessary in-
formation. A common repository for data notes, which describe datasets and encourage reuse,
could be coupled with analysis notes that allow identification of downstream compendiums and
how they were processed, enabling researchers to coordinate compute efforts more efficiently.
By leveraging portable and reproducible compute and participating in persistent outreach ef-
forts, Treehouse has expanded its access to critical pediatric data that otherwise would have
been almost impossible to access in an expeditious manner. We believe this is a useful model
for enabling data sharing. As the genomics community continues to fund large-scale projects
that will generate petabyte-scale datasets, the future of bioinformatic collaboration will likely
revolve around cloud-based storage where Dockerized analysis workflows can be sent to run
on the data removing the costs and legal concerns of storing and transferring the data to a new
location while removing the lengthy back-and-forth exchanges that often take place between
research groups and data stewards before critical analysis can be done (Figure 3.1). Despite
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these advantages, the genomics community will have to remain vigilant to protect patient pri-
vacy and stay aware of potential risks that will be exposed during this paradigm shift, such as
maliciously-designed software that scrapes personal data and attempts to export it alongside ap-
proved output. We at Treehouse hope our experience inspires other research groups to persist in
acquiring critical data by circumventing these common data barriers that impede collaborative
research.
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Figure 3.1: Deploying a single workflow to both large-scale cloud environments as well as
individual repositories containing controlled access data. Non-controlled secondary output from
these workflows can then be consolidated into large public data repositories that any researcher
can access. This method of shipping a portable and reproducible workflow directly to the data
is an effective way to target large genomic cloud repositories as well as individual data centers.
Costs surrounding data transfer and storage are circumvented as well as any requirements to
obtain access to the underlying data the workflow is running on, assuming the output of the
workflow does not require controlled access.
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4A Bayesian Framework for Detecting Gene
Expression Outliers in Individual Samples
“My greatest concern was what to call it. I thought of calling it ‘infor-
mation,’ but the word was overly used, so I decided to call it ‘uncertainty.’ When I
discussed it with John von Neumann, he had a better idea. Von Neumann told me,
‘You should call it entropy, for two reasons. In the first place your uncertainty func-
tion has been used in statistical mechanics under that name, so it already has a name.
In the second place, and more important, no one really knows what entropy really is,
so in a debate you will always have the advantage.’”
– Claude Shannon, Scientific American (1971)
In this chapter, I describe my work on a robust statistical framework for detecting
gene expression outliers by appropriately choosing subsets of a large background comparison
cohort. This unsupervised process weights background datasets and then produces a posterior
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distribution for each gene of interest that can be used to calculate posterior predictive p-values.
Our method has several advantages over existing methods in the same space: continuous p-
values over binary output, automatic selection of the appropriate background dataset(s), as well
as being robust to false positives, imperfect or sparse comparison sets, and samples of unknown
origin or mixed lineage. This manuscript was submitted as a preprint in June 2019 under the
title “A Bayesian Framework for Detecting Gene Expression Outliers in Individual Samples,”
with the following co-authors: Jordan Eizenga, Holly C. Beale, Olena Morozova Vaske, and
Benedict Paten.
4.1 Abstract
Objective: Many antineoplastics are designed to target upregulated genes, but quantifying up-
regulation in a single patient sample requires an appropriate set of samples for comparison. In
cancer, the most natural comparison set is unaffected samples from the matching tissue, but
there are often too few available unaffected samples to overcome high inter-sample variance.
Moreover, some cancer samples have misidentified tissues or origin, or even composite-tissue
phenotypes. Even if an appropriate comparison set can be identified, most differential expres-
sion tools are not designed to accommodate comparing to a single patient sample. Materials
and Methods: We propose a Bayesian statistical framework for gene expression outlier de-
tection in single samples. Our method uses all available data to produce a consensus back-
ground distribution for each gene of interest without requiring the researcher to manually select
a comparison set. The consensus distribution can then be used to quantify over- and under-
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expression. Results: We demonstrate this method on both simulated and real gene expression
data. We show that it can robustly quantify overexpression, even when the set of comparison
samples lacks ideally matched tissues samples. Further, our results show that the method can
identify appropriate comparison sets from samples of mixed lineage and rediscover numerous
known gene-cancer expression patterns. Conclusions: This exploratory method is suitable for
identifying expression outliers from comparative RNA-seq analysis for individual samples and
Treehouse, a pediatric precision medicine group that leverages RNA-seq to identify potential
therapeutic leads for patients, plans to explore this method for processing their pediatric cohort.
4.2 Introduction
RNA-seq has been used in the cancer field for a number of purposes: to examine
differences between tumor and normal tissue, to classify cancers for diagnostics, and–with the
advent of single cell RNA-seq–to characterize tumor heterogeneity [102, 103, 104, 105, 106,
107]. Recently, precision medicine researchers have also begun exploring RNA-seqs potential
to aid in target selection and drug repositioning by identifying clinically actionable aberrations
in tumor samples [48, 49, 51, 50]. Clinical studies have demonstrated actionable findings for up
to 50% of patients through RNA-seq analysis, particularly for pediatric patients who often do
not possess actionable coding DNA mutations [108, 109, 110, 111, 112]. This has led to efforts
like Treehouse, a precision medicine initiative for pediatric cancer that evaluates the utility of
RNA-seq analysis to inform clinical interpretation. Treehouse has created a large compendium
of open-access cancer gene expression data, which is incorporated into their analysis [113, 114,
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115].
Protocols for such precision medicine initiatives involve identifying up-regulated drug-
gable gene targets as therapeutic leads. Differential expression is commonly used to identify up-
and down-regulation of genes between two groups of samples. However, most differential ex-
pression tools operate best under experimental conditions where both groups consist of several
technical replicates, or lacking that, biological replicates [56, 57, 58, 59]. Thus, most existing
tools are poorly suited to the clinical setting, where one group consists of only a single biolog-
ical replicate from one patient (N-of-1), and the other comparison group is a library of diverse
potential comparison samples. In particular, none of the existing methods have any way of sug-
gesting what an appropriate subset of the sample library should be used for comparison. This
limitation is especially acute in cancer, where uncertainty as to the cell of origin, histological
complexity, and metastasis can make it difficult to identify the appropriate reference tissue for a
sample [116]. While some work exists to address statistical uncertainty of working with N-of-1
samples [117], we focus on solving the second problem, which is the principled selection of an
appropriate comparison set.
Existing N-of-1 protocols compare targeted genes in an N-of-1 sample to an outlier
cutoff generated from a large compendium of either cancer samples or unaffected tissue in order
to determine whether a gene is up-regulated [118, 113, 119]. While this outlier cutoff method
is fast, there are some notable drawbacks. Applying a cutoff binarizes data, which makes it
difficult to meaningfully rank outliers or to be aware of samples just short of meeting the cutoff.
This cutoff method is also intended for Gaussian distributions, which is empirically common
for gene expression within a tissue group, but not typical when considering the distribution of
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expression across tissues [118].
Ultimately, the most difficult problem is justifying the choice of what samples con-
stitute the comparison set that generates the cutoff, since different comparison sets will identify
different genes as outliers. Many normal comparison datasets are small (almost half of The
Cancer Genome Atlas (TCGA) normal tissues have 10 or fewer samples), so they lack the sta-
tistical power to characterize the variability of expression landscape in the normal tissue on
their own [1]. This power can be increased by also including samples from different tissues,
but including tissues with larger sample sizes can drown out the information from the matched
tissue. In addition, it is unclear which other tissues should be included in the pooled comparison
set.
These concerns led us to propose a new approach for identifying outliers for N-of-1
samples. In contrast to previous methods, our method adaptively constructs a meaningful com-
parison set and avoids selection bias by automatically weighting the background sets to generate
a consensus distribution of expression. It then uses the consensus distribution to quantify over-
expression for genes of interest.
4.3 Materials and methods
The core of our method is a Bayesian statistical model for the N-of-1 samples gene
expression. The model implicitly assumes that the samples gene expression can be approxi-
mated by a convex mixture of the gene expression of the background datasets. The coefficients
of this mixture are shared across genes, much like a linear model in which each data point is
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the vector of expressions for a gene across the background datasets. In addition, we model ex-
pression for each gene from each background dataset as a random variable itself. This allows us
to incorporate statistical uncertainty from certain background sets small sample size directly in
the model without drowning out any background sets contribution through pooling Figure 4.1.
4.3.1 Model Specification
Suppose we have a n background datasets for expression, which we will call X1, · · · ,Xn.
Within each background set d = 1,2, · · · ,n, we model the expression of gene g as a normal-
distributed random variable:
xd,g ∼N (µd,g,σd,g)
The parameters of each of these normal distributions are distributed according to a
shallow but proper normal-inverse gamma prior:
µd,g,σ2d,g ∼N IG(0,1,1/2,1)
Next we assume there is another unobserved random variable xˆd,g from the same
distribution N (µd,g,σd,g). Conceptually, this corresponds to the expression value that the back-
ground distribution would influence the N-of-1 sample to take for that gene. We model the
expected expression yˆg from a new sample as a convex combination of the unobserved expres-
sion values across the datasets.
yˆg = β1xˆ1,g + · · ·+βnxˆn,g
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β∼ Dirichlet(1, · · · ,1)
Note that β is shared across all genes. A Dirichlet distribution was chosen for β to
enforce the convexity constraint. Finally, we model the observed expression of the new sample
yg, which adds Laplacian error to the expected expression yˆg:
yg = yˆg + εg
εg ∼ Laplace(0,τ)
τ∼ IG(1,1)
The distribution of the model error ε is shared between genes and incorporates un-
certainty into the posterior to account for variance generated by a poor match of the N-of-1 to
any particular background group, weak model fitting, and biological and technical noise. We
use a Laplace distribution instead of the more conventional normal because we are interested in
identifying expression outliers. The Laplace distribution is heavier-tailed, so it will fit to out-
liers less aggressively and thereby preserve their outlier status. This model fits the data well for
most cases. However, it behaves poorly on genes that have large variances in the background
dataset. The reason is that the ε parameter has a uniform scale across genes. This causes expres-
sion outliers that are modest relative to the variance appear to be more significant. To address
this limitation, we normalize the background datasets for variance, but not for location. This
normalization step must be incorporated into the model specification, since it is not known a
priori which background datasets the model will learn to be important, and different background
datasets have different variances. This leads to the following equation:
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which simplifies to
yg =
∑d
βd
σd xˆd + εg
∑d
βd
σd
The model can be explored using Markov chain Monte Carlo (MCMC) to obtain
samples for yg that approximate its posterior distribution. If we have an observed expression
value for a gene of interest (from the N-of-1 cancer sample), we can compare it to the sampled
values. The proportion of sampled values for yg that are greater (or lesser) than the observed
value is an estimate of the posterior predictive p-value for this expression value. The posterior
predictive p-value can be seen as a measure of how much of an outlier the expression is given
the expectations of the comparison set.
The model is implemented in PyMC3 and each N-of-1 sample is trained using the
No-U-turn MCMC sampler [120, 121]. Due to the computational burden of sampling from the
model, we employ some computational tricks to reduce runtime. First, we integrate out the µd,g
and σd,g parameters so that each xˆd,g is distributed according to a posterior predictive Student-t.
Given our choice of a Dirichlet distribution for β, most of the background datasets are assigned
0 weight which means it is inefficient to include all n background datasets for every training run.
Instead, background datasets are heuristically ranked for similarity to the N-of-1 sample by a
combination of analysis of variance (ANOVA) and pairwise distance, and then iteratively added
until the posterior predictive p-values converge to Pearson correlation > 0.99 (section D.6). The
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Figure 4.1: Bayesian plate notation of the model. The plates (G) and (D) stand for Gene and
Dataset respectively. x represents gene expression for one background dataset and is multiplied
by the dot product of βT to produce the convex combination yˆ. We specify ”jointly Dirichlet” as
there is not one Dirichlet distribution per background dataset. Instead, each background dataset
is one component of the Dirichlet α vector. We add Laplacian error ε to the expected expression
yˆ when modeling the observed expression of a new sample y.
model is available as a Python package for convenience, a Docker container for reproducibility,
and a Toil workflow for scalability. The software also provides comprehensive output to aid
users in interpreting model results (section D.9).
4.4 Results
4.4.1 TCGA & GTEx validation
We ran the model on 977 TCGA tumor samples – spanning ten different tissues that
had corresponding normals in The Genotype-Tissue Expression Consortium (GTEx) – using
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Figure 4.2: HeatMap of the average model weight assigned to GTEx tissues across tumor sub-
types in TCGA. The model assigns a majority of weight to the matched tissue in GTEx for
every tumor subtype. Only two tumor tissues, bladder and stomach, received less than 60%
of the average model weight. GTEx has only 9 bladder samples and PCA shows those bladder
samples cluster on top of minor salivary gland and vagina samples which helps explain its lower
average weight relative to other tumor types (subsection D.1.1).
normals from GTEx and TCGA as different background datasets (Figure 4.2, section D.1) [2].
For every group of samples within a tissue type, the matched tissue in GTEx or TCGA-normal
was afforded a majority of the model weight with only two groups of samples receiving less than
60% of all total weight: bladder and stomach. Dimensionality reduction reveals that bladder
and stomach samples tend to cluster near other tissue groups that the model assigns weight to
(subsection D.1.1). Despite GTEx and TCGA being independent projects and with no attempts
to correct for batch effects, the model identifies the corresponding tissue for most samples.
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4.4.2 Negative control
As a negative control experiment, we ran 100 samples across ten GTEx tissues using
three different backgrounds: TCGA tumor, TCGA normal, and GTEx. Our expectation was
that there would be relatively few outliers when either normal (non-cancer) dataset is used as
the background comparison set relative to TCGA-tumor. Figure 4.3A shows that when either
GTEx or TCGA-normals were used as the background dataset, the gene p-values shrink towards
the middle and outliers are rarely identified. The model tends to assign almost all weight to the
N-of-1s matched tissue in GTEx or TCGA-normal, and the N-of-1 does not deviate significantly
from other samples in that tissue group, with few exceptions.
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Figure 4.3: Different aspects of model robustness. (A) Robustness to false positives. Nega-
tive control experiment where 100 GTEx samples were run using GTEx, TCGA-normal, and
TCGA-tumor as different backgrounds. Since posterior predictive p-values measure how dif-
ferent the observed result is from model expectations, we assume that using normal tissues as
backgrounds for GTEx N-of-1 samples will result in a peak around 0.5 and very few outliers
compared to when TCGA-Tumor is used as a background. (B) Robustness to imperfect com-
parison sets. The effect that removing a matched tissue has on the gene p-values the model
generates as measured by Pearson correlation. The x-axis is the weight assigned to the matched
tissue by the model. Gene p-values are relatively consistent even when a matched tissue is re-
moved, particularly if the model can redistribute that weight to tissues of similar phenotypes.
(C) Robustness to mixed lineage samples. Average model weight of mixture samples generated
from random pairings of GTEx tissues. Samples were generated by averaging gene expression
between randomly sampled subsets of each tissue group. In most cases, the two tissues used
to generate the mixture are assigned the majority of the model weight, which is the expected
result. Three sets of mixture samples Adrenal-Brain, Brain-Lung, and Liver-Thyroid do not
get the same result. PCA of those mixture samples, in the context of similar tissues, shows
the generated mixture samples happen to cluster closer to other tissues than one or both of the
tissues used to generate the samples (subsection D.2.1). In these circumstances, we expect the
model to assign weight to those tissues that are more similar to the mixture samples.
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4.4.3 Testing model robustness by removing matched tissues
In most cases, our method is robust to situations in which there is no obvious matched normal
tissue (Figure 4.3B). To demonstrate this, we used our method with a comparison dataset in
which we artificially removed the tissue matched to the sample, and then we compared the
results with the restricted dataset to the results we obtain with the full dataset. The model will
often go from assigning almost all of the weight to the matched normal tissue to distributing it
among several other phenotypically similar tissues. However, in most tissues the model largely
compensates for the missing data in the final results: the p-values remain highly correlated to
those produced with the full dataset (section D.3). That said, the p-values do move slightly
away from the tails, indicating lower power to detect outliers.
4.4.4 Mixture simulation
We used a simulation to validate the methods ability to identify comparison sets in tumors of
non-specific lineage. Simulated N-of-1 samples were created by randomly selecting tissue pairs
from GTEx then averaging gene expression between random samples from those tissue pairs.
PCA of the mixture samples show a tight cluster in between the two clusters for the contributing
tissues (section D.2). Mixture samples were run through the model and the weights from the
two contributing tissues were collected (Figure 4.3C). Ideally, 50% of the model weight should
be assigned to each of the contributing tissues used to generate those mixture samples, which
is true for a majority of the tissue pairs. We would not want the model to split weight evenly
between the two contributing tissues if the generated mixtures happen to be more similar to
other tissue types in the background dataset. For mixture samples that did not match to the
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tissues used to generate them, dimensionality reduction clearly shows that other tissues happen
to cluster closer to the mixtures than one or both of the contributing tissues (subsection D.2.1).
4.4.5 Upregulated gene outlier counts across tumor subtypes
Gene amplification and overexpression are a common hallmark of cancer cells, resulting from
extra copies of a locus (amplicon) as well as other genetic and epigenetic changes. In many
cases, these changes occur in genes that are specific to their tissue of origin [122, 123, 124].
Many of these commonly mutated genes can be targeted by existing drugs [125]. Eighty-five
such druggable genes, mostly receptor tyrosine kinases, were curated and provided to us by
Treehouse. We calculated p-values for these genes using our method across the 977 TCGA
samples (Figure 4.4). Genes with p-values below a cutoff (¡ 0.05) that also appeared in more
than a third of the tumor samples within a subtype were all identified as known biomarkers
in the literature (subsection D.4.1). These include AURKA in both bladder and breast cancer
[126, 127, 128], AURKB, CDK4, EGFR, and PDGFRA in brain cancers and gliomas [129, 130,
131, 132, 133], MET in thyroid carcinomas and gastric cancers [134, 135, 136, 137], and ROS1
in lung cancers [138].
4.4.6 Exploring results for a single sample
To illustrate how our method is used in practice, we demonstrate the model on a single sam-
ple rather than summary statistics over many samples. Figure 4.5 compares our method on a
random tumor sample from TCGA to Treehouses standard practice approach of pooling normal
samples and applying a cutoff based on inner-quartile range on a selection of 85 cancer genes
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Figure 4.4: Outlier counts given an arbitrary p-value cutoff of 0.05. Eighty-five druggable
genes curated by Treehouse were used as the target gene set for this analysis. All genes with
counts for more than half of the samples within a tumor subtype were identified as known tumor
biomarkers within that subtype in the literature (subsection D.4.1.
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which could be targeted by an available therapy [119]. The random sample is labeled thyroid
carcinoma in TCGA. Over 8,000 samples from GTEx dataset were used as the comparative
normal dataset, categorized by tissue type. The model automatically weights each tissue group
and assigns a majority of the weight to thyroid tissue in GTEx. Where the pan-normal cut-
off method returns a binary classification for each of the selected genes, our method returns a
posterior predictive p-value generated from a distribution informed by the background datasets
that are most similar to the N-of-1 sample. Where there is disagreement in outlier classification
between the two methods (PIK3CB and CCND2), the posterior distribution can be examined in
the context of the highest weighted background dataset(s) to clearly understand how the p-value
was generated. For example, our method does not quantify PIK3CB as an outlier because it ig-
nores the expression contribution from non-thyroid tissues that have lower average expression
for this gene than normal thyroid tissue.
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Figure 4.5: Comparing results between a pan-normal cutoff approach and our model for a single
sample. (A) Gene expression distributions for 4 genes using the GTEx dataset, overlaid with
the gene expression value from our N-of-1 tumor in green and an outlier cutoff in red generated
from Tukey’s method (Q3 + IQR * 1.5). (B) Same plots as (A) along with the gene expres-
sion distribution for Thyroid in GTEx (orange) and the posterior predictive distribution (dotted
black). The posterior distribution closely matches the GTEx Thyroid distribution because the
model assigned almost all of the weight to that tissue. Posterior predictive p-values for each
gene were added to the plot titles which is based on the relative proportion of samples in the
posterior distribution greater than the value from the N-of-1 sample. (C) Trace plots for β and
ε from the MCMC sampling step. β is a Dirichlet distribution and sums to 1 and in this case
assigned essentially all model weight to Thyroid in GTEx.
4.5 Discussion
4.5.1 Method contribution
Our method avoids selection bias introduced by having to choose a single comparison back-
ground dataset. It also provides continuous p-values for genes that can be ranked and also avoid
missing borderline cases that would be ignored by existing cutoff methods. Moreover, in addi-
tion to under- and overexpression, the model quantifies the similarity of the analysts sample to
background comparison sets. Researchers can use this feature as a diagnostic diffuse weight
distributions suggest that the model did not identify a strong set of matches among the back-
53
ground datasets. The method can also be used to pose different questions. Instead of identifying
outlier genes for a tumor N-of-1 given the most appropriate normal dataset, a tumor sample can
be compared to a background of tumor samples to identify target genes that are unique to the
N-of-1 sample relative to other samples in the same population, which can also be a method for
identifying potential therapeutic leads [119].
These benefits do come with a tradeoff in computation calculating outliers via other methods
can be very fast whereas the runtime of this method quadratically increases with the number
of genes and datasets. The method is only appropriate for analyzing small targeted gene sets
fewer than 200 ideally due to the way model complexity scales. After 200 genes it is better to
parallelize multiple runs for a single sample, which is facilitated by a Toil-based version of the
workflow that makes scaling trivial and allows the method to run hundreds of samples in par-
allel on both standard local and cloud-based clusters [19]. The software provides intermediate
output at every step in the workflow so users can validate model convergence, assess the models
similarity metrics for background datasets to the N-of-1, and examine every model parameter
to reproduce how p-values were calculated for every gene.
4.5.2 Limitations
The model makes certain mathematical assumptions that we know to be unrealistic. First, it
implicitly assumes independence between the N-of-1 samples genes. It also assumes that the
samples gene expression can be approximated by a convex mixture of the gene expression of
the background datasets, which aids interpretability at the expense of descriptive accuracy.
These limitations could be addressed by extending the model. To incorporate correlation be-
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tween genes, random variables for each xd,g could be replaced with multivariate distributions
that are shared between all genes belonging to that group of coexpressed genes, where groups
could be formed through a clustering process or according to existing annotations. Prior knowl-
edge could also be used to introduce non-independence between genes into the model. For
instance, the independent error terms could be replaced by errors that are structured according
to the Laplacian of a gene interaction network [139]
4.5.3 Extensibility to single-cell RNA-seq
Our model could be theoretically extended to single cell RNA-seq analysis in addition to bulk.
However, without any modifications to the existing model, this would require training the model
for each cell, which would be computationally expensive. A faster alternative would be to
cluster the cells and sample a small number of representative cells from each cluster to run
through the model to get summary information about each of the single-cell clusters. However,
the high levels of technical noise, biological variability between cells, and dropouts, may require
too many training genes to obtain robust estimates of the model parameters [140]. Finally, the
distribution of the random variable xd,g would need to be replaced with a more appropriate
distribution to model single-cell expression, such as a beta-Poisson mixture model [141]
4.6 Conclusions
As clinicians have begun to demonstrate that RNA-seq analysis can produce actionable findings
for cancer patients, it is necessary to have informed and principled analytic tools for an individ-
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ual patient. The method we have proposed detects gene expression outliers among a panel of
target genes. It also provides additional information for researchers to explore and validate the
results through examination of the models parameters. For portability, scalability, and repro-
ducibility, we have made this open-source tool available as a Python package, Docker container,
and Toil workflow available at https://github.com/jvivian/gene-outlier-detection/.
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5Conclusion
“And will I tell you that these three lived happily ever after? I will not, for no one
ever does. But there was happiness. And they did live.”
– Stephen King, The Dark Tower
I have introduced a solution for large-scale genomic processing that leverages cloud computing
for scale and takes advantage of compute bidding to minimize cost as the workflow system can
resume from any combination of master/slave failure [19]. Unlike other workflow systems, Toil
can dynamically generate the job graph during execution, which lends itself to many biological
applications such as parallelizing a variable number of chromosomes based on species or an-
notation. Toil has been used in several major software projects such as the CACTUS multiple
sequence aligner, VG genome variation graph, toil-rnaseq RNA-seq expression quantification
workflow, ADAM genomics processing engine, and institutions such as the Treehouse pediatric
cancer group and collaborators, Color Genomics, University of North Carolina, Duke, and the
Pasteur Institute in Paris [142, 143, 144]. In keeping with our labs commitment to open-access
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data and software, Toil is freely available at https://github.com/DataBiosphere/toil.
I used Toil to write a portable and deterministic RNA-seq workflow and then processed ∼
20,000 patient samples from several clinically relevant datasets in under 4 days and coordinated
with the UCSC Xena team to publicly host the data on their visualization platform [62]. This
uniformly processed dataset constitutes the bulk of Treehouse’s compendium, which they use in
their pediatric cancer endeavors. The RNA-seq workflow, which is also open-source, has been
used by dozens of labs and hospitals around the world and is available at https://github.
com/BD2KGenomics/toil-rnaseq/ [101]. This dataset constituted the majority of data used
in the submission of two abstract submissions to the American Association for Cancer Research
[115, 114]. Treehouse has also implemented the RNA-seq workflow to circumvent data barriers
by assisting pediatric hospitals in running the software on-site so the anonymized expression
results can be shared back with Treehouse. This process avoids direct exposure of the sequence
data, infringing on patients privacy rights, or putting the data steward at risk.
I also developed and implemented a method to improve Treehouse’s capacity to identify poten-
tial therapeutic leads based on gene expression in individual patients. This statistically robust
method addresses several issues with existing N-of-1 protocols, such as incorporating statistical
uncertainty from small sample size directly in the model without drowning out any background
sets contribution through pooling. Not only are genes ranked by p-value, but analysts also get
weight information that contextualizes the similarity of their sample to the background compar-
ison sets, traceplots from sampling that confirm convergence of parameters, serialized model
and trace for reproducibility, and distance metrics relating their N-of-1 sample to all background
datasets.
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The future of genomics is certainly exciting – single-cell sequencing technologies allow us to
interrogate individual cells to better understand cell lineage and heterogeneity, the race to com-
mercialize lab-grown synthetic meat will have drastic and positive impacts on the environment
and culture, machine-learning image recognition systems are making their way into clinical
practice to assist oncologists in cancer detection, advances in gene editing and CRISPR will
improve our ability to genetically modify crops and organisms to produce goods such as bio-
fuels or prevent mosquitoes from transmitting malaria, and the cost of sequencing will dovetail
with precision medicine and lead to improved patient outcomes across the spectrum of disease
[145, 146, 147, 148, 149, 150].
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Appendix A
Supplementary material for Chapter 1
A.1 Genomic sequencing
A.1.1 Early sequencing
Nucleic acid sequencing become a major goal for scientists shortly after Rosalind Franklin
verified the helical structure of DNA, Watson and Crick published the structure of DNA and
Sanger published the amino acid sequence for insulin [151]. The very first publication of a
nucleic acid sequence was the sequence of alanine transfer RNA in 1964, only 11 years after
the structure of DNA was discovered [152]. It was another 13 years before the completion of
the first fully sequenced DNA-based genome – the bacteriophage φX174 – by Fred Sanger’s
group using radiolabelled nucleotides fractionated by polyacrylamide gel electrophoresis, an
early version the famous Sanger method of sequencing which uses chain-terminating inhibitors
of DNA polymerase to get different length DNA fragments [153, 154, 155]. Sanger sequencing
spawned the completion of several important genome sequencing projects over the next 20
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years: the human mitochondrion was sequenced in 1981, the first chloroplast genome in 1986,
the first free-living organism in 1995, and the first complete eukarytotic genome sequence,
Sachharomyces cerevisiae [156, 157, 158, 159].
Coinciding with the dawn of the digital era and with competition from private industry, the
Human Genome Project (HGP) succesfully assembled the first human genome which was then
hosted on The Genome Browser at UC Santa Cruz [160, 161]. The primary phase of the HGP
involved whole-genome shotgun sequencing which was an effective technique to deal with mul-
ticellular genomes which are more diffiuclt to clone, sequence, and assemble than unicellular
genomes which often lack repetitive regions that make sequencing particularly difficult [162].
In whole-genome shotgun sequencing the entire genome is fragmented into sizes ranging from
2 kilobases to 300 kilobases, then these fragments are sequenced and assemebled in multiple
stages using computers – first into contigs, then scaffolds, then finally assembled into a genome
map [162, 163]. Shotgun sequencing combined with the Sanger method as the underlying tech-
nology was only supplanted by the arrival of massively parallel sequencing methods termed
”high-throughput” or ”next-generation” sequencing.
A.1.2 High-throughput sequencing
The first demonstrably useful and accurate parallel sequencing method was Polony sequenc-
ing, a form of sequencing-by-ligation, and was developed by George Church’s lab and used
to sequence Escherichia coli at less than one error per million consensus bases in 2005 at a
fraction of the cost of traditional Sanger sequencing [164]. Polony sequencing uses an in vitro
amplification step shared by several sequencing platforms called emulsion PCR, where individ-
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ual DNA molecules are bound to primer-coated beads within droplets and PCR subsequently
creates clonal copies of the DNA for downstream sequencing [165]. This amplification method
is also used in 454 pyrosequencing which, in contrast to Polony sequencing’s sequencing-by-
ligation, is a sequence-by-synthesis technique that uses the firefly luciferase enzyme to generate
detectable amounts of light following nucleotide incorporation [166]. One complication with
454 sequencing is homopolymer regions, which it has difficulty estimating since nucleotides are
no always added one at a time [167]. Another technology based on sequencing-by-synthesis,
and arguably the most successful next-generation sequencing method, is Illumina dye sequenc-
ing which uses reversible dye-terminators that allow for single nucleotide identification as they
are incorporated into clusters of DNA [168] (Figure A.1). The process starts with standard li-
brary preparation but uses a clever method called bridge amplification to create clonal clusters.
Bridge amplification starts once an prepared DNA’s adapter attaches to its complementary oligo
on the flow cell lane [168]. Polymerases are added which create a complementary strand and
the original strand is washed away leaving a complementary strand with an adapter sequence at
the top. The DNA then bends and attaches to the oligo that is a compliment of its top adapter se-
quence and is polyermized again and finally denatured to leave a copy of the original sequence
behind. After clonal amplification the rerversible dye-terminated nucleotides are added and a
single base is incorporated in each round and the unique fluorescent emission is recorded before
teh fluorescent molecule is cleaved and the next round can begin. Overall, the process occurs
for millions of clusters simultaneously producing read fragments of about 90 basepairs in length
[168].
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RFigure A.1: A summary of Illumina sequencing chemistry. (A) library preparation, (B), clus-
ter generation, (C) sequencing, and (D) alignment and data analysis. Figure taken from An
introduction to Next-Generation Sequencing Technology, https://tinyurl.com/yyo7kwja.
Copyright by Illumina Inc.
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A.1.3 Third generation sequencing
After the resounding success of next-generation sequence technologies, new technologies
started working on two weak points of Illumina sequencing: single-molecule analysis and long-
reads. Single-molecule real-time sequencing (SMRT) was commercialized by PacBio in 2011
and is based on sequencing-by-synthesis but leverages advances in optics to measure single
nucleotide incorporation during incorporation into the DNA strand [169]. A single DNA poly-
merase is positioned at the bottom of a zero-mode waveguide along with a single DNA molecule
that acts as a template. Each nucleotide has its own unique fluorescent dye and as the nucleotide
is incpororated into the template by the polymerase this fluorescent tag is cleaved off and which
is detected to make the base call [170]. Production sequencing is done on chips that contain
multiplexed zero-mode waveguides, each with their own DNA polymerase and single-stranded
DNA template – as of 2019 the company plans on releasing a chip with 8 million zero-mode
waveguide wells and is capable of reads above 30,000 bases in length [171].
The other big third generation sequencing technology is nanopore sequencing, a concept first
ideated by David Deamer at UC Santa Cruz in 1996 and expanded upon in the following years
[172, 173, 174]. The general principle is translocation of single-stranded DNA via electrophore-
sis through a very small aperture (10−9) that sits in a buffer solution with a constant voltage
applied across the aperature in order to perturb an electric current signal to indicate the individ-
ual nucleotides passing through the aperture [174]. Left unfettered, DNA moves far too quickly
through the aperture for single-base identification and must be controlled by binding the DNA
to a protein the regulates its speed through the aperture, which is often a biological protein pore
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[175]. Nanopore technology is rapidly being improved by collaboration between academic and
private institutions and recent successes include read lengths greater than 2 megabases – these
long-reads are instrumental to assembly of complex homopolymer regions like the major histo-
compatbility complex locus and telomere regions [176].
Sequencing usually refers to DNA sequencing, but is more broadly the sequence determination
of some biological structure like RNA, protein, or even polysaccharides. Protein sequencing
has limited uses as DNA sequencing is much easier and the protein sequence can be directly
inferred if the encoding gene is sequenced. RNA sequencing, or RNA-seq, on the other hand
serves a very different purpose than DNA sequencing. Instead of just determining the sequence,
RNA-seq captures a snapshot of the presence and quantity of RNA in a biological sample which
is a reflection of gene expression. RNA-seq gives insight into gene expression and has many
applications such as profiling gene expression between a study and control sample, investigating
alternative splicing events, discovery of gene fusions, post-transcriptional modifications, and
changes in gene expression over time [37, 47].
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Appendix B
Supplementary methods for Chapter 2
B.1 Toil architecture
Figure B.1: Merge sort using Toil’s dynamic job
scheduling capabilities.
Figure B.2: Diagram of Toil’s Architecture.
A workflow comprises a set of tasks, or jobs, that are orchestrated by specification of a set
of dependencies that map the inputs and outputs between jobs. This means workflows can be
visualized as a graph, where the nodes represent jobs and the directed lines represent dependen-
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cies. Toil’s atomic unit of work is the job, which is checkpointed after successful completion so
that workflows can be restarted in case of failure and is most often written as a single Python
function. Toil supports traditional static declaration of jobs (Static Job Example C.1), but also
boasts support for dynamic job generation (Dynamic Job Creation C.2). For example, this
means a workflow can be written such that a single job is run per-chromosome. Dynamic job
declaration combined with Toil’s use of promises and multiple job types encourages simplified
and elegant workflow design (Figure B.1). A parent job can have child jobs and follow-on
jobs – child jobs are run following the successful completion of the parent job in parallel and
follow-on jobs of a job are run after its child jobs and their successors have completed, also
run in parallel. Follow-ons allow the easy specification of cleanup tasks that happen after a
set of parallel child tasks. A parent job can pass the results of children jobs to follow-on jobs
through the use of promises (Promises C.3), which create a promised object that is later fulfilled
upon completion of the child job. Toil also has a special service job for hosting long-running
processes or services that other jobs must interact with during the course of a workflow, like a
database or SPARK cluster).
Toil’s software architecture has six basic components: the leader, the batch system, workers,
the job store, the statistics and logging monitor, and conditionally, the node provisioner (Fig-
ure B.2). The leader is responsible for deciding which jobs should be run by traversing the
job graph. Toil orchestrates running jobs on hardware using a modular batch system interface
that supports a variety of systems such as Slurm, GridEngine, Mesos, Parasol, in addition to a
built-in batch system for running on single machines like a laptop, which is useful for develop-
ment and testing before deployment [79, 80]. Workers are temporary processes responsible for
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running one job at a time. The worker monitors its job and reports back success or failure to the
leader by editing the job’s state in the job store. As jobs are run by the batch system, intermedi-
ate files and job information are stored atomically in Toil’s job store, ensuring the workflow can
be resumed upon failure. Files are written to the job store in exchange for a FileStoreID object
that can be passed to other jobs and later exchanged for a path to the file. Toil’s default job store
is a location on disk, but support also exists for Amazon’s cloud storage, and comprehensive
support for Microsoft Azure and Google Cloud are both in active development. The statistics
and logging monitor collects information from the workers over the course of the run and dis-
tills it into a report, which describes both the overall run as well as individual jobs. The node
provisioner is a recent feature that allows the creation of worker nodes which the batch system
then includes in the pool of resources to which jobs are scheduled.
Toil implements several optimizations designed for scalability, including a read-only leader, job
chaining, preemptable node support, and caching. Toil’s leader process is currently constrained
to a single thread, but steps were taken to ensure its not a bottleneck. Most of the leader’s tasks
revolve around processing the state of jobs, which are stored as a file within the job store. To
minimize the load on this thread, each worker does as much as possible to manage the state of
its own job. As a result, with a couple of negligent exceptions, the leader process never needs
to write or update the state of a job within the job store. For example, when a job is complete
and has no further successors the responsible worker deletes the job from the job store, marking
it complete. The leader then only has to check for the existence of the file when it receives
a signal from the batch system to know that the job is complete. This off-loading of state
management is orthogonal to future parallelization of the leader. Scheduling of successor jobs
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is also partially managed by the worker, again reducing the number of jobs the leader needs
to process. This job chaining heuristic is simple: if there is a single next successor job to run
and its resources fit within the resources of the current job and closely match the resources
of the current job then the job is run immediately on the worker without interaction with the
leader. These optimizations cause the leader to use∼4-6% CPU when running a workflow with
∼10,000 jobs and 10 worker nodes running ∼32 jobs at a time per worker. Critical to running
at large-scale is dealing with intermittent node failures. Toil is therefore designed to always
be resumable providing the job store does not become corrupt. This robustness allows Toil to
run on preemptable nodes, which are only available when others are not willing to pay more
to use them. Designing workflows that divide into many short individual jobs can capitalize on
preemptable nodes allowing for workflows to be efficiently scheduled and executed. Running
bioinformatic workflows often require the passing of large datasets between jobs. Toil caches
the results from jobs such that child jobs running on the same node can directly use the same
file objects, thereby eliminating the need for an intermediary transfer to the job store. Caching
also reduces the burden on the local disks, because multiple jobs can share a single file. The
resulting drop in I/O allows workflows to run faster, and, by the sharing of files, allows users to
run more jobs in parallel by reducing overall disk requirements.
B.2 Toil RNA-seq workflow
Issues with the TCGA mRNA-seq workflow spurned the development of a faster RNA-seq
workflow with additional features. An obvious step missing from the TCGA mRNA-seq work-
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Figure B.3: Dependency graph of the toil-RNAseq workflow. The workflow is completely mod-
ular and every tool in the workflow is contained within its own Docker container. RNA-seq
reads, as FASTQ input or converted to FASTQ from BAM, are preprocessed to trim sequencing
adapters, before being either aligned and quantified or quantified directly from the reads. A QC
step is also run to for each sample.
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flow is adapter trimming of the reads. When RNA is sequenced during RNA-seq, the resulting
reads are usually longer than the RNA and therefore contain parts of the 3’ adapter, which must
be found and removed from each read before downstream in order to avoid errors [177]. Pro-
cessing the same sample with and without CutAdapt results in 13,559 non-zero differences,
with the largest difference being several thousand counts (Figure C.2). Correcting for low-end
expression counts is becoming a more important issue with the rise of single-cell RNA-seq
methodologies and the Human Cell Atlas – an initiative to profile a billion cells in the human
body [178].
Another issue with the TCGA mRNA-seq workflow is a lack of quality control (QC) steps which
provide information about the quality of the input FASTQs – this information is particularly
valuable when examining unexpected or novel results. FastQC produces a comprehensive report
on base and sequence quality, sequence base and GC content, sequence length and duplication
distributions, adapter content, and overrepresented sequences – often ribosomal RNA in RNA-
seq [179]. STAR, an alignment tool, also outputs log files with mapping information and other
statistics that are saved as part of the workflow’s standard output [82].
Kallisto is a recent expression estimation program that achieves its notable speed by estimating
counts directly from the sequencing reads [60]. The key insight to Kallisto is that it only at-
tempts to find which transcripts a read could belong to, not where inside the transcripts the read
may have come from. This approach allows Kallisto to run >95% faster than other quantifica-
tion methods that rely on alignment first, yet retains accuracy comparable to leading expression
tools like RSEM [57]. This speed is achieved using a method the authors call ‘pseudoalign-
ment’, which is read assignment to target sequences without any base-level sequence alignment.
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Pseudoalignment of a read to a set of transcripts T is a subset S ⊂ T with out any specific co-
ordinates mapping each base in the read to a specific position in each of the transcripts S, as
is present in typical read alignment. Kallisto generates psuedoalignments for reads by hashing
k-mers together with a colored de Bruijn graph of the transcriptome, where nodes represent
k-mers and each transcript corresponds to a path [60]. Redundant nodes that map to the same
transcript are skipped and the final set of transcripts the reads maps to is determined by taking
the intersection of all transcripts mapped to. Finally, quantification of transcript abundances
from the pseudoalignments is done using a likelihood function adapted for RNA-seq.
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Where F is the set of fragments, T the set of transcripts, lt the effective length of transcript t,
and yt, f is a compatibility matrix defined as 1 if f is compatible with t, otherwise it is set to 0.
αt is the probability of selecting fragments from transcripts, and ce are the number of counts
observed from equivalence class e [60].
Alternatively, RNA-seq quantification can be achieved by first aligning reads to the transcrip-
tome and then expression abundance is derived from the aligned reads. The CGL RNA-seq
workflow uses STAR for alignment, and then passes the aligned reads to RSEM for transcrip-
tion [57, 82]. STAR was chosen for alignment because it is about a factor of 50 faster than
Mapsplice with similar accuracy and has the ability to output a file that can be fed directly into
RSEM without any post-processing [180]. The only notable downside to STAR in comparison
to Mapsplice is that it uses uncompressed suffix arrays which it loads into memory – this trans-
72
lates into about 60GB of memory when aligning to the human genome. STAR works by finding
the Maximal Mappable Prefix (MMP), which for a read sequence R, read location i and a ref-
erence genome G, MMP(R, i,G) is the longest substring (Ri,Ri+1, · · · ,Ri+MML−1) that matches
one or more substrings of G, where MML is the maximum mappable length [82]. STAR builds
alignments from all reads that were aligned to the genome during the MMP phase by first clus-
tering reads by proximity, creating a possible set of local alignments based on a standard scoring
scheme for matches, mismatches, indels, and splice junction gaps, and then choosing the high-
est score as the best final alignment for a read [82]. These aligned reads are then fed into RSEM
(RNA-seq by Expectation Maximization) which computes Maximum Likelihood (ML) abun-
dance estimates using the Expectation Maximization (EM) algorithm. The probability a read
is derived from a given transcript, θi for transcript i and θ0 for unmapped reads, is computed
during each iteration of the EM algorithm using a restricted set of transcripts derived from the
alignment data [57].
B.2.1 Formal definition of read mapping
The workflow produces expression estimates using two different approaches: one approach
derives estimated counts for transcripts directly from the sequencing reads themselves, and the
other estimates counts after the transcripts have been aligned, specifically to the transcriptome
of the reference genome. To understand how these tools work, a concrete definition of “read
mapping” is necessary. A set of reads F with each read F ∈ F consisting of a sequence so
that F is an ordered set F = {θ1, · · · ,θl}, where θ ∈ {A,C,G,T}. Denoting an ordered set of
target sequences or contigs T with each sequence T ∈ T , where each sequence is comprised
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only of values in θ. Read alignment in early read alignment tools consisted of a pair of maps.
First ψ : F → T ⋃{ /0} which specifies the contig each read maps to, or in case of an unaligned
read, a mapping to { /0}. The second mapping LF : F → ψ(F)⋃ /0, which assigns each base in
the read to a corresponding base in the contig (or to { /0} in case of a gap). Now all that’s needed
is a model and algorithm, which for several programs consisted of modified versions of the
Smith-Waterman algorithm with an accompanying scoring scheme for matches and mismatches,
and an affine gap penalty which penalizes starting a gap and extending a gap differently. This
algorithm and model produce global alignments LF , where order is preserved between elements
of F and ψ(F) [181].
B.2.2 Workflow design philosophy
The CGL RNA-seq workflow (Figure B.3) was designed for portability, reproducibility, mod-
ularity, and ease-of-use. Featuring detailed documentation, a wiki, and distribution through
PyPi which allows installation from any computer with a valid Python installation and internet
connection pip install toil-rnaseq [64]. Since all tools used in the workflow are encap-
sulated in Docker containers for portability and reproducibility, the only software dependencies
required on the host machine or nodes is Python and Docker. The workflow is also completely
modular, allowing users to select any combination of tools and output Like many workflows, the
CGL RNA-seq workflow has a plethora of configurable options that dictate how the workflow
runs. To minimize the number of command line arguments a user has to provide, the work-
flow generates an editable config and manifest for the user to set workflow options and provide
sample information. The workflow’s source code remains stable through the use of continuous
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integration which runs all tests in the repository and require that they pass before any code is
merged, which includes concordance validation to ensure the output remains deterministic. To
capitalize on services that rely on automating calls to Docker containers, the entire workflow is
also released as a stand-alone Docker container.
B.2.3 Docker-encapsulated workflow
Figure B.4: Diagram showing how the host
Docker socket is mounted into the child con-
tainer containing the toil-rnaseq workflow.
When that child container executes commands
to Docker containers, they are spawned by the
host as siblings instead of nested children.
Several genomics services work by running
stand-alone Docker containers and by design
are incapable of running the CGL RNA-seq
workflow from its Python entrypoint [97]. To
accommodate these services, the workflow
was encapsulated into a Docker image, but
this caused performance issues as the parent
Docker container was executing child Docker
containers inside of the parent’s virtual state.
This issue was solved by mounting the host
Docker socket into parent container’s socket
which means when the parent container ex-
ecutes a Docker container the host actually
runs the container as a sibling to the parent
container instead of nested within as a child
process (Figure B.4). Mounting the host socket into the parent container isn’t problem-free,
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as it imposes a requirement that the host version of Docker’s server matches the Docker client
version installed in the parent container. To deal with this, the build process for the Dockerized
workflow uses a templating scheme to iterate through a range of Docker versions and builds
multiple containers.
B.2.4 Concordance
While the CGL RNA-seq workflow is about an order of magnitude faster than its TCGA coun-
terpart, it is far less useful if it produces results that vary significantly. To validate concordance
of expression values, 10,000 samples and 10,000 genes were randomly selected to create sam-
ple/gene pairs. Expression values from TCGA for each sample/gene pair were collected by
querying the UCSC Xena browser, and then plot against the expression value for the sample/-
gene pair computed with the CGL RNA-seq workflow. Results show the two workflows are
significantly concordant (pearsonR of 0.98) and heteroskedasticity in the plot shows greater
variance for lower-expressed values as expected (Figure 2.1).
To ensure stability of the CGL RNA-seq workflow, new versions of the workflow are validated
only if all gene expression values are identical to earlier versions. This version concordance
became standard practice after an innocuous change to STAR that keeps unmapped key pairs
was found to cause downstream expression differences.
B.2.5 Production use
The CGL RNA-seq workflow has become the primary workflow run by the Genomics Insti-
tute Analysis Core which provides sample analysis for Treehouse, a pediatric cancer research
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group at UCSC, as well as collaborators outside of UCSC [182]. The CGL RNA-seq workflow
has been run by several major institutions including: Children’s Hospital of Philadelphia, Cal-
ifornia Kid’s Cancer Comparison, West Coast Dream Team, Canada’s Michael Smith Genome
Sciences Centre, Genomic Data Commons Chicago, Treehouse Childhood Cancer Initiative,
Broad Institute, and University of Washington. Treehouse incorporated this gene expression
data into their pan-cancer gene expression analysis alongside mutation data to nominate molec-
ular pathways that may be driving the disease in each child, providing useful information to the
medical teams [114, 183].
B.3 Large-scale compute logistics
B.3.1 Datasets and storage
To demonstrate Toil, the CGL RNA-seq workflow was used to compute gene- and isoform-level
expression values for 19,952 samples from four studies: The Cancer Genome Atlas (TCGA),
The Genotype Tissue Expression Consortium (GTEx), Therapeutically Applicable Research to
Generate Effective Treatments (TARGET), and Pacific Pediatric Neuro-Oncology Consortium
(PNOC) (Figure C.4). In preparation of the large-scale compute, a Toil workflow was written
that downloaded, consistently formatted, and uploaded all samples to Amazon Web Services
(AWS) Simple Storage System (S3). Storage in S3 was required because the transfer between
S3 storage and AWS’s Elastic Compute Cloud (EC2) is sufficient to not bottleneck the workflow
as it scales horizontally across more nodes.
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B.3.2 Metrics and automation
EC2 metrics can be queried through Amazon’s Cloudwatch except for memory and disk. At
the time of this large-scale compute, EC2 clusters were being spun up using CGCloud which
spawns an “agent daemon” on every node that was originally responsible for managing SSH
keys and privileges [184]. I wrote a daemon thread that piggy-backs off deployment of the
agent daemon to collect disk and memory usage as percentages via psutil, then injects these
custom metrics into Cloudwatch at 5-minute intervals. To minimize the cost of the compute,
all EC2 nodes were provisioned from EC2’s ‘spot market’, Amazon’s name for preemptable
nodes that are 50-80% cheaper than on-demand nodes, but if the market’s current active bid
price exceeds the user’s bid price the node is terminated without warning. Toil is excellent for
preemptable nodes as long as the workflow consists of mostly temporally fine-grained steps
that run in less than an hour. I wrote automation code that spawned an initial cluster on the spot
market, managed credentials, launched the CGL RNA-seq workflow, and then blocks while
collecting metrics from EC2 in real time. Over the course of several hours (Figure 2.2), the
number of nodes was increased by manually calling CGCloud’s grow-cluster to periodically
add 50-100 nodes until reaching 1,000 nodes, which provided a pool of 32,000 cores and 60TB
of memory. This step was done manually as scaling to that size was untested and heuristics
for managing cluster growth would have been made naively. For example, we did not foresee
encountering the problem of having a direct impact on the spot market, and blindly growing
the cluster – not realizing nodes were being removed due to competition with our earlier bids –
would have contributed to a sizable increase in cost. As an additional cost-saving measure, idle
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nodes were terminated automatically during metric collection cycles as the workflow neared
completion.
Metrics were parsed by creating a sparse matrix with nodes as rows and 5-minute interval times-
tamps as columns for each metric. At each timestamp, all nodes with values were used to com-
pute mean and standard deviation (Figure C.3), and by counting all non-empty values for a
timestamp column, the number of actively running instances – and consequently the number of
cores – could be measured (Figure 2.2).
79
Appendix C
Supplementary materials for Chapter 2
C.1 Static Job Example
from toil.job import Job
def helloWorld(job, message, memory="2G", cores=2, disk="3G"):
job.fileStore.logToMaster("Hello world, "
"I have a message: %s" % message) # This uses a logging function
# of the toil.fileStore.FileStore class
j1 = Job.wrapJobFn(helloWorld, "first")
j2 = j1.addChildJobFn(helloWorld, "second or third")
j3 = j1.addChildJobFn(helloWorld, "second or third")
j4 = j1.addFollowOnJobFn(helloWorld, "last")
if __name__=="__main__":
options = Job.Runner.getDefaultOptions("./toilWorkflowRun")
options.logLevel = "INFO"
Job.Runner.startToil(j1, options)
C.2 Dynamic Job Creation
from toil.job import Job
def binaryStringFn(job, depth, message=""):
if depth > 0:
job.addChildJobFn(binaryStringFn, depth-1, message + "0")
job.addChildJobFn(binaryStringFn, depth-1, message + "1")
else:
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job.fileStore.logToMaster("Binary string: %s" % message)
if __name__=="__main__":
options = Job.Runner.getDefaultOptions("./toilWorkflowRun")
options.logLevel = "INFO"
Job.Runner.startToil(Job.wrapJobFn(binaryStringFn, depth=5), options)
C.3 Promises
from toil.job import Job
def fn(job, i):
job.fileStore.logToMaster("i is: %s" % i, level=100)
return i+1
j1 = Job.wrapJobFn(fn, 1)
j2 = j1.addChildJobFn(fn, j1.rv())
j3 = j1.addFollowOnJobFn(fn, j2.rv())
if __name__=="__main__":
options = Job.Runner.getDefaultOptions("./toilWorkflowRun")
options.logLevel = "INFO"
Job.Runner.startToil(j1, options)
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C.4 Spark Cluster using Toil Services
Figure C.1: Running ADAM, a genomics processing workflow, which interacts with a SPARK
cluster. Toil runs the SPARK cluster as a service job which is maintained for the duration of the
workflow.
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C.5 Expression Concordance Modified by CutAdapt
Figure C.2: Expression differences from a sample obtained by running the toil-rnaseq workflow
with and without CutAdapt. A total of 13,559 non-zero count differences were detected, with
the largest differences being several thousand counts.
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C.6 Large-scale Compute Metrics
Figure C.3: Aggregate metrics collected during the Toil RNA-seq large-scale compute. Metrics
were collected every 5 minutes and averaged across every instance running at that time point.
Complete termination of the Mesos framework occurred around hours 10 and 20, from which
the workflow was resumed. 85
C.7 Large-scale Compute Datasets
Figure C.4: RNA-seq datasets chosen for large-scale compute. The Cancer Genome Atlas
(TCGA), the Genotype Tissue Expression Consortium (GTEx), Therapeutically Applicable
Research to Generate Effective Treatments (TARGET), and Pacific Pediatric Neuro-Oncology
Consortium (PNOC) [1, 2].
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Appendix D
Supplementary methods for Chapter 4
D.1 Assignment of model weight to background datasets
This section explores assignment of model weight to different background datasets in GTEx
across ˜1,000 TCGA tumor samples. Despite no attempt to correct for batch effects and GTEx
and TCGA being completely separate projects with different laboratory protocols, the model
is able to accurately assign model weight to the appropriate tissue in GTEx for a majority of
samples across ten different tumor types.
All data used to generate the following section is avilable at http://courtyard.gi.ucsc.
edu/˜jvivian/outlier-paper/experiments/gtex-1000.tar.gz.
D.1.1 Dimensionality Reduction of Low-Weight Samples
This section explores low model weight assignment to bladder and stomach samples. The sub-
sections below show dimensionality reduction plots of samples from two tissues – bladder and
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Figure D.1: HeatMap of the average model weight assigned to GTEx tissues across tumor
subtypes in TCGA. The model assigns a majority of weight to the matched tissue in GTEx for
every tumor subtype. Only two tumor tissues, bladder and stomach, received less than 60%
of the average model weight. GTEx has only 9 bladder samples and PCA shows those bladder
samples cluster on top of minor salivary gland and vagina samples which helps explain its lower
average weight relative to other tumor types
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stomach – that the model had difficulty assigning the correct weight to. Since the model assigns
weights based on tissues that are most similar to the N-of-1 sample, it can only perform as well
as the data provided. Performing PCA of bladder tumor samples alongside tissues the model
assigned weight to reveal why the model has difficulty associating the normal bladder tissue in
GTEx to the bladder tumor samples. GTEx possesses only 9 bladder samples and these sam-
ples cluster into two distinct groups – one near the bladder tumor samples and the other near
vagina and minor salivary gland samples, which are the other two groups that were assigned a
significant percentage of weight. Finally, it is apparent why the model struggled to correctly as-
sign GTEx stomach as the primary weight for stomach cancer samples. GTEx stomach samples
are split into two sub-populations and small intestine, which is proximal to and phenotypically
similar to stomach tissue, clusters closely to stomach tumor samples.
Figure D.2: Dimensionality reductions of bladder and stomach tumors and their proximal tis-
sues. PCA helps explain why the model has difficulty assigning all of the weight to the matched
tissue in GTEx.
89
D.2 Mixture simulation validation
We validate the model’s ability to assign weights to samples of mixed phenotypes by simulating
mixture samples from pairs of different tissues and then checking if the model splits the weights
between those two contributing tissues.
All data used to generate the following section is avilable at http://courtyard.gi.
ucsc.edu/˜jvivian/outlier-paper/experiments/mixture-simulation.tar.gz. This
archive contains both the results from running the model on the mixture samples as well as the
simulated matrices.
D.2.1 Dimensionality Reductions of Mismatched Mixture Samples
Some of the mixture samples did not quite meet our expectation of being assigned a majority of
the model weight. We can contextualize these results by plotting dimensionality reductions of
those mixture samples alongside tissues that the model assigned weight to.
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Figure D.3: Average model weight of mixture samples generated from random pairings of
GTEx tissues. Samples were generated by averaging gene expression between randomly sam-
pled subsets of each tissue group. In most cases, the two tissues used to generate the mixture are
assigned the majority of the model weight, which is the expected result. Three sets of mixture
samples Adrenal-Brain, Brain-Lung, and Liver-Thyroid do not get the same result. PCA of
those mixture samples, in the context of similar tissues, shows the generated mixture samples
happen to cluster closer to other tissues than one or both of the tissues used to generate the
samples. In these circumstances, we expect the model to assign weight to those tissues that are
more similar to the mixture samples
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Figure D.4: PCA of Brain-Lung mixture samples alongside model weights assigned to GTEx.
Brain-Lung simulated mixture samples cluster more closely with prostate and breast tissue than
brain or lung, which is reflected in the model’s assignment of weight.
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Figure D.5: PCA of Adrenal-Brain mixture samples alongside model weights assigned to
GTEx. Simulated Adrenal-Brain samples cluster near pituitary and kidney tissues. Adrenal
tissue is also more homogenous than brain which might explain why the model prefers assign
weight to adrenal samples over brain.
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Figure D.6: PCA of Liver-Thyroid mixture samples alongside model weights assigned to
GTEx. Liver-Thyroid mixture samples don’t get weight assigned to liver, but to thyroid, kid-
ney, and minor salivary gland tissues. Although more proximal to liver than minor salivary
gland across the first two principal components, minor samples are likely closer to the mixture
samples along another component axis.
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D.3 Effect of removing matched normal on gene p-value
To test the robustness of the model, we explore the assocation between the model weight as-
signed to a particular normal tissue in the background for a sample and how removing that tissue
effects the generated p-values.
All data used to generate the following section is avilable at http://courtyard.gi.ucsc.
edu/˜jvivian/outlier-paper/experiments/gtex-1000-match-removed.tar.gz. This
data is compared directly to data in the gtex-1000.tar.gz archive in the same directory.
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Figure D.7: The effect that removing a matched tissue has on the gene p-values the model
generates as measured by Pearson correlation. The x-axis is the weight assigned to the matched
tissue by the model. Gene p-values are relatively consistent even when a matched tissue is
removed, particularly if the model can redistribute that weight to tissues of similar phenotypes.
D.4 Quantify outliers across tumor subtypes
Given an arbitrary p-value cutoff of 0.05, quantify up-regulated expression outliers across 10
tumor subtypes for ˜1,000 TCGA samples when GTEx is used as the background comparison
set. All data used to generate the following section is avilable at http://courtyard.gi.ucsc.
edu/˜jvivian/outlier-paper/experiments/gtex-1000.tar.gz.
D.4.1 Literature Corroboration of Outlier Findings
After quantifying outliers across the 10 different tumor subyptes, we assessed whether the high-
count outliers we found were corroborated by literature as previously identified tumor markers
for these cancer subtypes (Table D.1). We found evidence for amplification of Aurora Kinase
A (AURKA), a gene involved in microtubule formation, in bladder cancers, which has been
used as a biomarker for early detection [126, 127]. AURKA is also frequently amplified in
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Figure D.8: Outlier counts given an arbitrary p-value cutoff of 0.05. 85 druggable genes curated
by Treehouse were used as the target gene set for this analysis. All genes with counts for more
than half of the samples within a tumor subtype were identified as known tumor biomarkers
within that subtype in the literature.
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certain breast cancers [128]. Aurora Kinase B (AURKB) is often amplified in gliomas relative
to normal brain tissue and is associated with histopathological grades [129]. Epidermal Growth
Factor Receptor (EGFR) amplification is also commonly seen in both lower grade gliomas as
well as high grade gliomas [185, 131, 132]. Many inhibitor drugs of EGFR also target Platelet
Derived Growth Factor Receptor Alpha (PDGFRA), which is another gene often overexpressed
in gliomas [133]. Both thyroid carcinomas and gastric cancers report high expression of the
MET proto-oncogene [186, 135, 136, 187]. Finally, despite being more commonly known for
forming fusion genes, ROS1 has also been identified as overexpressed in lung adenocarcinomas
[138]. While RNA-seq quantification will still map reads from a fusion gene to the original
gene, the high outlier count for ROS1 is likely due to weight assignment of lung tumors to
minor salivary gland in GTEx which has no ROS1 expression. Lung adenocarcinomas with <
15% of model weight assigned to minor salivary gland reduced the percentage of lung samples
that counted ROS1 as an outlier from 50% to 37%, which is more consistent with the litera-
ture values. Due to minor salivary gland samples clustering closely to several phenotypically
distinct tissues (bladder, breast, lung, stomach), it would likely improve the overall analysis
if removed from the GTEx cohort. Minor salivary gland was not removed for our analysis as
it was discovered only after the performing the experiments and without a valid mathematical
justification for removing it, would constitute an unprincipled decision.
We also see very little overexpression of HER2 (ERBB2) in breast cancers which is a relatively
well-known overexpressed gene in a subset of breast cancers. This is due to the extreme gene
expression variance seen in the normal tissue of breast in GTEx, which ranges from log2(0)
to log2(10) transcripts per million. This means that HER2 in breast tumors would have to
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express HER2 > log2(12) or log2(13) in order to count as an outlier. Based on the relatively
large variance and bimodal features of many gene expression distributions in GTEx breast, it
is possible that the GTEx breast dataset is comprised of several phenotypically distinct parts of
the normal breast tissue. If GTEx breast tissues could be divided into sub-populations based
on Clustering, it could potentially reduce the variance of many of these genes and improve the
ability to detect outliers in breast tumor samples. We chose to use the unadulterated GTEx
dataset for our analysis to keep things simple and easily reproducible.
Gene Cancer Paper Author Notes / Quotes
AURKA Bladder
Urothelial
Carcinoma
POTENTIAL NEW
MARKERS IN THE
EARLY DETEC-
TION OF BLADDER
CANCER
Samir P.
Shirod-
kar and
Vinata B.
Lokesh-
war
In a case control study,
involving bladder cancer,
normal individuals and
patients with benign condi-
tions, they reported 96.6%
specificity and 87% sensitiv-
ity for AURKA-FISH test to
detect bladder cancer.
99
AURKA Bladder
Urothelial
Carcinoma
Quantitation of Au-
rora Kinase A Gene
Copy Number in Urine
Sediments and Blad-
der Cancer Detection
HS Park
et al.
Forced overexpression
of AURKA in urothelial
cells induced amplification
of centrosomes, chromo-
some missegregation, and
aneuploidy, and natural over-
expression was detectable in
in situ lesions from patients
with bladder cancer
AURKA Bladder
Urothelial
Carcinoma
Quantitation of Au-
rora Kinase A Gene
Copy Number in Urine
Sediments and Blad-
der Cancer Detection
HS Park
et al.
The Aurora kinase A (AU-
RKA) gene, which encodes
a key regulator of mitosis,
is frequently amplified and/or
overexpressed in cancer cells
AURKA Breast Can-
cer
Aurora-A gene is fre-
quently amplified in
basal-like breast can-
cer
S Staff et
al.
AURKA amplification
(found in 21%) showed an
association with basal-like
tumor phenotype (p=0.046)
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AURKA Stomach
Cancer
AURKA regulates
JAK2eSTAT3 activity
in human gastric and
esophageal cancers
A Katsha
et al.
Aurora kinase A is a fre-
quently amplified and
overexpressed gene in upper
gastrointestinal adenocarci-
nomas (UGCs).
AURKB Brain Can-
cer
Kinesin fam-
ily member 2C
(KIF2C/MCAK) is
a novel marker for
prognosis in human
gliomas
L Bie et
al.
We found that KIF2C and
AURKB genes were higher
expression in glioma samples
when were compared with
normal brain tissues. KIF2C
and AURKB expression were
associated with histopatho-
logical grades.
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CCND1 Thyroid Car-
cinoma
Tissue array for Tp53,
C-myc, CCND1 gene
over-expression in dif-
ferent tumors
GY Liu
et al.
In this study, a significant
difference was found in car-
cinomatous and paracancer-
ous tissue samples, includ-
ing those of stomach, rec-
tum, thyroid gland, liver,
and mammary gland. Our
data indicate that CCND1 ex-
pression was significantly as-
sociated with carcinomatous
change.
CCNE1 Bladder
Urothelial
Carcinoma
A multi-stage
genome-wide associa-
tion study of bladder
cancer identifies mul-
tiple susceptibility
loci
N Roth-
man et al.
Cyclin E1 expression in blad-
der cancer has been asso-
ciated with high-grade or
muscle-invasive tumors and
poor clinical outcome
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CCNE1 Bladder
Urothelial
Carcinoma
High-Throughput
Tissue Microarray
Analysis of Cyclin E
Gene Amplification
and Overexpression
in Urinary Bladder
Cancer
J Richter
et al.
Overexpression of cyclin E
by mechanisms other than
amplification seems common
and is characteristic to a sub-
set of bladder carcinomas, es-
pecially at the stage of early
invasion.
CCNE1 Bladder
Urothelial
Carcinoma
Tumour-suppressive
microRNA-144-
5p directly targets
CCNE1/2 as potential
prognostic markers in
bladder cancer
R Mat-
sushita et
al.
The patients with high
CCNE1 or CCNE2 ex-
pression had lower overall
survival probabilities than
those with low expression
(P=0.025 and P=0.032).
CDK4 Brain Can-
cer
Combinations of
genetic mutations in
the adult neural stem
cell compartment de-
termine brain tumour
phenotypes
Thomas
S Jacques
et al.
The 5 transcript of Cdk4 is
significantly (P<0.001) up-
regulated in brain tumours,
whereas there is a statis-
tically nonsignificant upreg-
ulation of p16/Ink4a and
p19/Arf transcripts.
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EGFR Brain Can-
cer
Genetic Pathways
to Primary and Sec-
ondary Glioblastoma
H Ohgaki
and P
Kleihues
They affect mainly the el-
derly and are genetically
characterized by loss of het-
erozygosity 10q (70% of
cases), EGFR amplification
(36%), p16INK4a deletion
(31%), and PTEN mutations
(25%)
EGFR Brain Can-
cer
Clinical and Molecu-
lar Characteristics of
Malignant Transfor-
mation of Low-Grade
Glioma in Children
A Bro-
niscer et
al.
Although EGFR and ERBB4
overexpression were seen in
both LGGs and HGGs, they
occurred more commonly in
the latter group.
EGFR Brain Can-
cer
Gene expression pro-
filing of metastatic
brain cancer
VM
Zohra-
bian et
al.
Studies have examined the
differences in EGFR expres-
sion between primary and
secondary glioblastoma mul-
tiforme (GBM), and have
found that EGFR overexpres-
sion is associated with tumor
growth and angiogenesis
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MET Thyroid Car-
cinoma
Overexpression of the
c-MET/HGF receptor
gene in human thyroid
carcinomas
MFR Di
et al.
The receptor is barely de-
tectable, however, in normal
thyroids and in specimens
from patients affected by
non-neoplastic thyroid dis-
eases. Now we report that the
expression of the Met/HGF
receptor is increased a hun-
dred fold in 22 out of 41
human carcinomas derived
from the thyroid follicular
epithelium
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MET Stomach
Cancer
MET Expression and
Amplification in Pa-
tients with Localized
Gastric Cancer
YY Janji-
gian et al.
Although high levels of MET
protein and mRNA were
commonly encountered (in
63% and 50% of resected
tumor specimens, respec-
tively), none of these tumors
had MET gene amplification
by FISH, and only 6.6% had
evidence of MET tyrosine
kinase activity by p-MET
IHC.
MET Stomach
Cancer
Durable Complete Re-
sponse of Metastatic
Gastric Cancer with
Anti-Met Therapy Fol-
lowed by Resistance at
Recurrence
DVT
Cate-
nacci et
al.
The primary tumor had high
MET gene polysomy and ev-
idence for an autocrine pro-
duction of hepatocyte growth
factor, the growth factor lig-
and of Met.
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MET Stomach
Cancer
Impact of MET am-
plification on gastric
cancer: Possible roles
as a novel prognostic
marker and a potential
therapeutic target
J Lee et
al.
Although the definitive role
of MET oncogene is yet to
be determined in carcinogen-
esis of gastric cancer, overex-
pression and amplification of
c-Met has been demonstrated
in gastric cancer cell lines
PDGFRA Brain Can-
cer
Amplification of KIT,
PDGFRA, VEGFR2,
and EGFR in Gliomas
Marjut
Puputti et
al.
In conclusion, besides
glioblastoma, amplified KIT,
PDGFRA, and VEGFR may
also occur in lower-grade
gliomas and in their recurrent
tumors.
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ROS1 Lung Cancer Targeting ROS1 with
Anaplastic Lymphoma
Kinase Inhibitors:
A Promising Ther-
apeutic Strategy for
a Newly Defined
Molecular Subset of
NonSmall-Cell Lung
Cancer
Leow
PayChin
et al.
Microarray analysis of
NSCLC demonstrated sig-
nificantly elevated ROS1
expressions in 20% to 30%
of cases, and elevated ROS1
expression was found to be
part of a molecular signature
for lung adenocarcinoma
subtype
Table D.1: References that corroborate outlier findings for all genes identified as outliers in over
half of samples within a tumor subtype.
D.5 Negative Control
This section shows the p-value distributions of 100 GTex samples when different background
datasets are used in the model. Comparing normal samples to other normals should result in a
posterior predictive p-value distribution that is peaked around 0.5 (centered). Ergo, there should
be far fewer outliers when GTEx and TCGA-normal are the backgrounds compared to TCGA-
tumor. We expect the p-value distribution when tumor is the background to have longer tails
that extend below 0.05 and above 0.95.
All data used to generate the following section is avilable at http://courtyard.gi.ucsc.
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edu/˜jvivian/outlier-paper/experiments/negative-control.tar.gz.
Figure D.9: Negative control experiment where 100 GTEx samples were run using GTEx,
TCGA-normal, and TCGA-tumor as different backgrounds. Since posterior predictive p-values
measure how different the observed result is from model expectations, we assume that using
normal tissues as backgrounds for GTEx N-of-1 samples will result in a peak around 0.5 and
very few outliers compared to when TCGA-Tumor is used as a background.
Figure D.10: Same data as Figure D.9, but grouped by tissue type.
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D.6 Background dataset selection
Due to the choice of Dirichlet distribution for the β coefficients, which results in most back-
ground tissues being assigned ∼ 0 weight, it is reasonable to select a subset of background
tissues to keep runtime low. Instead of choosing an arbitrary number of background datasets,
the model can be iteratively run with more and more background datasets until the p-values
converge. Background datasets are first ranked by selecting 10% of the genes via ANOVA F-
value and then calculating the pairwise distance between the N-of-1 sample and the background
datasets. The model is then run, starting with the most proximal dataset, and datasets are itera-
tively added until p-values converge to a Pearson correlation > than 0.99. This can drastically
reduce runtime for N-of-1 samples with a strong match to one of the background datasets and is
flexible for samples that are more appropriately modeled by multiple background datasets. The
complete method for ranking background sets is shown in section E.2.
D.7 Number of genes effect on model output
This section explores the effect of varying the number of training genes on different aspects of
the model output.
Additional training genes help the model identify background datasets most similar to the N-of-
1 sample so the model can appropriately assign coefficient weights and produce an appropriate
posterior distribution. Choosing a subset of genes that accurately discriminate between the
different background datasets allows the model appropriately assign a majority of the weight to
the ”correct” background dataset that is most similar to the N-of-1. A fast method for selecting
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genes that fits this definition is to calculate the ANOVA F-value for each background dataset
using all available genes and selecting those with the highest F-values.
F =
variation between sample means
variation within samples
ANOVA was compared with Chi2, which measures dependence between variables, and was
found to produce model weights that were more consistent with the appropriate matched tissue.
All data used to generate the following section is avilable at http://courtyard.gi.ucsc.
edu/˜jvivian/outlier-paper/experiments/variable-genes.tar.gz.
Figure D.11: Effect of changing the number of training genes on x distribution (left) as well as
the posterior distribution (right) for two randomly selected genes. After only a few genes are
added, there is very little effect on the either x or posterior distribution.
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Figure D.12: Effect of additional training genes on gene p-values. This can be visualized by
calculating the Pearson correlation between all variable runs. For this sample, adding only 10
additional genes (based on ANOVA F-value) produces the same gene p-values as if we had
added 215 additional training genes.
D.8 Number of background datasets effect on model output
This section explores the effect that varying the number of background datasets has
on different aspects of model output. All data used to generate the following section
is avilable at http://courtyard.gi.ucsc.edu/˜jvivian/outlier-paper/experiments/
variable-backgrounds.tar.gz.
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Figure D.13: Effect of changing the number of background datasets has on the x distribution
(left) as well as the posterior distribution (right) for two randomly selected genes.
Figure D.14: Effect of additional background datasets on gene p-values. Similar to the previous
section, we want to know the effect of additional background training sets on the p-values
the model generates. This can be visualized by calculating the Pearson correlation between
all variable runs. For this sample, the first background dataset was the matched normal from
GTEx, which is why the pearson correlation between gene p-values remains static regardless of
the number of additional background datasets that are added.
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D.9 Software engineering
The codebase for our outlier detection method is open source (https://github.
com/jvivian/gene-outlier-detection/) and available as a Python package
(pip install --pre gene-outlier-detection), a Docker container (docker pull
jvivian/gene-outlier-detection), and a Toil workflow (see Github repository). The
software provides a plethora of output: ranked pairwise distances of the background datasets as
compared to the N-of-1 sample, a serialized PyMC3 trace and model for reproducibility, trace
plots for important model parameters to confirm model convergence, β weight table and plot
to see confidence of model in assignment of weight to the background datasets, and posterior
predictive p-values for every gene of interest (Figure D.15). The software also includes an info
subdirectory that contains Pearson correlations between iterative runs, p-values for those runs,
and a run info.tsv table that contains every parameter setting used in that run of the model in
addition to runtime.
The PyMC3 model and trace can be directly examined from the serialized model:
import pickle
with open(pkl_path, ’rb’) as buff:
data = pickle.load(buff)
model, trace = data[’model’], data[’trace’]
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Figure D.15: Graph of the outlier modeling software. Dark grey boxes indicate inputs and
shadowed boxes indicate outputs. Background datasets are first ranked by calculating pairwise
distance from the n-of-1 samples to the top 10% ANOVA genes (section D.6). By default,
background datasets are iteratively added until the provided genes converge with a p-value
> 0.99.
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Appendix E
Supplementary materials for Chapter 4
For reproducibility, we have included all code used to generate figures in the paper here along
with additional experiments that show the effect of additional datasets and training genes on
parameters in the model (section D.7, section D.8). We have also hosted all data used in this
paper at a public URL http://courtyard.gi.ucsc.edu/˜jvivian/outlier-paper/. The
expression-matrices subdirectory contains HD5 matrices with metadata and gene expression
information for GTEx, TCGA tumors, and TCGA normals. In Python, these matrices can be
opened with Pandas, e.g. (df = pd.read_hdf(’tumor.hd5’)). The experiments subdirectory
contains compressed archives of data generated for figures in the paper as well as the supple-
ment. Each section in the supplement explictly references a URL to the data used to generate
figures in that section.
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Tissue Tumor Subtype Number of Samples
Adrenal Adrenocortical Carcrinoma 77
Bladder Bladder Urothelial Carcinoma 100
Brain Brain Lower Grade Glioma 100
Breast Breast Invasive Carcinoma 100
Kidney Kidney Renal Clear Cell Carcinoma 100
Liver Liver Hepatocellular Carcinoma 100
Lung Lung Adenocarcinoma 100
Prostate Prostate Adenocarcinoma 100
Stomach Stomach Adenocarcinoma 100
Thyroid Thyroid Carcinoma 100
Table E.1: Tissues and corresponding tumor subtypes for the 977 samples used to generate data
for section D.1 and section D.4. 100 samples were chosen randomly from each subtype, except
for adrenocortical carcinoma which only has 77 samples.
E.1 Code for figures
This section contains the code used to generate every figure in Appendix D.
E.1.1 Model weight
The code in this section was used to generate every figure in section D.1.
import os
import matplotlib.pyplot as plt
import pandas as pd
import seaborn as sns
from sklearn.decomposition import pca
sns.set(font_scale=1.0)
sns.set_style("whitegrid")
class Weights:
def __init__(self, tumor_path: pd.DataFrame, sample_dir: str):
self.tumor_path = tumor_path
self.tumor = self._load_tumor()
self.genes = self.tumor.columns[5:]
self.sample_dir = sample_dir
self.df = self._weight_df()
self.tissue_perc = self._perc_df()
self.subtype_perc = self._perc_df("subtype")
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self.num_samples = len(self.df["sample"].unique())
def _weight_df(self) -> pd.DataFrame:
"""
Creates DataFrame of sample weights from a directory of samples
Columns: tissue, normal_tissue, weight, sample_id
Returns:
DataFrame of Weights
"""
# DataFrame: cols=tissue, normal_tissue, weight
weights = []
tissues = self.tumor.tissue
subtypes = self.tumor.subtype
for sample in os.listdir(self.sample_dir):
sample_tissue = tissues.loc[sample]
sample_subtype = subtypes.loc[sample]
w = pd.read_csv(
os.path.join(self.sample_dir, sample, "weights.tsv"), sep="\t"
)
w.columns = ["normal_tissue", "Median", "std"]
w["tissue"] = sample_tissue
w["subtype"] = sample_subtype
w["sample"] = sample
# Add zero weight if missing
if sample_tissue not in w.normal_tissue.values:
w.loc[len(w)] = [
sample_tissue,
0,
0,
sample_tissue,
sample_subtype,
sample,
]
weights.append(w.drop("std", axis=1))
return pd.concat(weights).reset_index(drop=True)
def _perc_df(self, group="tissue") -> pd.DataFrame:
"""
Converts DataFrame of weights into a DataFrame of percentages
Returns:
Weight percentage DataFrame
"""
c = self.df.groupby([group,
"normal_tissue"])["Median"].sum().rename("count")
perc = c / c.groupby(level=0).sum() * 100
return perc.reset_index()
def _load_tumor(self):
print(f"Reading in {self.tumor_path}")
if self.tumor_path.endswith(".csv"):
df = pd.read_csv(self.tumor_path, index_col=0)
elif self.tumor_path.endswith(".tsv"):
df = pd.read_csv(self.tumor_path, sep="\t", index_col=0)
else:
try:
df = pd.read_hdf(self.tumor_path)
except Exception as e:
print(e)
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raise RuntimeError(f"Failed to open DataFrame: {self.tumor_path}")
return df
def plot_match_scatter(self, out_dir: str = None):
"""
Scatterplot of samples by tissue and their matched tissue model weight
Args:
out_dir: Optional output directory
Returns:
Plot axes object
"""
df = self.df
# Subset for matched-tissue samples
df = df[df.normal_tissue == df.tissue].sort_values("tissue")
f, ax = plt.subplots(figsize=(12, 4))
sns.swarmplot(data=df, x="tissue", y="Median")
plt.xticks(rotation=45)
plt.xlabel("Tissue")
plt.ylabel("GTEx Matched Tissue Weight")
plt.title("TCGA Tumor Samples and Model Weight for GTEx Matched Tissue")
if out_dir:
plt.savefig(os.path.join(out_dir, "matched_weight_scatter.svg"))
return ax
def plot_perc_heatmap(self, out_dir: str = None, subtype=False):
"""
Heatmap of weight percentages
Args:
out_dir: Optional output directory
Returns:
Plot axes object
"""
df = self.subtype_perc if subtype else self.tissue_perc
column = "subtype" if subtype else "tissue"
f, ax = plt.subplots(figsize=(8, 7))
perc_heat = df.pivot(index="normal_tissue", columns=column,
values="count")
sns.heatmap(
perc_heat.apply(lambda x: round(x, 1)),
cmap="Blues",
annot=True,
linewidths=0.5,
)
plt.xlabel("Tumor Tissue")
plt.ylabel("GTEx Tissue")
title = f"Average Weight (%) of Tumor to GTEx Tissue
(n={self.num_samples})"
plt.title(title)
if out_dir:
plt.savefig(os.path.join(out_dir, "weight_perc_heatmap.svg"))
return ax
def plot_pca_nearby_tissues(self, background_path: str, tissues,
tumor_tissue):
"""
PCA of nearby tissues
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Args:
background_path: Path to background dataframe
tissues: Tissues to include in PCA
tumor_tissue: Label for tumor tissue
Returns:
Plot axes object
"""
df = pd.read_hdf(background_path)
tumor = self.tumor
tumor = tumor[tumor.tissue == tumor_tissue]
tumor["tissue"] = f"{tumor_tissue}-Tumor"
sub = df[df.tissue.isin(tissues)]
pca_df = pd.concat([tumor, sub]).dropna(axis=1)
embedding = pca.PCA(n_components=2).fit_transform(pca_df[self.genes])
embedding = pd.DataFrame(embedding)
embedding.columns = ["PCA1", "PCA2"]
embedding["tissue"] = list(pca_df["tissue"])
f, ax = plt.subplots(figsize=(8, 8))
sns.scatterplot(
data=embedding, x="PCA1", y="PCA2", hue="tissue", style="tissue"
)
plt.title(f"PCA of {tumor_tissue} and Nearby GTEx Tissues")
return ax
E.1.2 Mixture simulations
The code in this section was used to generate every figure in section D.2.
import os
from itertools import combinations
import matplotlib.pyplot as plt
import numpy as np
import pandas as pd
import seaborn as sns
from sklearn.decomposition import pca
sns.set_style("whitegrid")
class Mixture:
def __init__(self, df_path):
self.df_path = df_path
self.df = self._load_df(df_path)
self.genes = list(self.df.columns[5:])
@staticmethod
def _load_df(path):
"""Loads DataFrame"""
print(f"Reading in {path}")
if path.endswith(".csv"):
120
df = pd.read_csv(path, index_col=0)
elif path.endswith(".tsv"):
df = pd.read_csv(path, sep="\t", index_col=0)
else:
try:
df = pd.read_hdf(path)
except Exception as e:
print(e)
raise RuntimeError(f"Failed to open DataFrame: {path}")
return df
def select_mixture_tissues(self, number_of_pairs=10):
"""Generates N tissue pairs"""
# Choose a tissue subset with relevant matches to TCGA
tissues_to_include = [
"Adrenal",
"Bladder",
"Brain",
"Breast",
"Kidney",
"Liver",
"Lung",
"Prostate",
"Stomach",
"Thyroid",
]
df = self.df[self.df.tissue.isin(tissues_to_include)]
df = df.groupby("tissue").filter(lambda x: len(x) > 100)
tissues = list(combinations(df.tissue.unique(), 2))
ix = np.random.choice(range(len(tissues)), number_of_pairs, replace=False)
pairs = []
for i in ix:
pairs.append(tissues[i])
return pairs
def mixture_matrix(self, t1, t2, out_dir):
"""Create mixture_matrix for one tissue pair"""
df = self.df
df1 = df[df.tissue == t1]
df2 = df[df.tissue == t2]
path = os.path.join(out_dir, f"{t1}-{t2}.hd5")
if os.path.exists(path):
return pd.read_hdf(path)
samples = []
for i in range(50):
s1 = np.random.choice(df1.index, 100, replace=False)
s2 = np.random.choice(df2.index, 100, replace=False)
g1 = df1.loc[s1]
g2 = df2.loc[s2]
vec = pd.concat([g1, g2])[self.genes].median()
samples.append(vec)
mixture_matrix = pd.concat(samples, axis=1).T
mixture_matrix.index = [f"{t1}-{t2}-{i}" for i in range(50)]
mixture_matrix.to_hdf(path, key="exp")
return mixture_matrix
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def mixture_matrices(self, tissues, out_dir):
"""Create mixture matrices for all tissue pairs"""
matrices = {}
for t1, t2 in tissues:
label = f"{t1}-{t2}"
print(f"Creating mixture matrix for {label}")
matrices[label] = self.mixture_matrix(t1, t2, out_dir)
return matrices
def manifest(self, tissues, matrix_dir, output_dir):
"""Create manifest for outlier Toil run"""
path = os.path.join(output_dir, "manifest.tsv")
with open(path, "w") as f:
f.write("id\tsample\n")
for t1, t2 in tissues:
label = f"{t1}-{t2}"
for i in range(10):
matrix_path = os.path.join(matrix_dir, f"{label}.hd5")
f.write(f"{label}-{i}\t{matrix_path}\n")
@staticmethod
def weight_df(sample_dir: str, only_contributing_tissues=True) ->
pd.DataFrame:
"""Creates DataFrame from weights across samples"""
samples = os.listdir(sample_dir)
weights = []
for sample in samples:
t1, t2 = sample.split("-")[:-1]
label = f"{t1}-{t2}"
path = os.path.join(sample_dir, sample, "weights.tsv")
w = pd.read_csv(path, sep="\t")
w.columns = ["tissue", "Median", "std"]
w["sample"] = sample
w["label"] = label
if only_contributing_tissues:
w = w[w.tissue.isin([t1, t2])]
weights.append(w.drop("std", axis=1))
weights = pd.concat(weights).reset_index(drop=True)
return weights.sort_values("label")
def plot_mixture_pca(self, matrix_dir: str):
"""PCA of mixture samples and the tissues used to generate them"""
os.listdir(matrix_dir)
f, ax = plt.subplots(3, 4, figsize=(12, 4 * 3))
ax = ax.flatten()
for i, matrix in enumerate(os.listdir(matrix_dir)):
t1, t2 = os.path.splitext(matrix)[0].split("-")
mix_df = pd.read_hdf(os.path.join(matrix_dir, matrix))
mix_df["tissue"] = "Mixture"
sub = self.df[self.df.tissue.isin([t1, t2])]
pca_df = pd.concat([sub, mix_df]).dropna(axis=1)
embedding = pca.PCA(n_components=2).fit_transform(pca_df[self.genes])
embedding = pd.DataFrame(embedding)
embedding.columns = ["PCA1", "PCA2"]
embedding["tissue"] = list(pca_df["tissue"])
sns.scatterplot(
data=embedding,
x="PCA1",
y="PCA2",
hue="tissue",
style="tissue",
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ax=ax[i],
)
ax[i].set_title(f"{t1}-{t2}")
for i in [10, 11]:
f.delaxes(ax.flatten()[i])
plt.tight_layout()
return ax
def plot_pca_nearby_tissues(self, matrix_path: str, tissues):
st_df = pd.read_hdf(matrix_path)
label = os.path.splitext(os.path.basename(matrix_path))[0]
st_df["tissue"] = "Mixture"
sub = self.df[self.df.tissue.isin(tissues)]
pca_df = pd.concat([st_df, sub]).dropna(axis=1)
embedding = pca.PCA(n_components=2).fit_transform(pca_df[self.genes])
embedding = pd.DataFrame(embedding)
embedding.columns = ["PCA1", "PCA2"]
embedding["tissue"] = list(pca_df["tissue"])
f, ax = plt.subplots(figsize=(8, 8))
sns.scatterplot(
data=embedding, x="PCA1", y="PCA2", hue="tissue", style="tissue"
)
plt.title(f"PCA of {label} Mixtures and Nearby Tissues")
return ax
@staticmethod
def plot_weight_swarm(wdf: pd.DataFrame):
"""Swarmplot of weights for the tissues that comprise the mixture"""
f, ax = plt.subplots(figsize=(12, 4))
sns.swarmplot(data=wdf, x="label", y="Median", hue="tissue", size=8,
alpha=0.75)
plt.ylim([0, 1])
plt.xticks(rotation=45)
plt.legend(bbox_to_anchor=(1.01, 1))
plt.axhline(0.5, c="r", alpha=0.5, ls="--")
plt.xlabel("Mixture-Pairs")
plt.ylabel("Beta Coefficient Median")
plt.title(f"Average Beta Coefficient Weight Across Mixture Samples
(n=100)")
return ax
@staticmethod
def plot_weight_boxplot(wdf, label):
"""Boxplot of weigts for a single label"""
weights = wdf[wdf.label == label]
f, ax = plt.subplots(figsize=(8, 4))
sns.boxplot(data=weights, x="tissue", y="Median")
plt.title(f"Boxplot of Weights for {label} Mixtures")
plt.xlabel("Tissue")
plt.ylabel("Average Weight")
plt.ylim([0, 1])
return ax
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E.1.3 Effect of removing matched tissue on gene p-values
The code in this section was used to generate every figure in section D.3.
import os
import pandas as pd
from scipy.stats import pearsonr
class MatchRemove:
def __init__(self, background_path):
self.df = self._load_df(background_path)
@staticmethod
def _load_df(path):
"""Loads DataFrame"""
print(f"Reading in {path}")
if path.endswith(".csv"):
df = pd.read_csv(path, index_col=0)
elif path.endswith(".tsv"):
df = pd.read_csv(path, sep="\t", index_col=0)
else:
try:
df = pd.read_hdf(path)
except Exception as e:
print(e)
raise RuntimeError(f"Failed to open DataFrame: {path}")
return df
def create_backgrounds(self, tissues, out_dir):
for tissue in tissues:
sub = self.df[self.df.tissue != tissue]
out = os.path.join(out_dir, f"gtex-{tissue}-removed.hd5")
sub.to_hdf(out, key="exp")
def manifest(self, samples, sample_path, background_dir, out_dir):
df = self._load_df(sample_path)
tissues = df.tissue
out_dir = os.path.join(out_dir, "manifest.tsv")
with open(out_dir, "w") as f:
f.write("sample\tbackground\n")
for sample in samples:
tissue = tissues.loc[sample]
bg_path = os.path.join(background_dir,
f"gtex-{tissue}-removed.hd5")
f.write(f"{sample}\t{bg_path}\n")
@staticmethod
def weight_pearsonR_df(out_dir, mr_dir, sample_path):
samples = os.listdir(mr_dir)
df = MatchRemove._load_df(sample_path)
tissues = df.tissue
rows = []
for sample in samples:
tissue = tissues.loc[sample]
# Collect median weight
weight_path = os.path.join(out_dir, sample, "weights.tsv")
weights = pd.read_csv(weight_path, sep="\t", index_col=0)
try:
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w = weights.loc[tissue].Median
except KeyError:
w = 0
# Collect pvals and calculate PearsonR
norm_path = os.path.join(out_dir, sample, "pvals.tsv")
norm_pvals = pd.read_csv(norm_path, sep="\t", index_col=0)
mr_path = os.path.join(mr_dir, sample, "pvals.tsv")
mr_pvals = pd.read_csv(mr_path, sep="\t", index_col=0)
pvals = pd.concat([norm_pvals, mr_pvals], axis=1).dropna()
pvals.columns = ["norm", "mr"]
r, _ = pearsonr(pvals["norm"], pvals["mr"])
rows.append([w, r, tissue, sample])
columns = ["Weight", "PearsonR", "Tissue", "Sample"]
return pd.DataFrame(rows, columns=columns)
E.1.4 Quantify outliers
The code in this section was used to generate every figure in section D.4.
import pandas as pd
import numpy as np
import os
import scipy.stats as st
import matplotlib.pyplot as plt
import seaborn as sns
sns.set(font_scale=1.20)
sns.set_style("whitegrid")
class Outliers:
def __init__(self, sample_dir, sample_path):
self.sample_dir = sample_dir
self.sample_path = sample_path
self.df = self._load_df(sample_path)
self.tissue = self.df.tissue
self.subtype = self.df.subtype
self.pval_df = self._pval_df()
def _pval_df(self) -> pd.DataFrame:
pvals = []
for sample_name in os.listdir(self.sample_dir):
# Check if matched tissue was used in the weight
w_path = os.path.join(self.sample_dir, sample_name, "weights.tsv")
w = pd.read_csv(w_path, sep="\t", index_col=0)
tissue = self.tissue.loc[sample_name]
if not tissue in w.index:
continue
pval_path = os.path.join(self.sample_dir, sample_name, "pvals.tsv")
p = pd.read_csv(pval_path, sep="\t")
p["sample"] = sample_name
p["tissue"] = self.tissue.loc[sample_name]
p["subtype"] = self.subtype.loc[sample_name]
pvals.append(p)
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pvals = pd.concat(pvals)
return pvals.sort_values("tissue").reset_index(drop=True)
@staticmethod
def _load_df(path):
"""Loads DataFrame"""
print(f"Reading in {path}")
if path.endswith(".csv"):
df = pd.read_csv(path, index_col=0)
elif path.endswith(".tsv"):
df = pd.read_csv(path, sep="\t", index_col=0)
else:
try:
df = pd.read_hdf(path)
except Exception as e:
print(e)
raise RuntimeError(f"Failed to open DataFrame: {path}")
return df
E.1.5 Variable gene and variable dataset code
The code in this section was used to generate every figure in section D.7 as well as section D.8.
import os
import pickle
import matplotlib.pyplot as plt
import pandas as pd
import seaborn as sns
import numpy as np
from scipy.stats import pearsonr
sns.set_style("whitegrid")
class Genes:
def __init__(
self, sample_dir, background_path, sample_path, sample_name, genes_path
):
self.sample_dir = sample_dir
self.background_path = background_path
self.sample_path = sample_path
self.sample_name = sample_name
self.classes = None
self.w = self._weight_df()
self.p = self._pval_df()
self.traces = {}
self.dfs = {}
self.genes = [
x.strip() for x in open(genes_path, "r").readlines() if not
x.isspace()
]
def _weight_df(self) -> pd.DataFrame:
weights = []
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for subdir in os.listdir(self.sample_dir):
max_genes = int(subdir)
sample_name = os.listdir(os.path.join(self.sample_dir, subdir))[0]
weight_path = os.path.join(
self.sample_dir, subdir, sample_name, "weights.tsv"
)
w = pd.read_csv(weight_path, sep="\t")
w.columns = ["tissue", "Median", "std"]
w["sample"] = sample_name
w["max_genes"] = int(max_genes)
w["num_training_genes"] = int(max_genes) - 85
weights.append(w.drop("std", axis=1))
weights = pd.concat(weights).reset_index(drop=True)
self.classes = sorted(weights.tissue)
return weights.sort_values("max_genes")
def _pval_df(self) -> pd.DataFrame:
pvals = []
for subdir in os.listdir(self.sample_dir):
max_genes = int(subdir)
sample_name = os.listdir(os.path.join(self.sample_dir, subdir))[0]
pval_path = os.path.join(self.sample_dir, subdir, sample_name,
"pvals.tsv")
p = pd.read_csv(pval_path, sep="\t")
p["sample"] = sample_name
p["max_genes"] = int(max_genes)
p["num_training_genes"] = int(max_genes) - 85
pvals.append(p)
pvals = pd.concat(pvals).reset_index(drop=True)
return pvals.sort_values("max_genes")
def _load_df(self, path):
if path in self.dfs:
return self.dfs[path]
print(f"Reading in {path}")
if path.endswith(".csv"):
df = pd.read_csv(path, index_col=0)
elif path.endswith(".tsv"):
df = pd.read_csv(path, sep="\t", index_col=0)
else:
try:
df = pd.read_hdf(path)
except Exception as e:
print(e)
raise RuntimeError(f"Failed to open DataFrame: {path}")
self.dfs[path] = df
return df
@staticmethod
def _load_model(pkl_path):
with open(pkl_path, "rb") as buff:
data = pickle.load(buff)
return data["model"], data["trace"]
def _df(self, gene, tissue) -> pd.DataFrame:
p = []
for i, subdir in enumerate(os.listdir(self.sample_dir)):
max_genes = int(subdir)
sample_name = os.listdir(os.path.join(self.sample_dir, subdir))[0]
if subdir in self.traces:
t = self.traces[subdir]
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else:
if i == 0:
print("Loading traces to extract posterior distribution")
model_path = os.path.join(
self.sample_dir, subdir, sample_name, "model.pkl"
)
m, t = self._load_model(model_path)
self.traces[subdir] = t
# Calculate PPC
ppc = self._posterior_predictive_check(t, [gene])
df = pd.DataFrame()
df["ppc"] = ppc[gene]
df["x"] = t[f"{gene}={tissue}"]
df["max_genes"] = max_genes
df["num_training_genes"] = int(max_genes) - 85
p.append(df)
p = pd.concat(p).reset_index(drop=True)
return p.sort_values("max_genes")
def t_fits(self, backgrounds, group="tissue"):
"""
StudentT distribution fits for every dataset/gene pair
Args:
df: Background dataframe to use in comparison
genes: Genes to fit
backgrounds: Background datasets to fit
group: Column in background dataset to use as labels
Returns:
StudentT fits for every gene-dataset pair
"""
df = self._load_df(self.background_path)
genes = self.genes
fits = {}
for gene in genes:
for i, dataset in enumerate(backgrounds):
# "intuitive" prior parameters
prior_mean = 0.0
prior_std_dev = 1.0
pseudocounts = 1.0
# convert to prior params of normal-inverse gamma
kappa_0 = pseudocounts
mu_0 = prior_mean
alpha_0 = 0.5 * pseudocounts
beta_0 = 0.5 / prior_std_dev ** 2
# collect summary statistics for data
observations = np.array(df[df[group] == dataset][gene])
n = len(observations)
obs_sum = np.sum(observations)
obs_mean = obs_sum / n
obs_ssd = np.sum(np.square(observations - obs_mean))
# compute the posterior params
kappa_n = kappa_0 + n
mu_n = (kappa_0 * mu_0 + obs_sum) / (kappa_0 + n)
alpha_n = alpha_0 + 0.5 * n
beta_n = beta_0 + 0.5 * (
obs_ssd + kappa_0 * n * (obs_mean - mu_0) ** 2 / (kappa_0 + n)
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)# from
https://www.seas.harvard.edu/courses/cs281/papers/murphy-2007.pdf,
equation (110)
# convert to the params of a PyMC student-t (i.e. integrate out
the prior)
mu = mu_n
nu = 2.0 * alpha_n
lam = alpha_n * kappa_n / (beta_n * (kappa_n + 1.0))
fits[f"{gene}={dataset}"] = (mu, nu, lam, np.sqrt(1 / lam))
return fits
def _posterior_predictive_check(self, trace, genes):
"""
Posterior predictive check for a list of genes trained in the model
Args:
trace: PyMC3 trace
fits: StudentT fits for background dataset/gene expression
genes: List of genes of interest
Returns:
Dictionary of [genes, array of posterior sampling]
"""
fits = self.t_fits(self.classes)
d = {}
for gene in genes:
d[gene] = self._gene_ppc(trace, fits, gene)
return d
@staticmethod
def _gene_ppc(trace, fits, gene: str) -> np.array:
"""
Calculate posterior predictive for a gene
Args:
trace: PyMC3 Trace
fits: StudentT fits for background dataset/gene expression
gene: Gene of interest
Returns:
Random variates representing PPC of the gene
"""
y_gene = [x for x in trace.varnames if x.startswith(f"{gene}=")]
y, norm_term = 0, 0
multiple_backgrounds = "b" in trace.varnames
for i, y_name in enumerate(y_gene):
nu, mu, lam, sd = fits[y_name]
b = trace["b"][:, i] if multiple_backgrounds else 1
y += (b / sd) * trace[y_name]
norm_term += b / sd
return np.random.laplace(loc=(y / norm_term), scale=(trace["eps"] /
norm_term))
def _pearson_pvalue_matrix(self):
df = self.p
matrix = []
df = df[df.Gene.isin(self.genes)]
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ntg_vector = df.num_training_genes.unique()
for i in ntg_vector:
row = []
d1 = df[df.num_training_genes == i]
d1.index = d1.Gene
for j in ntg_vector:
d2 = df[df.num_training_genes == j]
d2.index = d2.Gene
# Combine and index by gene
c = pd.concat([d1.Pval, d2.Pval], axis=1)
c.columns = [0, 1]
r, _ = pearsonr(c[0], c[1])
row.append(r)
matrix.append(row)
matrix = pd.DataFrame(matrix, index=ntg_vector, columns=ntg_vector)
return matrix.apply(lambda x: round(x, 4))
def plot_genes_by_weights(self):
_, ax = plt.subplots(figsize=(8, 4))
sns.lineplot(data=self.w, x="num_training_genes", y="Median",
hue="tissue")
plt.xlabel("Number of Additional Training Genes")
plt.ylabel("Median Beta Coefficient")
plt.ylim([0, 1])
plt.title("Effect of Adding Training Genes on Beta Weights")
return ax
def plot_x(self, gene, tissue):
bg = self._load_df(self.background_path)
sg = self._load_df(self.sample_path)
df = self._df(gene, tissue)
_, ax = plt.subplots(figsize=(8, 5))
plt.axvline(sg.loc[self.sample_name][gene], label="N-of-1", c="r")
gr = df.groupby("num_training_genes")["x"]
for label, arr in gr:
sns.kdeplot(arr, label=label)
sns.kdeplot(bg[bg.tissue == tissue][gene], shade=True, label="Observed")
plt.xlabel("Transcripts per Million (log2(TPM +1))")
plt.ylabel("Density")
plt.title(f"Effect of n Genes on x Distribution - {gene}")
return ax
def plot_posterior(self, gene, tissue):
sg = self._load_df(self.sample_path)
bg = self._load_df(self.background_path)
df = self._df(gene, tissue)
_, ax = plt.subplots(figsize=(8, 5))
plt.axvline(sg.loc[self.sample_name][gene], label="N-of-1", c="r")
gr = df.groupby("num_training_genes")["ppc"]
for label, arr in gr:
sns.kdeplot(arr, label=label)
sns.kdeplot(bg[bg.tissue == tissue][gene], shade=True, label="Observed")
plt.xlabel("Transcripts per Million (log2(TPM +1))")
plt.ylabel("Density")
plt.title(f"Effect of n Genes on Posterior Distribution - {gene}")
return ax
def plot_pval_heatmap(self):
matrix = self._pearson_pvalue_matrix()
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f, ax = plt.subplots(figsize=(12, 4))
sns.heatmap(matrix, cmap="Blues", annot=True, linewidths=0.5)
plt.xlabel("Number of Additional Training Genes")
plt.ylabel("Number of Additional Training Genes")
plt.title(
"Pearson Correlation of Gene P-values (n=85) as Training Genes are
Added"
)
return ax
E.2 Ranking scheme for background datasets
Python implementation for ranking background datasets
def anova_distances(
sample: pd.Series,
df: pd.DataFrame,
genes: List[str],
group: str = "tissue",
percent_genes=0.10,
):
"""
Calculates distance to each group via pairwise distance using top N ANOVA
genes
Args:
sample: n-of-1 sample. Gets own label
df: background dataset
genes: genes to use for pairwise distance
group: Column to use as class discriminator
percent_genes: Percent of ANOVA genes to use for pairwise distance
Returns:
DataFrame of pairwise distances
"""
click.echo(f"Ranking background datasets by {group} via ANOVA")
n_genes = int(percent_genes * len(genes))
skb_genes = select_k_best_genes(df, genes, n=n_genes)
dist = pairwise_distances(np.array(sample[skb_genes]).reshape(1, -1),
df[skb_genes])
dist = pd.DataFrame([dist.ravel(), df["tissue"]]).T
dist.columns = ["Distance", "Group"]
# Median by group and sort
med_dist = (
dist.groupby("Group").apply(lambda x:
x["Distance"].median()).reset_index()
)
med_dist.columns = ["Group", "MedianDistance"]
return med_dist.sort_values("MedianDistance").reset_index(drop=True)
131
Bibliography
[1] The Cancer Genome Atlas Research Network, John N Weinstein, Eric A Collisson, Gor-
don B Mills, Kenna R Mills Shaw, Brad A Ozenberger, Kyle Ellrott, Ilya Shmulevich,
Chris Sander, and Joshua M Stuart. The Cancer Genome Atlas Pan-Cancer analysis
project. Nature Genetics, 45(10):1113–1120, October 2013.
[2] The GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: Multi-
tissue gene regulation in humans. Science, 348(6235):648–660, May 2015.
[3] Eric Normandeau. Scripts developped over time. Contribute to enormandeau/Scripts
development by creating an account on GitHub, May 2019.
[4] Initial sequencing and analysis of the human genome. Nature, 409(6822):860, February
2001.
[5] Paul Muir, Shantao Li, Shaoke Lou, Daifeng Wang, Daniel J. Spakowicz, Leonidas Sali-
chos, Jing Zhang, George M. Weinstock, Farren Isaacs, Joel Rozowsky, and Mark Ger-
stein. The real cost of sequencing: Scaling computation to keep pace with data genera-
tion. Genome Biology, 17(1):53, March 2016.
[6] Joel Diamond. Don’t lock genomic data into silos, July 2018.
[7] Martin Hilbert and Priscila Lo´pez. The World’s Technological Capacity to Store, Com-
municate, and Compute Information. Science, 332(6025):60–65, April 2011.
[8] John Gantz and David Reinsel. Extracting value from chaos. IDC iview, 2011.
[9] The Event Horizon Telescope Collaboration, Kazunori Akiyama, Antxon Alberdi, Wal-
ter Alef, Keiichi Asada, Rebecca Azulay, Anne-Kathrin Baczko, David Ball, Mislav
Balokovic´, John Barrett, Dan Bintley, Lindy Blackburn, Wilfred Boland, Katherine L.
Bouman, Geoffrey C. Bower, Michael Bremer, Christiaan D. Brinkerink, Roger Bris-
senden, Silke Britzen, Avery E. Broderick, Dominique Broguiere, Thomas Bronzwaer,
Do-Young Byun, John E. Carlstrom, Andrew Chael, Chi-kwan Chan, Shami Chatter-
jee, Koushik Chatterjee, Ming-Tang Chen, Yongjun Chen, Ilje Cho, Pierre Christian,
John E. Conway, James M. Cordes, Geoffrey B. Crew, Yuzhu Cui, Jordy Davelaar,
Mariafelicia De Laurentis, Roger Deane, Jessica Dempsey, Gregory Desvignes, Jason
Dexter, Sheperd S. Doeleman, Ralph P. Eatough, Heino Falcke, Vincent L. Fish, Ed Fo-
malont, Raquel Fraga-Encinas, William T. Freeman, Per Friberg, Christian M. Fromm,
132
Jose´ L. Go´mez, Peter Galison, Charles F. Gammie, Roberto Garcı´a, Olivier Gentaz, Boris
Georgiev, Ciriaco Goddi, Roman Gold, Minfeng Gu, Mark Gurwell, Kazuhiro Hada,
Michael H. Hecht, Ronald Hesper, Luis C. Ho, Paul Ho, Mareki Honma, Chih-Wei L.
Huang, Lei Huang, David H. Hughes, Shiro Ikeda, Makoto Inoue, Sara Issaoun, David J.
James, Buell T. Jannuzi, Michael Janssen, Britton Jeter, Wu Jiang, Michael D. John-
son, Svetlana Jorstad, Taehyun Jung, Mansour Karami, Ramesh Karuppusamy, Tomohisa
Kawashima, Garrett K. Keating, Mark Kettenis, Jae-Young Kim, Junhan Kim, Jongsoo
Kim, Motoki Kino, Jun Yi Koay, Patrick M. Koch, Shoko Koyama, Michael Kramer,
Carsten Kramer, Thomas P. Krichbaum, Cheng-Yu Kuo, Tod R. Lauer, Sang-Sung Lee,
Yan-Rong Li, Zhiyuan Li, Michael Lindqvist, Kuo Liu, Elisabetta Liuzzo, Wen-Ping
Lo, Andrei P. Lobanov, Laurent Loinard, Colin Lonsdale, Ru-Sen Lu, Nicholas R.
MacDonald, Jirong Mao, Sera Markoff, Daniel P. Marrone, Alan P. Marscher, Iva´n
Martı´-Vidal, Satoki Matsushita, Lynn D. Matthews, Lia Medeiros, Karl M. Menten,
Yosuke Mizuno, Izumi Mizuno, James M. Moran, Kotaro Moriyama, Monika Mosci-
brodzka, Cornelia Mu¨ller, Hiroshi Nagai, Neil M. Nagar, Masanori Nakamura, Ramesh
Narayan, Gopal Narayanan, Iniyan Natarajan, Roberto Neri, Chunchong Ni, Aristeidis
Noutsos, Hiroki Okino, He´ctor Olivares, Gisela N. Ortiz-Leo´n, Tomoaki Oyama, Fer-
yal O¨zel, Daniel C. M. Palumbo, Nimesh Patel, Ue-Li Pen, Dominic W. Pesce, Vincent
Pie´tu, Richard Plambeck, Aleksandar PopStefanija, Oliver Porth, Ben Prather, Jorge A.
Preciado-Lo´pez, Dimitrios Psaltis, Hung-Yi Pu, Venkatessh Ramakrishnan, Ramprasad
Rao, Mark G. Rawlings, Alexander W. Raymond, Luciano Rezzolla, Bart Ripperda,
Freek Roelofs, Alan Rogers, Eduardo Ros, Mel Rose, Arash Roshanineshat, Helge
Rottmann, Alan L. Roy, Chet Ruszczyk, Benjamin R. Ryan, Kazi L. J. Rygl, Salvador
Sa´nchez, David Sa´nchez-Arguelles, Mahito Sasada, Tuomas Savolainen, F. Peter Schlo-
erb, Karl-Friedrich Schuster, Lijing Shao, Zhiqiang Shen, Des Small, Bong Won Sohn,
Jason SooHoo, Fumie Tazaki, Paul Tiede, Remo P. J. Tilanus, Michael Titus, Kenji
Toma, Pablo Torne, Tyler Trent, Sascha Trippe, Shuichiro Tsuda, Ilse van Bemmel,
Huib Jan van Langevelde, Daniel R. van Rossum, Jan Wagner, John Wardle, Jonathan
Weintroub, Norbert Wex, Robert Wharton, Maciek Wielgus, George N. Wong, Qing-
wen Wu, Ken Young, Andre´ Young, Ziri Younsi, Feng Yuan, Ye-Fei Yuan, J. Anton
Zensus, Guangyao Zhao, Shan-Shan Zhao, Ziyan Zhu, Juan-Carlos Algaba, Alexander
Allardi, Rodrigo Amestica, Jadyn Anczarski, Uwe Bach, Frederick K. Baganoff, Christo-
pher Beaudoin, Bradford A. Benson, Ryan Berthold, Jay M. Blanchard, Ray Blundell,
Sandra Bustamente, Roger Cappallo, Edgar Castillo-Domı´nguez, Chih-Cheng Chang,
Shu-Hao Chang, Song-Chu Chang, Chung-Chen Chen, Ryan Chilson, Tim C. Chuter,
Rodrigo Co´rdova Rosado, Iain M. Coulson, Thomas M. Crawford, Joseph Crowley, John
David, Mark Derome, Matthew Dexter, Sven Dornbusch, Kevin A. Dudevoir, Sergio A.
Dzib, Andreas Eckart, Chris Eckert, Neal R. Erickson, Wendeline B. Everett, Aaron
Faber, Joseph R. Farah, Vernon Fath, Thomas W. Folkers, David C. Forbes, Robert Fre-
und, Arturo I. Go´mez-Ruiz, David M. Gale, Feng Gao, Gertie Geertsema, David A. Gra-
ham, Christopher H. Greer, Ronald Grosslein, Fre´de´ric Gueth, Daryl Haggard, Nils W.
Halverson, Chih-Chiang Han, Kuo-Chang Han, Jinchi Hao, Yutaka Hasegawa, Jason W.
Henning, Antonio Herna´ndez-Go´mez, Rube´n Herrero-Illana, Stefan Heyminck, Akihiko
133
Hirota, James Hoge, Yau-De Huang, C. M. Violette Impellizzeri, Homin Jiang, Atish
Kamble, Ryan Keisler, Kimihiro Kimura, Yusuke Kono, Derek Kubo, John Kuroda,
Richard Lacasse, Robert A. Laing, Erik M. Leitch, Chao-Te Li, Lupin C.-C. Lin, Ching-
Tang Liu, Kuan-Yu Liu, Li-Ming Lu, Ralph G. Marson, Pierre L. Martin-Cocher, Kyle D.
Massingill, Callie Matulonis, Martin P. McColl, Stephen R. McWhirter, Hugo Messias,
Zheng Meyer-Zhao, Daniel Michalik, Alfredo Montan˜a, William Montgomerie, Matias
Mora-Klein, Dirk Muders, Andrew Nadolski, Santiago Navarro, Joseph Neilsen, Chi H.
Nguyen, Hiroaki Nishioka, Timothy Norton, Michael A. Nowak, George Nystrom, Hideo
Ogawa, Peter Oshiro, Tomoaki Oyama, Harriet Parsons, Scott N. Paine, Juan Pen˜alver,
Neil M. Phillips, Michael Poirier, Nicolas Pradel, Rurik A. Primiani, Philippe A. Raffin,
Alexandra S. Rahlin, George Reiland, Christopher Risacher, Ignacio Ruiz, Alejandro F.
Sa´ez-Madaı´n, Remi Sassella, Pim Schellart, Paul Shaw, Kevin M. Silva, Hotaka Sh-
iokawa, David R. Smith, William Snow, Kamal Souccar, Don Sousa, T. K. Sridharan,
Ranjani Srinivasan, William Stahm, Anthony A. Stark, Kyle Story, Sjoerd T. Timmer,
Laura Vertatschitsch, Craig Walther, Ta-Shun Wei, Nathan Whitehorn, Alan R. Whitney,
David P. Woody, Jan G. A. Wouterloot, Melvin Wright, Paul Yamaguchi, Chen-Yu Yu,
Milagros Zeballos, Shuo Zhang, and Lucy Ziurys. First M87 Event Horizon Telescope
Results. I. The Shadow of the Supermassive Black Hole. The Astrophysical Journal
Letters, 875(1):L1, April 2019.
[10] Zachary D. Stephens, Skylar Y. Lee, Faraz Faghri, Roy H. Campbell, Chengxiang Zhai,
Miles J. Efron, Ravishankar Iyer, Michael C. Schatz, Saurabh Sinha, and Gene E. Robin-
son. Big Data: Astronomical or Genomical? PLOS Biology, 13(7):e1002195, July 2015.
[11] R Newman and J Tseng. Cloud Computing and the Square Kilometre Array. May 2011.
[12] Data from the NHGRI Genome Sequencing Program (GSP), 2015.
[13] The 1000 Genomes Project Consortium. A global reference for human genetic variation.
Nature, 526(7571):68–74, October 2015.
[14] Monkol Lek, Konrad J. Karczewski, Eric V. Minikel, Kaitlin E. Samocha, Eric Banks,
Timothy Fennell, Anne H. O’Donnell-Luria, James S. Ware, Andrew J. Hill, Beryl B.
Cummings, Taru Tukiainen, Daniel P. Birnbaum, Jack A. Kosmicki, Laramie E. Dun-
can, Karol Estrada, Fengmei Zhao, James Zou, Emma Pierce-Hoffman, Joanne Bergh-
out, David N. Cooper, Nicole Deflaux, Mark DePristo, Ron Do, Jason Flannick, Men-
achem Fromer, Laura Gauthier, Jackie Goldstein, Namrata Gupta, Daniel Howrigan,
Adam Kiezun, Mitja I. Kurki, Ami Levy Moonshine, Pradeep Natarajan, Lorena Orozco,
Gina M. Peloso, Ryan Poplin, Manuel A. Rivas, Valentin Ruano-Rubio, Samuel A.
Rose, Douglas M. Ruderfer, Khalid Shakir, Peter D. Stenson, Christine Stevens, Brett P.
Thomas, Grace Tiao, Maria T. Tusie-Luna, Ben Weisburd, Hong-Hee Won, Dongmei
Yu, David M. Altshuler, Diego Ardissino, Michael Boehnke, John Danesh, Stacey Don-
nelly, Roberto Elosua, Jose C. Florez, Stacey B. Gabriel, Gad Getz, Stephen J. Glatt,
Christina M. Hultman, Sekar Kathiresan, Markku Laakso, Steven McCarroll, Mark I.
McCarthy, Dermot McGovern, Ruth McPherson, Benjamin M. Neale, Aarno Palotie,
134
Shaun M. Purcell, Danish Saleheen, Jeremiah M. Scharf, Pamela Sklar, Patrick F. Sulli-
van, Jaakko Tuomilehto, Ming T. Tsuang, Hugh C. Watkins, James G. Wilson, Mark J.
Daly, Daniel G. MacArthur, and Exome Aggregation Consortium. Analysis of protein-
coding genetic variation in 60,706 humans. Nature, 536(7616):285–291, August 2016.
[15] Michael Albrecht, Patrick Donnelly, Peter Bui, and Douglas Thain. Makeflow: A
portable abstraction for data intensive computing on clusters, clouds, and grids. In Pro-
ceedings of the 1st ACM SIGMOD Workshop on Scalable Workflow Execution Engines
and Technologies, page 1. ACM, 2012.
[16] Jeremy Goecks, Anton Nekrutenko, James Taylor, and Galaxy Team. Galaxy: A compre-
hensive approach for supporting accessible, reproducible, and transparent computational
research in the life sciences. Genome Biology, 11(8):R86, 2010.
[17] Brian D O’Connor, Barry Merriman, and Stanley F. Nelson. SeqWare Query Engine:
Storing and searching sequence data in the cloud. BMC bioinformatics, 11(12):S2, 2010.
[18] Erik Bernhardsson and Elias Freider. Luigi is a Python module that helps you build com-
plex pipelines of batch jobs. It handles dependency resolution, workflow management,
visualization etc. It also comes with Hadoop support built in. .. Spotify, February 2019.
[19] John Vivian, Arjun Arkal Rao, Frank Austin Nothaft, Christopher Ketchum, Joel Arm-
strong, Adam Novak, Jacob Pfeil, Jake Narkizian, Alden D. Deran, Audrey Musselman-
Brown, Hannes Schmidt, Peter Amstutz, Brian Craft, Mary Goldman, Kate Rosenbloom,
Melissa Cline, Brian O’Connor, Megan Hanna, Chet Birger, W. James Kent, David A.
Patterson, Anthony D. Joseph, Jingchun Zhu, Sasha Zaranek, Gad Getz, David Haus-
sler, and Benedict Paten. Toil enables reproducible, open source, big biomedical data
analyses. Nature Biotechnology, 35:314–316, April 2017.
[20] Docker. https://www.docker.com/.
[21] Docker Hub. https://hub.docker.com/.
[22] Quay Container Registry · Quay. https://quay.io/.
[23] Ryan Chamberlain and Jennifer Schommer. Using Docker to support reproducible re-
search. DOI: http://dx. doi. org/10.6084/m9. figshare, 1101910, 2014.
[24] Erika Check Hayden. Data barriers limit genetic diagnosis. Nature, 494(7436):156–157,
February 2013.
[25] Jessica Jardine Wilkes. The Creation of HIPAA Culture: Prioritizing Privacy Paranoia
over Patient Care Comments. Brigham Young University Law Review, 2014:1213–1250,
2014.
[26] Bartha Maria Knoppers. Framework for responsible sharing of genomic and health-
related data. The HUGO Journal, 8(1):3, October 2014.
135
[27] Robert Cook-Deegan and Amy L. McGuire. Moving beyond Bermuda: Sharing data to
build a medical information commons. Genome Research, page gr.216911.116, April
2017.
[28] Mark D. Wilkinson, Michel Dumontier, IJsbrand Jan Aalbersberg, Gabrielle Appleton,
Myles Axton, Arie Baak, Niklas Blomberg, Jan-Willem Boiten, Luiz Bonino da Silva
Santos, Philip E. Bourne, Jildau Bouwman, Anthony J. Brookes, Tim Clark, Merce`
Crosas, Ingrid Dillo, Olivier Dumon, Scott Edmunds, Chris T. Evelo, Richard Finkers,
Alejandra Gonzalez-Beltran, Alasdair J. G. Gray, Paul Groth, Carole Goble, Jeffrey S.
Grethe, Jaap Heringa, Peter A. C. ’t Hoen, Rob Hooft, Tobias Kuhn, Ruben Kok, Joost
Kok, Scott J. Lusher, Maryann E. Martone, Albert Mons, Abel L. Packer, Bengt Pers-
son, Philippe Rocca-Serra, Marco Roos, Rene van Schaik, Susanna-Assunta Sansone,
Erik Schultes, Thierry Sengstag, Ted Slater, George Strawn, Morris A. Swertz, Mark
Thompson, Johan van der Lei, Erik van Mulligen, Jan Velterop, Andra Waagmeester, Pe-
ter Wittenburg, Katherine Wolstencroft, Jun Zhao, and Barend Mons. The FAIR Guiding
Principles for scientific data management and stewardship. Scientific Data, 3:160018,
March 2016.
[29] Vasiliki Rahimzadeh, Stephanie O.M. Dyke, and Bartha M. Knoppers. An International
Framework for Data Sharing: Moving Forward with the Global Alliance for Genomics
and Health. Biopreservation and Biobanking, 14(3):256–259, April 2016.
[30] Mark Lawler, Lillian L. Siu, Heidi L. Rehm, Stephen J. Chanock, Gil Alterovitz, John
Burn, Fabien Calvo, Denis Lacombe, Bin Tean Teh, Kathryn N. North, and Charles L.
Sawyers. All the World’s a Stage: Facilitating Discovery Science and Improved Can-
cer Care through the Global Alliance for Genomics and Health. Cancer Discovery,
5(11):1133–1136, November 2015.
[31] Robert L. Grossman, Allison P. Heath, Vincent Ferretti, Harold E. Varmus, Douglas R.
Lowy, Warren A. Kibbe, and Louis M. Staudt. Toward a Shared Vision for Cancer Ge-
nomic Data. New England Journal of Medicine, 375(12):1109–1112, September 2016.
[32] Matthew D. Mailman, Michael Feolo, Yumi Jin, Masato Kimura, Kimberly Tryka, Ri-
nat Bagoutdinov, Luning Hao, Anne Kiang, Justin Paschall, Lon Phan, Natalia Popova,
Stephanie Pretel, Lora Ziyabari, Moira Lee, Yu Shao, Zhen Y. Wang, Karl Sirotkin,
Minghong Ward, Michael Kholodov, Kerry Zbicz, Jeffrey Beck, Michael Kimelman,
Sergey Shevelev, Don Preuss, Eugene Yaschenko, Alan Graeff, James Ostell, and
Stephen T. Sherry. The NCBI dbGaP database of genotypes and phenotypes. Nature
Genetics, 39:1181–1186, October 2007.
[33] The Sequence Read Archive. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3013647/.
[34] Scott Newman, Xin Zhou, Clay McLeod, Michael Rusch, Gang Wu, Edgar Sioson,
Shuoguo Wang, J. Robert Michael, Aman Patel, Michael N. Edmonson, Andrew Frantz,
Ti-Cheng Chang, Yongjin Li, Robert I. Davidson, Singer Ma, Irina McGuire, Nedra Ro-
bison, Xing Tang, Lance Palmer, Ed Suh, Leigh Tanner, James McMurry, Keith Perry,
136
Zhaoming Wang, Carmen Wilson, Yong Cheng, Mitch Weiss, Leslie L. Robison, Yutaka
Yasui, Kim E. Nichols, David W. Ellison, James R. Downing, and Jinghui Zhang. Ab-
stract 922: Access, visualize and analyze 5,000 whole-genomes from pediatric cancer
patients on St. Jude Cloud. Cancer Research, 78(13 Supplement):922–922, July 2018.
[35] James R. Downing, Richard K. Wilson, Jinghui Zhang, Elaine R. Mardis, Ching-Hon
Pui, Li Ding, Timothy J. Ley, and William E. Evans. The Pediatric Cancer Genome
Project. Nature Genetics, 44(6):619–622, June 2012.
[36] Katrina Learned, Ann Durbin, Robert Currie, Holly Beale, Du Linh Lam, Theodore
Goldstein, Sofie R. Salama, David Haussler, Olena Morozova, and Isabel Bjork. Abstract
LB-338: A critical evaluation of genomic data sharing: Barriers to accessing pediatric
cancer genomic datasets: A Treehouse Childhood Cancer Initiative experience. Cancer
Research, 77(13 Supplement):LB–338–LB–338, July 2017.
[37] Zhong Wang, Mark Gerstein, and Michael Snyder. RNA-Seq: A revolutionary tool for
transcriptomics. Nature Reviews Genetics, 10(1):57–63, January 2009.
[38] Ga´bor Csa´rdi, Alexander Franks, David S. Choi, Edoardo M. Airoldi, and D. Allan
Drummond. Accounting for Experimental Noise Reveals That mRNA Levels, Ampli-
fied by Post-Transcriptional Processes, Largely Determine Steady-State Protein Levels
in Yeast. PLOS Genetics, 11(5):e1005206, May 2015.
[39] Floyd Taub, E., James M. DeLEO, and E. Brad Thompson. Sequential Comparative Hy-
bridizations Analyzed by Computerized Image Processing Can Identify and Quantitate
Regulated RNAs. DNA, 2(4):309–327, December 1983.
[40] Kimberly R. Kukurba and Stephen B. Montgomery. RNA Sequencing and Analysis.
Cold Spring Harbor Protocols, 2015(11):pdb.top084970, January 2015.
[41] Emily A. Chen, Tade Souaiaia, Jennifer S. Herstein, Oleg V. Evgrafov, Valeria N. Spit-
syna, Danea F. Rebolini, and James A. Knowles. Effect of RNA integrity on uniquely
mapped reads in RNA-Seq. BMC Research Notes, 7(1):753, October 2014.
[42] Ali Mortazavi, Brian A. Williams, Kenneth McCue, Lorian Schaeffer, and Barbara Wold.
Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nature Methods,
5(7):621–628, July 2008.
[43] Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and
DNA microarray for expression profiling — BMC Genomics — Full Text.
https://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-15-419.
[44] Evaluation of two main RNA-seq approaches for gene quantification in clinical
RNA sequencing: polyA+ selection versus rRNA depletion — Scientific Reports.
https://www.nature.com/articles/s41598-018-23226-4.
137
[45] Je-Hyun Yoon, Kotb Abdelmohsen, and Myriam Gorospe. Posttranscriptional Gene Reg-
ulation by Long Noncoding RNA. Journal of Molecular Biology, 425(19):3723–3730,
October 2013.
[46] Nicholas T. Ingolia, Gloria A. Brar, Silvia Rouskin, Anna M. McGeachy, and Jonathan S.
Weissman. The ribosome profiling strategy for monitoring translation in vivo by deep
sequencing of ribosome-protected mRNA fragments. Nature Protocols, 7(8):1534–1550,
August 2012.
[47] Christopher A. Maher, Chandan Kumar-Sinha, Xuhong Cao, Shanker Kalyana-
Sundaram, Bo Han, Xiaojun Jing, Lee Sam, Terrence Barrette, Nallasivam Palanisamy,
and Arul M. Chinnaiyan. Transcriptome sequencing to detect gene fusions in cancer.
Nature, 458(7234):97–101, March 2009.
[48] Janessa Laskin, Steven Jones, Samuel Aparicio, Stephen Chia, Carolyn Ch’ng, Rebecca
Deyell, Peter Eirew, Alexandra Fok, Karen Gelmon, Cheryl Ho, David Huntsman, Mar-
tin Jones, Katayoon Kasaian, Aly Karsan, Sreeja Leelakumari, Yvonne Li, Howard
Lim, Yussanne Ma, Colin Mar, Monty Martin, Richard Moore, Andrew Mungall, Karen
Mungall, Erin Pleasance, S. Rod Rassekh, Daniel Renouf, Yaoqing Shen, Jacqueline
Schein, Kasmintan Schrader, Sophie Sun, Anna Tinker, Eric Zhao, Stephen Yip, and
Marco A. Marra. Lessons learned from the application of whole-genome analysis to
the treatment of patients with advanced cancers. Molecular Case Studies, 1(1):a000570,
January 2015.
[49] Adam S. Brown, Sek Won Kong, Isaac S. Kohane, and Chirag J. Patel. ksRepo: A gen-
eralized platform for computational drug repositioning. BMC Bioinformatics, 17(1):78,
February 2016.
[50] Noe¨l J.-M. Raynal, Elodie M. Da Costa, Justin T. Lee, Vazganush Gharibyan, Saira
Ahmed, Hanghang Zhang, Takahiro Sato, Gabriel G. Malouf, and Jean-Pierre J. Issa.
Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Repro-
gram Colon Cancer Epigenome. Molecular Cancer Therapeutics, 16(2):397–407, Febru-
ary 2017.
[51] B. Chen and A. J. Butte. Leveraging big data to transform target selection and drug
discovery. Clinical Pharmacology & Therapeutics, 99(3):285–297, 2016.
[52] Michael F. Berger, Joshua Z. Levin, Krishna Vijayendran, Andrey Sivachenko, Xian
Adiconis, Jared Maguire, Laura A. Johnson, James Robinson, Roel G. Verhaak, Carrie
Sougnez, Robert C. Onofrio, Liuda Ziaugra, Kristian Cibulskis, Elisabeth Laine, Jordi
Barretina, Wendy Winckler, David E. Fisher, Gad Getz, Matthew Meyerson, David B.
Jaffe, Stacey B. Gabriel, Eric S. Lander, Reinhard Dummer, Andreas Gnirke, Chad
Nusbaum, and Levi A. Garraway. Integrative analysis of the melanoma transcriptome.
Genome Research, 20(4):413–427, January 2010.
138
[53] Xiao-Feng Le, Franz Pruefer, and Robert C. Bast. HER2-targeting Antibodies Modulate
the Cyclin-dependent Kinase Inhibitor p27Kip1 via Multiple Signaling Pathways. Cell
Cycle, 4(1):87–95, January 2005.
[54] Trastuzumab Monograph for Professionals. https://www.drugs.com/monograph/trastuzumab.html.
[55] PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy — Molecular
Cancer Therapeutics. http://mct.aacrjournals.org/content/14/4/847.short.
[56] Michael I. Love, Wolfgang Huber, and Simon Anders. Moderated estimation of fold
change and dispersion for RNA-seq data with DESeq2. Genome Biology, 15(12):550,
December 2014.
[57] Bo Li and Colin N. Dewey. RSEM: Accurate transcript quantification from RNA-Seq
data with or without a reference genome. BMC Bioinformatics, 12(1):323, August 2011.
[58] Xiaobei Zhou, Helen Lindsay, and Mark D. Robinson. Robustly detecting differential
expression in RNA sequencing data using observation weights. Nucleic Acids Research,
42(11):e91–e91, June 2014.
[59] Charlotte Soneson and Mauro Delorenzi. A comparison of methods for differential ex-
pression analysis of RNA-seq data. BMC Bioinformatics, 14(1):91, March 2013.
[60] Nicolas L. Bray, Harold Pimentel, Pa´ll Melsted, and Lior Pachter. Near-optimal proba-
bilistic RNA-seq quantification. Nature Biotechnology, 34(5):525–527, May 2016.
[61] Cath Tyner, Galt P. Barber, Jonathan Casper, Hiram Clawson, Mark Diekhans, Christo-
pher Eisenhart, Clayton M. Fischer, David Gibson, Jairo Navarro Gonzalez, Luvina Gu-
ruvadoo, Maximilian Haeussler, Steve Heitner, Angie S. Hinrichs, Donna Karolchik,
Brian T. Lee, Christopher M. Lee, Parisa Nejad, Brian J. Raney, Kate R. Rosen-
bloom, Matthew L. Speir, Chris Villarreal, John Vivian, Ann S. Zweig, David Haussler,
Robert M. Kuhn, and W. James Kent. The UCSC Genome Browser database: 2017
update. Nucleic Acids Research, 45(D1):D626–D634, January 2017.
[62] Mary Goldman, Brian Craft, Jingchun Zhu, and David Haussler. The UCSC
Xena Platform for cancer genomics data visualization and interpretation — bioRxiv.
https://www.biorxiv.org/content/10.1101/326470v3.abstract, 2018.
[63] GTEx Consortium. Genetic effects on gene expression across human tissues. Nature,
550(7675):204–213, October 2017.
[64] John Vivian. UC Santa Cruz Computational Genomics Lab’s Toil-based RNA-seq
pipeline: BD2KGenomics/toil-rnaseq. UC Santa Cruz Genomics Institute - Computa-
tional Genomics Lab, January 2019.
[65] Holly Beale, Du Linh Lam, John Vivian, Yulia Newton, Avanthi Tayi Shah, Isabel
Bjork, Ted Goldstein, Angela N. Brooks, Josh Stuart, Sofie Salama, E. Alejandro Sweet-
Cordero, David Haussler1, and Olena Morozova. Abstract 2466: Identifying confidently
139
measured genes in single pediatric cancer patient samples using RNA sequencing. Can-
cer Research, 77(13 Supplement):2466–2466, July 2017.
[66] Olena Morozova, Yulia Newton, Avanthi Tayi Shah, Holly Beale, Du Linh Lam, John
Vivian, Isabel Bjork, Theodore Goldstein, Josh Stuart, Sofie Salama, E. Alejandro Sweet-
Cordero, and David Haussler. Abstract 4890: A pan-cancer analysis framework for
incorporating gene expression information into clinical interpretation of pediatric cancer
genomic data. Cancer Research, 77(13 Supplement):4890–4890, July 2017.
[67] Rob Edwards. Code from the Edwards lab, including bioinformatics, image analysis and
more. All this code is created and maintained by folks at Rob Edwards’ bioinformatics
lab at SDSU.: Linsalrob/EdwardsLab, May 2019.
[68] Nicholas D. Matsakis and Felix S. Klock, II. The Rust Language. In Proceedings of the
2014 ACM SIGAda Annual Conference on High Integrity Language Technology, HILT
’14, pages 103–104, New York, NY, USA, 2014. ACM.
[69] Junjun Zhang, Joachim Baran, A. Cros, Jonathan M. Guberman, Syed Haider, Jack Hsu,
Yong Liang, Elena Rivkin, Jianxin Wang, Brett Whitty, Marie Wong-Erasmus, Long Yao,
and Arek Kasprzyk. International Cancer Genome Consortium Data Portal—a one-stop
shop for cancer genomics data. Database, 2011, January 2011.
[70] Nayanah Siva. UK gears up to decode 100 000 genomes from NHS patients. The Lancet,
385(9963):103–104, January 2015.
[71] Aaron McKenna, Matthew Hanna, Eric Banks, Andrey Sivachenko, Kristian Cibulskis,
Andrew Kernytsky, Kiran Garimella, David Altshuler, Stacey Gabriel, Mark Daly, and
Mark A. DePristo. The Genome Analysis Toolkit: A MapReduce framework for analyz-
ing next-generation DNA sequencing data. Genome Research, July 2010.
[72] UNC Bioinformatics. TCGA mRNA-seq pipeline for UNC data.
https://webshare.bioinf.unc.edu/public/mRNAseq TCGA/UNC mRNAseq summary.pdf,
2013.
[73] Michael Albrecht, Patrick Donnelly, Peter Bui, and Douglas Thain. Makeflow: A
Portable Abstraction for Data Intensive Computing on Clusters, Clouds, and Grids. In
Proceedings of the 1st ACM SIGMOD Workshop on Scalable Workflow Execution En-
gines and Technologies, SWEET ’12, pages 1:1–1:13, New York, NY, USA, 2012. ACM.
[74] Peter Amstutz. Common Workflow Language, draft 3.
https://escholarship.org/uc/item/6wd8h2z1.
[75] Scott Frazer. Worfklow Description Language. https://software.broadinstitute.org/wdl/.
[76] John Vivian. Toil workflows for common genomic pipelines. UC Santa Cruz Genomics
Institute - Computational Genomics Lab, June 2018.
140
[77] Matt Massie, Frank Austin Nothaft, Christopher Hartl, Christos Kozanitis, Andre Schu-
macher, Anthony D Joseph, and David Patterson. ADAM: Genomics Formats and Pro-
cessing Patterns for Cloud Scale Computing. page 24, 2013.
[78] Matei Zaharia, Reynold S. Xin, Patrick Wendell, Tathagata Das, Michael Armbrust,
Ankur Dave, Xiangrui Meng, Josh Rosen, Shivaram Venkataraman, Michael J. Franklin,
Ali Ghodsi, Joseph Gonzalez, Scott Shenker, and Ion Stoica. Apache Spark: A Unified
Engine for Big Data Processing. Commun. ACM, 59(11):56–65, October 2016.
[79] W. Gentzsch. Sun Grid Engine: Towards creating a compute power grid. In Proceedings
First IEEE/ACM International Symposium on Cluster Computing and the Grid, pages
35–36, May 2001.
[80] Andy B. Yoo, Morris A. Jette, and Mark Grondona. SLURM: Simple Linux Utility for
Resource Management. In Dror Feitelson, Larry Rudolph, and Uwe Schwiegelshohn,
editors, Job Scheduling Strategies for Parallel Processing, Lecture Notes in Computer
Science, pages 44–60. Springer Berlin Heidelberg, 2003.
[81] Apache Software Foundation. Apache Mesos. http://mesos.apache.org/.
[82] Alexander Dobin, Carrie A. Davis, Felix Schlesinger, Jorg Drenkow, Chris Zaleski, Son-
ali Jha, Philippe Batut, Mark Chaisson, and Thomas R. Gingeras. STAR: Ultrafast uni-
versal RNA-seq aligner. Bioinformatics, 29(1):15–21, January 2013.
[83] A. D. Barker, C. C. Sigman, G. J. Kelloff, N. M. Hylton, D. A. Berry, and L. J. Esser-
man. I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant
Chemotherapy. Clinical Pharmacology & Therapeutics, 86(1):97–100, 2009.
[84] W. James Kent, Charles W. Sugnet, Terrence S. Furey, Krishna M. Roskin, Tom H.
Pringle, Alan M. Zahler, and and David Haussler. The Human Genome Browser at
UCSC. Genome Research, 12(6):996–1006, January 2002.
[85] Regeneron. RGC: One of the World’s Largest Sequencing Efforts.
https://www.regeneron.com/genetics-center.
[86] A. O. Ojo. NIH ALL OF US RESEARCH PROGRAM (AOU RP). Innovation in Aging,
2(suppl 1):768–768, November 2018.
[87] Mark Peplow. The 100 000 Genomes Project. BMJ, 353:i1757, April 2016.
[88] TOPMed. Trans-omics for precision medicine (TOPMed) program.
https://www.nhlbi.nih.gov/science/trans-omics-precision-medicine-topmed-program,
2016.
[89] NIH. National Institutes of Health. Centers for common disease genomics (UM1). Tech-
nical report.
141
[90] Wellcome Trust. Sharing data from large-scale biological research projects: A system of
tripartite responsibility. The Fort Lauderdale Report, 2003.
[91] Jenny Reardon, Rachel A. Ankeny, Jenny Bangham, Katherine W. Darling, Stephen Hil-
gartner, Kathryn Maxson Jones, Beth Shapiro, and Hallam Stevens. Bermuda 2.0: Re-
flections from Santa Cruz. GigaScience, 5(1):1–4, December 2016.
[92] Henry Rodriguez, Mike Snyder, Mathias Uhle´n, Phil Andrews, Ronald Beavis, Christoph
Borchers, Robert J. Chalkley, Sang Yun Cho, Katie Cottingham, Michael Dunn, Tomasz
Dylag, Ron Edgar, Peter Hare, Albert J.R. Heck, Roland F. Hirsch, Karen Kennedy, Pa-
trik Kolar, Hans-Joachim Kraus, Parag Mallick, Alexey Nesvizhskii, Peipei Ping, Fredrik
Ponte´n, Liming Yang, John R. Yates, Stephen E. Stein, Henning Hermjakob, Christo-
pher R. Kinsinger, and Rolf Apweiler. Recommendations from the 2008 International
Summit on Proteomics Data Release and Sharing Policy - The Amsterdam Principles.
Journal of proteome research, 8(7):3689–3692, July 2009.
[93] NHGRI. Required Elements of the Consent Form — NHGRI.
https://www.genome.gov/about-genomics/policy-issues/Informed-Consent-for-
Genomics-Research/Required-Elements-of-Consent-Form.
[94] Matthew D. Burstein, Jill Oliver Robinson, Susan G. Hilsenbeck, Amy L. McGuire, and
Ching C. Lau. Pediatric Data Sharing in Genomic Research: Attitudes and Preferences
of Parents. Pediatrics, 133(4):690–697, April 2014.
[95] Jean Louis Raisaro, Florian Trame`r, Zhanglong Ji, Diyue Bu, Yongan Zhao, Knox Carey,
David Lloyd, Heidi Sofia, Dixie Baker, Paul Flicek, Suyash Shringarpure, Carlos Bus-
tamante, Shuang Wang, Xiaoqian Jiang, Lucila Ohno-Machado, Haixu Tang, XiaoFeng
Wang, and Jean-Pierre Hubaux. Addressing Beacon re-identification attacks: Quantifi-
cation and mitigation of privacy risks. Journal of the American Medical Informatics
Association : JAMIA, 24(4):799–805, July 2017.
[96] National Cancer Institute. TARGET: Therapeutically Applicable Research to Generate
Effective Treatments.
[97] Brian D. O’Connor, Denis Yuen, Vincent Chung, Andrew G. Duncan, Xiang Kun Liu,
Janice Patricia, Benedict Paten, Lincoln Stein, and Vincent Ferretti. The Dockstore: En-
abling modular, community-focused sharing of Docker-based genomics tools and work-
flows. F1000Research, 6, January 2017.
[98] Paolo Di Tommaso, Maria Chatzou, Evan W. Floden, Pablo Prieto Barja, Emilio
Palumbo, and Cedric Notredame. Nextflow enables reproducible computational work-
flows. Nature Biotechnology, 35(4):316, April 2017.
[99] Jordi Barretina, Giordano Caponigro, Nicolas Stransky, Kavitha Venkatesan, Adam A.
Margolin, Sungjoon Kim, Christopher J. Wilson, Joseph Leha´r, Gregory V. Kryukov,
Dmitriy Sonkin, Anupama Reddy, Manway Liu, Lauren Murray, Michael F. Berger,
142
John E. Monahan, Paula Morais, Jodi Meltzer, Adam Korejwa, Judit Jane´-Valbuena, Fe-
lipa A. Mapa, Joseph Thibault, Eva Bric-Furlong, Pichai Raman, Aaron Shipway, Ingo H.
Engels, Jill Cheng, Guoying K. Yu, Jianjun Yu, Peter Aspesi, Melanie de Silva, Kalpana
Jagtap, Michael D. Jones, Li Wang, Charles Hatton, Emanuele Palescandolo, Supriya
Gupta, Scott Mahan, Carrie Sougnez, Robert C. Onofrio, Ted Liefeld, Laura MacConaill,
Wendy Winckler, Michael Reich, Nanxin Li, Jill P. Mesirov, Stacey B. Gabriel, Gad Getz,
Kristin Ardlie, Vivien Chan, Vic E. Myer, Barbara L. Weber, Jeff Porter, Markus War-
muth, Peter Finan, Jennifer L. Harris, Matthew Meyerson, Todd R. Golub, Michael P.
Morrissey, William R. Sellers, Robert Schlegel, and Levi A. Garraway. The Cancer Cell
Line Encyclopedia enables predictive modeling of anticancer drug sensitivity. Nature,
483(7391):603–607, March 2012.
[100] Carl Boettiger. An Introduction to Docker for Reproducible Research. SIGOPS Oper.
Syst. Rev., 49(1):71–79, January 2015.
[101] John Vivian. BD2KGenomics/toil-rnaseq. https://github.com/BD2KGenomics/toil-
rnaseq.
[102] T. R. Golub, D. K. Slonim, P. Tamayo, C. Huard, M. Gaasenbeek, J. P. Mesirov, H. Coller,
M. L. Loh, J. R. Downing, M. A. Caligiuri, C. D. Bloomfield, and E. S. Lander. Molec-
ular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression
Monitoring. Science, 286(5439):531–537, October 1999.
[103] Sridhar Ramaswamy, Pablo Tamayo, Ryan Rifkin, Sayan Mukherjee, Chen-Hsiang
Yeang, Michael Angelo, Christine Ladd, Michael Reich, Eva Latulippe, Jill P. Mesirov,
Tomaso Poggio, William Gerald, Massimo Loda, Eric S. Lander, and Todd R. Golub.
Multiclass cancer diagnosis using tumor gene expression signatures. Proceedings of the
National Academy of Sciences, 98(26):15149–15154, December 2001.
[104] Leng Han, Yuan Yuan, Siyuan Zheng, Yang Yang, Jun Li, Mary E. Edgerton, Lixia
Diao, Yanxun Xu, Roeland G. W. Verhaak, and Han Liang. The Pan-Cancer analysis
of pseudogene expression reveals biologically and clinically relevant tumour subtypes.
Nature Communications, 5:3963, July 2014.
[105] Myron G. Best, Nik Sol, Irsan Kooi, Jihane Tannous, Bart A. Westerman, Franc¸ois
Rustenburg, Pepijn Schellen, Heleen Verschueren, Edward Post, Jan Koster, Bauke Yl-
stra, Najim Ameziane, Josephine Dorsman, Egbert F. Smit, Henk M. Verheul, David P.
Noske, Jaap C. Reijneveld, R. Jonas A. Nilsson, Bakhos A. Tannous, Pieter Wessel-
ing, and Thomas Wurdinger. RNA-Seq of Tumor-Educated Platelets Enables Blood-
Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell,
28(5):666–676, November 2015.
[106] Anoop P. Patel, Itay Tirosh, John J. Trombetta, Alex K. Shalek, Shawn M. Gillespie,
Hiroaki Wakimoto, Daniel P. Cahill, Brian V. Nahed, William T. Curry, Robert L.
Martuza, David N. Louis, Orit Rozenblatt-Rosen, Mario L. Suva`, Aviv Regev, and
143
Bradley E. Bernstein. Single-cell RNA-seq highlights intratumoral heterogeneity in pri-
mary glioblastoma. Science, 344(6190):1396–1401, June 2014.
[107] Olena Morozova, Martin Hirst, and Marco A. Marra. Applications of New Sequenc-
ing Technologies for Transcriptome Analysis. Annual Review of Genomics and Human
Genetics, 10(1):135–151, August 2009.
[108] Challenges in initiating and conducting personalized cancer therapy tri-
als: Perspectives from WINTHER, a Worldwide Innovative Network
(WIN) Consortium trial — Annals of Oncology — Oxford Academic.
https://academic.oup.com/annonc/article/26/8/1791/247819.
[109] Rajen J. Mody, Yi-Mi Wu, Robert J. Lonigro, Xuhong Cao, Sameek Roychowdhury,
Pankaj Vats, Kevin M. Frank, John R. Prensner, Irfan Asangani, Nallasivam Palanisamy,
Jonathan R. Dillman, Raja M. Rabah, Laxmi Priya Kunju, Jessica Everett, Victoria M.
Raymond, Yu Ning, Fengyun Su, Rui Wang, Elena M. Stoffel, Jeffrey W. Innis, J. Scott
Roberts, Patricia L. Robertson, Gregory Yanik, Aghiad Chamdin, James A. Connelly,
Sung Choi, Andrew C. Harris, Carrie Kitko, Rama Jasty Rao, John E. Levine, Valerie P.
Castle, Raymond J. Hutchinson, Moshe Talpaz, Dan R. Robinson, and Arul M. Chin-
naiyan. Integrative clinical sequencing in the management of children and young adults
with refractory or relapsed cancer. JAMA, 314(9):913–925, September 2015.
[110] Wendy Chang, Andrew S. Brohl, Rajesh Patidar, Sivasish Sindiri, Jack F. Shern, Jun S.
Wei, Young K. Song, Marielle E. Yohe, Berkley Gryder, Shile Zhang, Kathleen A.
Calzone, Nityashree Shivaprasad, Xinyu Wen, Thomas C. Badgett, Markku Miettinen,
Kip R. Hartman, James C. League-Pascual, Toby N. Trahair, Brigitte C. Widemann,
Melinda S. Merchant, Rosandra N. Kaplan, Jimmy C. Lin, and Javed Khan. Multi-
Dimensional Omics for Precision Therapy of Children and Adolescent Young Adults
with Relapsed and Refractory Cancer: Report from Pediatric Oncology Branch, NCI.
Clinical cancer research : an official journal of the American Association for Cancer
Research, 22(15):3810–3820, August 2016.
[111] Barbara C. Worst, Cornelis M. van Tilburg, Gnana Prakash Balasubramanian, Petra
Fiesel, Ruth Witt, Angelika Freitag, Miream Boudalil, Christopher Previti, Stephan
Wolf, Sabine Schmidt, Sasithorn Chotewutmontri, Melanie Bewerunge-Hudler, Matthias
Schick, Matthias Schlesner, Barbara Hutter, Lenka Taylor, Tobias Borst, Christian Sut-
ter, Claus R. Bartram, Till Milde, Elke Pfaff, Andreas E. Kulozik, Arend von Stack-
elberg, Roland Meisel, Arndt Borkhardt, Dirk Reinhardt, Jan-Henning Klusmann, Gu-
drun Fleischhack, Stephan Tippelt, Uta Dirksen, Heribert Ju¨rgens, Christof M. Kramm,
Andre O. von Bueren, Frank Westermann, Matthias Fischer, Birgit Burkhardt, Wil-
helm Wo¨ßmann, Michaela Nathrath, Stefan S. Bielack, Michael C. Fru¨hwald, Si-
mone Fulda, Thomas Klingebiel, Ewa Koscielniak, Matthias Schwab, Roman Tremmel,
Pablo Herna´iz Driever, Johannes H. Schulte, Benedikt Brors, Andreas von Deimling,
Peter Lichter, Angelika Eggert, David Capper, Stefan M. Pfister, David T. W. Jones, and
144
Olaf Witt. Next-generation personalised medicine for high-risk paediatric cancer patients
– The INFORM pilot study. European Journal of Cancer, 65:91–101, September 2016.
[112] Jennifer A. Oberg, Julia L. Glade Bender, Maria Luisa Sulis, Danielle Pendrick, An-
thony N. Sireci, Susan J. Hsiao, Andrew T. Turk, Filemon S. Dela Cruz, Hanina Hib-
shoosh, Helen Remotti, Rebecca J. Zylber, Jiuhong Pang, Daniel Diolaiti, Carrie Koval,
Stuart J. Andrews, James H. Garvin, Darrell J. Yamashiro, Wendy K. Chung, Stephen G.
Emerson, Peter L. Nagy, Mahesh M. Mansukhani, and Andrew L. Kung. Implementa-
tion of next generation sequencing into pediatric hematology-oncology practice: Moving
beyond actionable alterations. Genome Medicine, 8, December 2016.
[113] Olena Morozova, Yulia Newton, Melissa Cline, Jingchun Zhu, Katrina Learned,
Josh Stuart, Sofie Salama, Robert Arceci, and David Haussler. Abstract LB-
212: Treehouse Childhood Cancer Project: A resource for sharing and mul-
tiple cohort analysis of pediatric cancer genomics data — Cancer Research.
http://cancerres.aacrjournals.org/content/75/15 Supplement/LB-212, April 2015.
[114] Holly Beale, Du Linh Lam, John Vivian, Yulia Newton, Avanthi Tayi Shah, Isabel
Bjork, Ted Goldstein, Angela N. Brooks, Josh Stuart, Sofie Salama, E. Alejandro Sweet-
Cordero, David Haussler1, and Olena Morozova. Abstract 2466: Identifying confidently
measured genes in single pediatric cancer patient samples using RNA sequencing. Can-
cer Research, 77(13 Supplement):2466–2466, July 2017.
[115] Olena Morozova, Yulia Newton, Avanthi Tayi Shah, Holly Beale, Du Linh Lam, John
Vivian, Isabel Bjork, Theodore Goldstein, Josh Stuart, Sofie Salama, E. Alejandro Sweet-
Cordero, and David Haussler. Abstract 4890: A pan-cancer analysis framework for
incorporating gene expression information into clinical interpretation of pediatric cancer
genomic data. Cancer Research, 77(13 Supplement):4890–4890, July 2017.
[116] Andriy Marusyk and Kornelia Polyak. Tumor heterogeneity: Causes and consequences.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1805(1):105–117, January
2010.
[117] Jianxing Feng, Clifford A. Meyer, Qian Wang, Jun S. Liu, X. Shirley Liu, and Yong
Zhang. GFOLD: A generalized fold change for ranking differentially expressed genes
from RNA-seq data. Bioinformatics, 28(21):2782–2788, November 2012.
[118] John Tukey and JR Beniger. Exploratory Data Analysis. 1978.
[119] Vaske, Olena, Bjork, Isabel, Salama, Sofie, Beale, Holly, Sha, Avanthi, Sanders, Lau-
ren, Pfeil, Jacob, Lam, Du, Learned, Katrina, Durbin, Ann, Kephart, Ellen, Currie,
Rob, Newton, Yulia, Swatloski, Teresa, McColl, Duncan, Vivian, John, Zhu, Jingchun,
Lee, Alex, Leung, Stanley, Spillinger, Aviv, Liu, Heng-Yi, Liang, Winnie, Byron, Sara,
Berens, Michael, Resnick, Adam, Lacayo, Norman, Spunt, Sheri, Rangaswami, Arun,
Huynh, Van, Torno, Lilibeth, Plant, Ashley, Kirov, Ivan, Zabokrsky, Keri, Rasskeh, S,
Deyell, Rebecca, Laskin, Janessa, Marra, Marco, Sender, Leonard, Mueller, Sabine,
145
Sweet-Cordero, Alejandro, Goldstein, Theodore, and Haussler, David. Feasibility of
comparative RNA-Seq analysis for children with cancer. Submitted.
[120] Matthew D Hoffman and Andrew Gelman. The No-U-Turn Sampler: Adaptively Setting
Path Lengths in Hamiltonian Monte Carlo. page 31.
[121] John Salvatier, Thomas V. Wiecki, and Christopher Fonnesbeck. Probabilistic program-
ming in Python using PyMC3. PeerJ Computer Science, 2:e55, April 2016.
[122] Jacob Bock Axelsen, Joseph Lotem, Leo Sachs, and Eytan Domany. Genes overex-
pressed in different human solid cancers exhibit different tissue-specific expression pro-
files. Proceedings of the National Academy of Sciences of the United States of America,
104(32):13122–13127, August 2007.
[123] Joseph Lotem, Dvir Netanely, Eytan Domany, and Leo Sachs. Human cancers overex-
press genes that are specific to a variety of normal human tissues. Proceedings of the
National Academy of Sciences, 102(51):18556–18561, December 2005.
[124] Michael Hogarty and Garrett Brodeur. Gene Amplification in Human Can-
cers: Biological and Clinical Significance — The Online Metabolic and
Molecular Bases of Inherited Disease — OMMBID — McGraw-Hill Medical.
https://ommbid.mhmedical.com/content.aspx?bookid=971&sectionid=62658044&jumpsectionid=62658090.
[125] Ying Chen, Jeremy McGee, Xianming Chen, Thompson N. Doman, Xueqian Gong,
Youyan Zhang, Nicole Hamm, Xiwen Ma, Richard E. Higgs, Shripad V. Bhagwat, Sean
Buchanan, Sheng-Bin Peng, Kirk A. Staschke, Vipin Yadav, Yong Yue, and Hosein
Kouros-Mehr. Identification of Druggable Cancer Driver Genes Amplified across TCGA
Datasets. PLoS ONE, 9(5), May 2014.
[126] Samir P. Shirodkar and Vinata B. Lokeshwar. POTENTIAL NEW MARKERS IN
THE EARLY DETECTION OF BLADDER CANCER. Current opinion in urology,
19(5):488, September 2009.
[127] Hong-Seok Park, Weon Seo Park, Jolanta Bondaruk, Noriyoshi Tanaka, Hiroshi
Katayama, Sangkyou Lee, Philippe E. Spiess, Jordan R. Steinberg, Zhi Wang, Ruth L.
Katz, Colin Dinney, Keren J. Elias, Yair Lotan, Rizwan C. Naeem, Keith Baggerly, Sub-
rata Sen, H. Barton Grossman, and Bogdan Czerniak. Quantitation of Aurora Kinase A
Gene Copy Number in Urine Sediments and Bladder Cancer Detection. JNCI: Journal
of the National Cancer Institute, 100(19):1401–1411, October 2008.
[128] Synno¨ve Staff, Jorma Isola, Mervi Jumppanen, and Minna Tanner. Aurora-A gene is fre-
quently amplified in basal-like breast cancer. Oncology Reports, 23(2):307–312, Febru-
ary 2010.
[129] Li Bie, Gang Zhao, Yin-ping Wang, and Bo Zhang. Kinesin family member 2C
(KIF2C/MCAK) is a novel marker for prognosis in human gliomas. Clinical Neurol-
ogy and Neurosurgery, 114(4):356–360, May 2012.
146
[130] Thomas S. Jacques, Alexander Swales, Monika J. Brzozowski, Nico V. Henriquez,
Jacqueline M. Linehan, Zaman Mirzadeh, Catherine O’ Malley, Heike Naumann, Ar-
turo Alvarez-Buylla, and Sebastian Brandner. Combinations of genetic mutations in the
adult neural stem cell compartment determine brain tumour phenotypes. The EMBO
Journal, 29(1):222–235, January 2010.
[131] Alberto Broniscer, Suzanne J. Baker, Alina N. West, Melissa M. Fraser, Erika Proko,
Mehmet Kocak, James Dalton, Gerard P. Zambetti, David W. Ellison, Larry E. Kun,
Amar Gajjar, Richard J. Gilbertson, and Christine E. Fuller. Clinical and Molecular
Characteristics of Malignant Transformation of Low-Grade Glioma in Children. Journal
of Clinical Oncology, 25(6):682–689, February 2007.
[132] Vahe Michael Zohrabian, Hari Nandu, Nicholas Gulati, Greg Khitrov, Connie Zhao,
Avinash Mohan, Joseph DeMattia, Alex Braun, Kaushik Das, Raj Murali, and Meena
Jhanwar-Uniyal. Gene expression profiling of metastatic brain cancer. Oncology Re-
ports, 18(2):321–328, August 2007.
[133] Marjut Puputti, Olli Tynninen, Harri Sihto, Tea Blom, Hanna Ma¨enpa¨a¨, Jorma Isola, An-
ders Paetau, Heikki Joensuu, and Nina N. Nupponen. Amplification of KIT, PDGFRA,
VEGFR2, and EGFR in Gliomas. Molecular Cancer Research, 4(12):927–934, Decem-
ber 2006.
[134] MF Renzo Di, M. Olivero, S. Ferro, M. Prat, I. Bongarzone, S. Pilotti, A. Belfiore,
A. Costantino, R. Vigneri, and M. A. Pierotti. Overexpression of the c-MET/HGF recep-
tor gene in human thyroid carcinomas. Oncogene, 7(12):2549–2553, December 1992.
[135] Yelena Y. Janjigian, Laura H. Tang, Daniel G. Coit, David P. Kelsen, Todd D. Francone,
Martin R. Weiser, Suresh C. Jhanwar, and Manish A. Shah. MET Expression and Ampli-
fication in Patients with Localized Gastric Cancer. Cancer Epidemiology and Prevention
Biomarkers, 20(5):1021–1027, May 2011.
[136] Daniel V. T. Catenacci, Les Henderson, Shu-Yuan Xiao, Premal Patel, Robert L. Yauch,
Priti Hegde, Jiping Zha, Ajay Pandita, Amy Peterson, and Ravi Salgia. Durable Complete
Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance
at Recurrence. Cancer Discovery, 1(7):573–579, December 2011.
[137] Jeeyun Lee, Jin Won Seo, Hyun Jung Jun, Chang-Seok Ki, Se Hoon Park, Young Suk
Park, Ho Yeong Lim, Min Gew Choi, Jae Moon Bae, Tae Sung Sohn, Jae Hyung Noh,
Sung Kim, Hey-Lim Jang, Ji-Youn Kim, Kyoung-Mee Kim, Won Ki Kang, and Joon Oh
Park. Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic
marker and a potential therapeutic target. Oncology Reports, 25(6):1517–1524, June
2011.
[138] Leow Pay Chin, Ross A. Soo, Richie Soong, and Sai-Hong I. Ou. Targeting ROS1
with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a
Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer. Journal of Thoracic
Oncology, 7(11):1625–1630, November 2012.
147
[139] Artem Sokolov, Daniel E. Carlin, Evan O. Paull, Robert Baertsch, and Joshua M. Stuart.
Pathway-Based Genomics Prediction using Generalized Elastic Net. PLoS Computa-
tional Biology, 12(3), March 2016.
[140] Peter V. Kharchenko, Lev Silberstein, and David T. Scadden. Bayesian approach to
single-cell differential expression analysis. Nature Methods, 11(7):740–742, July 2014.
[141] Trung Nghia Vu, Quin F. Wills, Krishna R. Kalari, Nifang Niu, Liewei Wang, Mattias
Rantalainen, and Yudi Pawitan. Beta-Poisson model for single-cell RNA-seq data analy-
ses. Bioinformatics, 32(14):2128–2135, July 2016.
[142] Benedict Paten, Dent Earl, Ngan Nguyen, Mark Diekhans, Daniel Zerbino, and David
Haussler. Cactus: Algorithms for genome multiple sequence alignment. Genome Re-
search, 21(9):1512–1528, January 2011.
[143] Matt Massie, Frank Austin Nothaft, Christopher Hartl, Christos Kozanitis, Andre Schu-
macher, Anthony D Joseph, and David Patterson. ADAM: Genomics Formats and Pro-
cessing Patterns for Cloud Scale Computing. page 24.
[144] Erik Garrison, Jouni Sire´n, Adam M Novak, Glenn Hickey, Jordan M Eizenga, Eric T
Dawson, William Jones, Shilpa Garg, Charles Markello, Michael F Lin, Benedict Paten,
and Richard Durbin. Variation graph toolkit improves read mapping by representing
genetic variation in the reference. Nature Biotechnology, 36(9):875–879, August 2018.
[145] Muhammad Imran Razzak, Saeeda Naz, and Ahmad Zaib. Deep Learning for Medi-
cal Image Processing: Overview, Challenges and Future. arXiv:1704.06825 [cs], April
2017.
[146] Heidi Ledford. CRISPR, the disruptor. Nature News, 522(7554):20, June 2015.
[147] Luke Alphey. Can CRISPR-Cas9 gene drives curb malaria? Nature Biotechnology,
34(2):149–150, February 2016.
[148] Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma —
Science. https://science.sciencemag.org/content/344/6190/1396.
[149] Barbara Cheifet. Where is genomics going next? Genome Biology, 20(1):17, January
2019.
[150] Afrodita Marcu, Rui Gaspar, Pieter Rutsaert, Beate Seibt, David Fletcher, Wim Verbeke,
and Julie Barnett. Analogies, metaphors, and wondering about the future: Lay sense-
making around synthetic meat. Public Understanding of Science, 24(5):547–562, July
2015.
[151] Sequencing the genome from nematode to human:
Changing methods, changing science - ScienceDirect.
https://www.sciencedirect.com/science/article/pii/S0160932703000619.
148
[152] W Holley, George A Everett, and James T Madison. Nucleotide Sequences in the Yeast
Alanine Transfer Ribonucleic Acid. 240(5):8, 1965.
[153] F. Sanger, G. M. Air, B. G. Barrell, N. L. Brown, A. R. Coulson, J. C. Fiddes, C. A.
Hutchison, P. M. Slocombe, and M. Smith. Nucleotide sequence of bacteriophage ϕX174
DNA. Nature, 265(5596):687, February 1977.
[154] F. Sanger, S. Nicklen, and A. R. Coulson. DNA sequencing with chain-terminating
inhibitors. Proceedings of the National Academy of Sciences of the United States of
America, 74(12):5463–5467, December 1977.
[155] F. Sanger and A. R. Coulson. A rapid method for determining sequences in DNA by
primed synthesis with DNA polymerase. Journal of Molecular Biology, 94(3):441–448,
May 1975.
[156] K. Shinozaki, M. Ohme, M. Tanaka, T. Wakasugi, N. Hayashida, T. Matsubayashi,
N. Zaita, J. Chunwongse, J. Obokata, K. Yamaguchi-Shinozaki, C. Ohto, K. Torazawa,
B. Y. Meng, M. Sugita, H. Deno, T. Kamogashira, K. Yamada, J. Kusuda, F. Takaiwa,
A. Kato, N. Tohdoh, H. Shimada, and M. Sugiura. The complete nucleotide sequence
of the tobacco chloroplast genome: Its gene organization and expression. The EMBO
Journal, 5(9):2043–2049, September 1986.
[157] A. Goffeau, B. G. Barrell, H. Bussey, R. W. Davis, B. Dujon, H. Feldmann, F. Gal-
ibert, J. D. Hoheisel, C. Jacq, M. Johnston, E. J. Louis, H. W. Mewes, Y. Mu-
rakami, P. Philippsen, H. Tettelin, and S. G. Oliver. Life with 6000 Genes. Science,
274(5287):546–567, October 1996.
[158] S. Anderson, A. T. Bankier, B. G. Barrell, M. H. L. de Bruijn, A. R. Coulson, J. Drouin,
I. C. Eperon, D. P. Nierlich, B. A. Roe, F. Sanger, P. H. Schreier, A. J. H. Smith,
R. Staden, and I. G. Young. Sequence and organization of the human mitochondrial
genome. Nature, 290(5806):457, April 1981.
[159] R. D. Fleischmann, M. D. Adams, O. White, R. A. Clayton, E. F. Kirkness, A. R.
Kerlavage, C. J. Bult, J. F. Tomb, B. A. Dougherty, J. M. Merrick, and Et Al. Whole-
genome random sequencing and assembly of Haemophilus influenzae Rd. Science,
269(5223):496–512, July 1995.
[160] J. Craig Venter, Mark D. Adams, Eugene W. Myers, Peter W. Li, Richard J. Mural,
Granger G. Sutton, Hamilton O. Smith, Mark Yandell, Cheryl A. Evans, Robert A. Holt,
Jeannine D. Gocayne, Peter Amanatides, Richard M. Ballew, Daniel H. Huson, Jen-
nifer Russo Wortman, Qing Zhang, Chinnappa D. Kodira, Xiangqun H. Zheng, Lin
Chen, Marian Skupski, Gangadharan Subramanian, Paul D. Thomas, Jinghui Zhang,
George L. Gabor Miklos, Catherine Nelson, Samuel Broder, Andrew G. Clark, Joe
Nadeau, Victor A. McKusick, Norton Zinder, Arnold J. Levine, Richard J. Roberts, Mel
Simon, Carolyn Slayman, Michael Hunkapiller, Randall Bolanos, Arthur Delcher, Ian
149
Dew, Daniel Fasulo, Michael Flanigan, Liliana Florea, Aaron Halpern, Sridhar Han-
nenhalli, Saul Kravitz, Samuel Levy, Clark Mobarry, Knut Reinert, Karin Remington,
Jane Abu-Threideh, Ellen Beasley, Kendra Biddick, Vivien Bonazzi, Rhonda Bran-
don, Michele Cargill, Ishwar Chandramouliswaran, Rosane Charlab, Kabir Chaturvedi,
Zuoming Deng, Valentina Di Francesco, Patrick Dunn, Karen Eilbeck, Carlos Evange-
lista, Andrei E. Gabrielian, Weiniu Gan, Wangmao Ge, Fangcheng Gong, Zhiping Gu,
Ping Guan, Thomas J. Heiman, Maureen E. Higgins, Rui-Ru Ji, Zhaoxi Ke, Karen A.
Ketchum, Zhongwu Lai, Yiding Lei, Zhenya Li, Jiayin Li, Yong Liang, Xiaoying Lin,
Fu Lu, Gennady V. Merkulov, Natalia Milshina, Helen M. Moore, Ashwinikumar K.
Naik, Vaibhav A. Narayan, Beena Neelam, Deborah Nusskern, Douglas B. Rusch, Steven
Salzberg, Wei Shao, Bixiong Shue, Jingtao Sun, Zhen Yuan Wang, Aihui Wang, Xin
Wang, Jian Wang, Ming-Hui Wei, Ron Wides, Chunlin Xiao, Chunhua Yan, Alison
Yao, Jane Ye, Ming Zhan, Weiqing Zhang, Hongyu Zhang, Qi Zhao, Liansheng Zheng,
Fei Zhong, Wenyan Zhong, Shiaoping C. Zhu, Shaying Zhao, Dennis Gilbert, Suzanna
Baumhueter, Gene Spier, Christine Carter, Anibal Cravchik, Trevor Woodage, Feroze
Ali, Huijin An, Aderonke Awe, Danita Baldwin, Holly Baden, Mary Barnstead, Ian Bar-
row, Karen Beeson, Dana Busam, Amy Carver, Angela Center, Ming Lai Cheng, Liz
Curry, Steve Danaher, Lionel Davenport, Raymond Desilets, Susanne Dietz, Kristina
Dodson, Lisa Doup, Steven Ferriera, Neha Garg, Andres Gluecksmann, Brit Hart, Ja-
son Haynes, Charles Haynes, Cheryl Heiner, Suzanne Hladun, Damon Hostin, Jarrett
Houck, Timothy Howland, Chinyere Ibegwam, Jeffery Johnson, Francis Kalush, Lesley
Kline, Shashi Koduru, Amy Love, Felecia Mann, David May, Steven McCawley, Tina
McIntosh, Ivy McMullen, Mee Moy, Linda Moy, Brian Murphy, Keith Nelson, Cyn-
thia Pfannkoch, Eric Pratts, Vinita Puri, Hina Qureshi, Matthew Reardon, Robert Ro-
driguez, Yu-Hui Rogers, Deanna Romblad, Bob Ruhfel, Richard Scott, Cynthia Sitter,
Michelle Smallwood, Erin Stewart, Renee Strong, Ellen Suh, Reginald Thomas, Ni Ni
Tint, Sukyee Tse, Claire Vech, Gary Wang, Jeremy Wetter, Sherita Williams, Monica
Williams, Sandra Windsor, Emily Winn-Deen, Keriellen Wolfe, Jayshree Zaveri, Karena
Zaveri, Josep F. Abril, Roderic Guigo´, Michael J. Campbell, Kimmen V. Sjolander, Brian
Karlak, Anish Kejariwal, Huaiyu Mi, Betty Lazareva, Thomas Hatton, Apurva Narecha-
nia, Karen Diemer, Anushya Muruganujan, Nan Guo, Shinji Sato, Vineet Bafna, Sorin
Istrail, Ross Lippert, Russell Schwartz, Brian Walenz, Shibu Yooseph, David Allen,
Anand Basu, James Baxendale, Louis Blick, Marcelo Caminha, John Carnes-Stine, Par-
ris Caulk, Yen-Hui Chiang, My Coyne, Carl Dahlke, Anne Deslattes Mays, Maria Dom-
broski, Michael Donnelly, Dale Ely, Shiva Esparham, Carl Fosler, Harold Gire, Stephen
Glanowski, Kenneth Glasser, Anna Glodek, Mark Gorokhov, Ken Graham, Barry Grop-
man, Michael Harris, Jeremy Heil, Scott Henderson, Jeffrey Hoover, Donald Jennings,
Catherine Jordan, James Jordan, John Kasha, Leonid Kagan, Cheryl Kraft, Alexander
Levitsky, Mark Lewis, Xiangjun Liu, John Lopez, Daniel Ma, William Majoros, Joe Mc-
Daniel, Sean Murphy, Matthew Newman, Trung Nguyen, Ngoc Nguyen, Marc Nodell,
Sue Pan, Jim Peck, Marshall Peterson, William Rowe, Robert Sanders, John Scott,
Michael Simpson, Thomas Smith, Arlan Sprague, Timothy Stockwell, Russell Turner,
Eli Venter, Mei Wang, Meiyuan Wen, David Wu, Mitchell Wu, Ashley Xia, Ali Zandieh,
150
and Xiaohong Zhu. The Sequence of the Human Genome. Science, 291(5507):1304–
1351, February 2001.
[161] The Human Genome Browser at UCSC. https://genome.cshlp.org/content/12/6/996.short.
[162] Human Whole-Genome Shotgun Sequencing. https://genome.cshlp.org/content/7/5/401.short.
[163] R Staden. A strategy of DNA sequencing employing computer programs. Nucleic Acids
Research, 6(7):2601–2610, June 1979.
[164] Jay Shendure, Gregory J. Porreca, Nikos B. Reppas, Xiaoxia Lin, John P. McCutcheon,
Abraham M. Rosenbaum, Michael D. Wang, Kun Zhang, Robi D. Mitra, and George M.
Church. Accurate Multiplex Polony Sequencing of an Evolved Bacterial Genome. Sci-
ence, 309(5741):1728–1732, September 2005.
[165] Richard Williams, Sergio G. Peisajovich, Oliver J. Miller, Shlomo Magdassi, Dan S.
Tawfik, and Andrew D. Griffiths. Amplification of complex gene libraries by emulsion
PCR. Nature Methods, 3(7):545–550, July 2006.
[166] Marcel Margulies, Michael Egholm, William E. Altman, Said Attiya, Joel S. Bader,
Lisa A. Bemben, Jan Berka, Michael S. Braverman, Yi-Ju Chen, Zhoutao Chen, Scott B.
Dewell, Lei Du, Joseph M. Fierro, Xavier V. Gomes, Brian C. Godwin, Wen He, Scott
Helgesen, Chun He Ho, Gerard P. Irzyk, Szilveszter C. Jando, Maria L. I. Alenquer,
Thomas P. Jarvie, Kshama B. Jirage, Jong-Bum Kim, James R. Knight, Janna R. Lanza,
John H. Leamon, Steven M. Lefkowitz, Ming Lei, Jing Li, Kenton L. Lohman, Hong
Lu, Vinod B. Makhijani, Keith E. McDade, Michael P. McKenna, Eugene W. Myers,
Elizabeth Nickerson, John R. Nobile, Ramona Plant, Bernard P. Puc, Michael T. Ro-
nan, George T. Roth, Gary J. Sarkis, Jan Fredrik Simons, John W. Simpson, Maithreyan
Srinivasan, Karrie R. Tartaro, Alexander Tomasz, Kari A. Vogt, Greg A. Volkmer,
Shally H. Wang, Yong Wang, Michael P. Weiner, Pengguang Yu, Richard F. Begley, and
Jonathan M. Rothberg. Genome sequencing in microfabricated high-density picolitre
reactors. Nature, 437(7057):376, September 2005.
[167] Mihai Pop. Genome assembly reborn: Recent computational challenges. Briefings in
Bioinformatics, 10(4):354–366, July 2009.
[168] Matthias Meyer and Martin Kircher. Illumina Sequencing Library Preparation for
Highly Multiplexed Target Capture and Sequencing. Cold Spring Harbor Protocols,
2010(6):pdb.prot5448, January 2010.
[169] M. J. Levene, J. Korlach, S. W. Turner, M. Foquet, H. G. Craighead, and W. W. Webb.
Zero-Mode Waveguides for Single-Molecule Analysis at High Concentrations. Science,
299(5607):682–686, January 2003.
[170] Real-Time DNA Sequencing from Single Polymerase Molecules — Science.
https://science.sciencemag.org/content/323/5910/133.
151
[171] PacBio Shares Early-Access Customer Experiences, New Applications for Se-
quel II. https://www.genomeweb.com/sequencing/pacbio-shares-early-access-customer-
experiences-new-applications-sequel-ii.
[172] David W Deamer and Mark Akeson. Nanopores and nucleic acids: Prospects for ultra-
rapid sequencing. Trends in Biotechnology, 18(4):147–151, April 2000.
[173] John J. Kasianowicz, Eric Brandin, Daniel Branton, and David W. Deamer. Characteriza-
tion of individual polynucleotide molecules using a membrane channel. Proceedings of
the National Academy of Sciences of the United States of America, 93(24):13770–13773,
November 1996.
[174] Stephen Winters-Hilt, Wenonah Vercoutere, Veronica S. DeGuzman, David Deamer,
Mark Akeson, and David Haussler. Highly Accurate Classification of Watson-Crick
Basepairs on Termini of Single DNA Molecules. Biophysical Journal, 84(2):967–976,
February 2003.
[175] Hagan Bayley. Sequencing single molecules of DNA. Current Opinion in Chemical
Biology, 10(6):628–637, December 2006.
[176] Nanopore sequencing and assembly of a human genome with ultra-long reads — Nature
Biotechnology. https://www.nature.com/articles/nbt.4060#main.
[177] Marcel Martin. Cutadapt removes adapter sequences from high-throughput sequencing
reads. EMBnet.journal, 17(1):10–12, May 2011.
[178] Science Forum: The Human Cell Atlas — eLife.
https://elifesciences.org/articles/27041#abstract.
[179] Simon Andrews. FastQC, 2010.
[180] Kai Wang, Darshan Singh, Zheng Zeng, Stephen J. Coleman, Yan Huang, Gleb L. Savich,
Xiaping He, Piotr Mieczkowski, Sara A. Grimm, Charles M. Perou, James N. MacLeod,
Derek Y. Chiang, Jan F. Prins, and Jinze Liu. MapSplice: Accurate mapping of RNA-seq
reads for splice junction discovery. Nucleic Acids Research, 38(18):e178–e178, October
2010.
[181] Harold Pimentel. What the FPKM? A review of RNA-Seq expression units — The far-
rago. https://haroldpimentel.wordpress.com/2014/05/08/what-the-fpkm-a-review-rna-
seq-expression-units/.
[182] Computational Genomics Platform (CGP) — A project of the UC Santa Cruz Genomics
Institute. https://cgp.genomics.ucsc.edu/.
[183] Olena Morozova, Yulia Newton, Avanthi Tayi Shah, Holly Beale, Du Linh Lam, John
Vivian, Isabel Bjork, Theodore Goldstein, Josh Stuart, Sofie Salama, E. Alejandro Sweet-
Cordero, and David Haussler. Abstract 4890: A pan-cancer analysis framework for
152
incorporating gene expression information into clinical interpretation of pediatric cancer
genomic data. Cancer Research, 77(13 Supplement):4890–4890, July 2017.
[184] Hannes Schmidt. Image and VM management for Jenkins, Spark and Mesos clusters
in EC2: BD2KGenomics/cgcloud. UC Santa Cruz Genomics Institute - Computational
Genomics Lab, April 2018.
[185] Hiroko Ohgaki and Paul Kleihues. Genetic Pathways to Primary and Secondary Glioblas-
toma. The American Journal of Pathology, 170(5):1445–1453, May 2007.
[186] MF Renzo Di, M. Olivero, S. Ferro, M. Prat, I. Bongarzone, S. Pilotti, A. Belfiore,
A. Costantino, R. Vigneri, and M. A. Pierotti. Overexpression of the c-MET/HGF recep-
tor gene in human thyroid carcinomas. Oncogene, 7(12):2549–2553, December 1992.
[187] Jeeyun Lee, Jin Won Seo, Hyun Jung Jun, Chang-Seok Ki, Se Hoon Park, Young Suk
Park, Ho Yeong Lim, Min Gew Choi, Jae Moon Bae, Tae Sung Sohn, Jae Hyung Noh,
Sung Kim, Hey-Lim Jang, Ji-Youn Kim, Kyoung-Mee Kim, Won Ki Kang, and Joon Oh
Park. Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic
marker and a potential therapeutic target. Oncology Reports, 25(6):1517–1524, June
2011.
153
